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Abbreviations 
 
°C Degree Celsius 
Å Angstrom (Å = 10-10 m) 
aa Amino acid 
AMC 7-amino-4-methylcoumarin 
APS Ammoniumpersulfate 
ATCC American Type Culture Collection 
bp Base pair 
BSA Bovine serum albumin 
CDC Centers for Disease Control and Prevention 
Cha Cyclohexylalanine 
DAPI 4′,6-diamidino-2-phenylindole 
def Deficient 
dH2O Deionized water 
DMEM Dulbecco‘s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediamine tetraacetic acid 
EK Enterokinase 
ER Endoplasmic reticulum 
et al. Et alii 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
for Forward 
fXa Factor Xa 
GSH Reduced glutathione 
GSSG Oxidized glutathione 
HA Hemagglutinin 
HA0 Hemagglutinin precursor 
HA1 / HA2 Hemagglutinin subunit 1 / 2 
HAI-I/ HAI-II Hepatocyte growth factor activator inhibitor I and II 
HEK Human Embryonic Kidney (cells) 
HPAIV Highly pathogenic avian influenza A virus 
hPhe Homo-phenylalanine 
HRP Horseradish peroxidase 
IAV Influenza A virus 
IB Inclusion body 
IF Immunofluorescence 
IgK Immunoglobulin kappa  
IMAC Immobilized metal ion affinity chromatography 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kcat Catalytic rate constant 
  kDa Kilodalton 
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Ki Dissociation constant of the enzyme inhibitor complex 
KM Michaelis-Menten constant 
LB Lysogeny broth 
LDLRA Low-density lipoprotein receptor A (domain) 
LPAIV Low pathogenic avian influenza A virus 
M Molar 
MCS Multiple cloning site 
MDCK Madin-Darby canine kidney (cells) 
Mes Methylsulfonyl 
MES 2-(N-morpholino)ethanesulfonic acid 
MI Marburg inhibitor 
MME Monomethyl ether 
MMS Microseed matrix screening 
N.D. Not determined 
NA Neuraminidase 
NMR Nuclear magnetic resonance 
nt  Nucleotide 
NTA Nitrilotriacetic acid  
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PBS     Phosphate buffered saline 
PCR Polymerase chain reaction 
PDB    Protein data bank 
PEG Polyethylene glycol 
pNA 4-nitroaniline 
PPMO Peptide-conjugated phosphorodiamidate morpholino oligomer 
PTM Post translational modification 
PVDF Polyvinylidene fluoride 
rev Reverse 
RFU Relative fluorescence unit 
RKI Robert Koch Institute 
RNA Ribonucleic acid 
rpm Rounds per minute 
RPMI Rosswell Park Memorial Institute (culture medium) 
RT Room temperature 
SAR Structure-activity relationship 
SDS Sodium dodecyl sulfate 
SP Signal peptide 
SPD Serine protease domain 
SRCR Group A scavenger receptor cysteine-rich (domain) 
ss Single stranded 
TAE Tris-acetate-EDTA (buffer) 
TBS Tris buffered saline 
TEMED Tetramethylethylenediamine 
TGN Trans-Golgi Network 
TMPRSS Transmembrane protease, serine, S1 family member 
Tos Toluenesulfonyl (Tosyl) 
tPA Tissue-type plasminogen activator 
Tris Tris(hydroxymethyl)aminomethane 
TRITC Tetramethylrhodamine 
TTSP 
 
Type II transmembrane serine protease 
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 C 
uPA Urokinase-type plasminogen activator 
  
  
UV/Vis Ultraviolet–visible 
v/v Volume per volume 
Vmax Maximum velocity of non-inhibited enzyme reaction 
w/v Weigth per volume 
WHO  World Health Organization 
wt Wild type 
α  Alpha, used as anti (antibodies) 
β-ME 2-mercaptoethanol   
Δ Delta, used as deficient or truncated 
 
 
Abbreviations of chemical compounds are taken from the relevant references like Methods of 
Organic Chemistry (Houben-Weyl), March's Advanced Organic Chemistry and Greene's 
Protective Groups in Organic Synthesis. 
 
Amino acid code table 
The abbreviations of the amino acids and their derivatives are used according to the 
recommendations of the International Union of Pure and Applied Chemistry (IUPAC) and 
International Union of Biochemistry and Molecular Biology (IUBMB) Joint Commission on 
Biochemical Nomenclature (JCBN) using the three or one letter code. Unless otherwise 
indicated, all amino acids and their derivatives have L-configurations. 
 
Amino acid Three letter 
code 
One letter 
code 
 Amino acid Three letter 
code 
One letter 
code 
Alanine Ala A Leucine Leu L 
Arginine Arg R Lysine Lys K 
Asparagine Asn N Methionine Met M 
Aspartic acid Asp D Phenylalanine Phe F 
Cysteine Cys C Proline Pro P 
Glutamic acid Glu E Serine Ser S 
Glutamine Gln Q Threonine Thr T 
Glycine Gly G Tryptophan Trp W 
Histidine His H Tyrosine Tyr Y 
Isoleucine Ile I Valine Val V 
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1. Research relevance and thesis overview 
 
“Influenza is a serious global health threat that impacts all countries: every year, there are 
an estimated 1 billion cases, 3-5 million severe cases, and 290,000-650,000 influenza-related 
respiratory deaths worldwide. In this interconnected world, the next influenza pandemic is a 
matter of when, not if and a severe pandemic is believed by many experts to be potentially the 
most devastating global health event with far reaching consequences.” 
- Global Influenza Strategy 2019-2030, WHO [1] – 
 
Influenza (short flu) is one of the commonest infections of humans. As a highly contagious 
acute respiratory disease caused by the influenza virus it affects millions of people every year. 
The characteristic symptoms include fever, headache, muscle pain, malaise, rhinitis and a non-
productive cough but can also cause serious complications such as acute bronchitis, secondary 
bacterial pneumonia, otitis media or even death. The highest morbidity rates are found in infants 
and the elderly with over 65 years of age. Furthermore, pregnant women, individuals with 
chronic disorders and persons with immunosuppression are at higher risk [2, 3]. On a 
phylogenetic-based taxonomy, influenza viruses are assigned to the Orthomyxoviridae family. 
Three genera of influenza viruses are known to infect humans, including influenza type A, B 
and C with type A and B being responsible for most of the infections. Between these two, 
influenza type A is the most prevalent one causing both, epidemic and pandemic outbreaks. 
The latter results from major genetic changes of the influenza virus and occur every 10-50 years 
with severe consequences for the immunological naive population. Historically, the most 
devastating flu pandemic occurred in 1918 during and shortly after the first world war and is 
referred to as the "Spanish flu". Between 1918 and 1920 the H1N1 influenza A subtype affected 
approximately one third of the world's population and caused approximately 40 million deaths 
worldwide [4]. A novel H1N1 subtype (swine-origin H1N1pdm09) was responsible for the most 
recent flu pandemic in 2009. Heavy casualties were estimated between 123,000 and 203,000 in 
the last 9 months of 2009 [5]. Whereas these pandemic outbreaks are from a rather unpredictable 
nature, the seasonal epidemic influenza infections mainly take place annually between 
December and February and are strictly monitored by global or regional organizations, such as 
the WHO (worldwide), the CDC (US) or the RKI in case of Germany. The most effective 
prevention against seasonal flu viruses is vaccination. By the virus’s capability to undergo 
constant continuous genetic changes, termed as antigenic drift or shift, the vaccine composition 
has to be annually updated based on predictions. Millions of people are affected by influenza
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viruses every year. Nine million influenza-attributable medically attended acute respiratory 
illnesses that resulted in approximately 45,000 influenza-related hospital admissions were 
estimated for the influenza season 2017/2018 by the RKI in Germany [6]. Except for these direct 
costs of medical care, absenteeism from work results in a huge economic burden of seasonal 
influenza. 5.3 million physician-signed sick leaves, including the need to stay home cases in 
case of non-employed persons such as children and the elderly were estimated for the 
2017/2018 influenza season in Germany. The actual influenza prevention strategy as well as 
the required medical care and the financial suffers through absenteeism making influenza a 
cost-intensive disease of the modern world. Not to forget the heavy casualties of around 290,000 
– 650,000 every year [7]. New strategies for influenza treatment in order to protect the human 
population from the recent influenza epidemics and prepare them for the next imminent 
pandemic are in demand. In the “Global influenza strategy 2019-2030” the WHO defined the 
main goals as to:   
• Reduce the burden of seasonal influenza, 
• Minimize the risk of zoonotic influenza and 
• Mitigate the impact of pandemic influenza. 
Improved tools for prevention, detection and treatment of influenza are required to address 
unmet public health needs. To do so, influenza research has to be promoted, including the 
research to better understand the virus characteristics and host factors that drive the impact of 
influenza [1].  
The following work addresses the characterization of host cell factors, with the main focus on 
the type-II transmembrane serine proteases TMPRSS2 and matriptase that are involved in (but 
not limited to) the activation of several influenza A virus surface glycoprotein hemagglutinin 
subtypes. The cleavage of hemagglutinin by host proteases is essential for virus spread and 
infectivity. The inhibition of these relevant proteases therefore provides a promising therapeutic 
approach. In detail, this thesis is divided into a general introduction (chapter 2), three main 
chapters covering three different projects (chapters 3, 4 and 5), a conclusion and outlook 
(chapter 6) and the experimental section (chapter 7). 
The three independent main chapters namely: 
I. Preparation and characterization of recombinant matriptase SPDs (Chapter 3), 
II. Computer-assisted matriptase inhibitor design and their characterization (Chapter 4), 
III. Characterization of truncated and mutated TMPRSS2 variants (Chapter 5), 
are separated each in introduction, results and discussion and a chapter specific summary. 
  
3 
2. General introduction 
2.1. Influenza-A-virus (IAV) 
IAV is an enveloped virus with a genome of segmented negatively sensed single-stranded (ss) 
RNA. Based on the antigen variability of the surface glycoproteins hemagglutinin (HA) and 
neuraminidase (NA) IAVs are divided into several subtypes. So far, sequences of 18 HA and 
11 NA subtypes have been identified [8]. Nearly all of the 144 theoretical combinations of H1-
H16 and N1-N9 are found in aquatic wild birds, which were determined as the natural main 
reservoir. Subtypes H17 and H18 as well as N10 and N11 have been exclusively identified in 
bats suggesting that wild birds are not the only natural reservoir [8-10].  
2.1.1. Virus and genomic structure 
The enveloped IAV particles possess a spherical (100 nm) (Figure 2-1 A) or more rarely a 
filamentous form (20 µm) [11]. The genome consists of 8 single-stranded negatively sensed 
RNAs ((-)ssRNA) encoding for at least 12 proteins that are required for virus survival and 
propagation (Table 2-1). The viral RNA is packed into viral ribonucleoprotein (vRNP) 
complexes where the virus RNA is associated with the viral heterotrimeric RNA polymerase 
(consisting of the polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2) and the 
polymerase acid protein (PA)) and is coated with multiple nucleoproteins (NPs). These RNP 
complexes are surrounded by multiple matrix protein 1 (M1) and located beneath the envelope. 
Besides HA and NA, the virus envelope contains the channel protein M2 (matrix protein 2). In 
addition, small quantities of non-structural proteins (NS) are found in the virion. A schematic 
illustration of a single virion is given in Figure 2-1 B.
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Figure 2-1: Spherical Influenza A virus particles. A: Electron micrograph of IAV subtype H1N1. HA and NA 
are visible in form of "spikes" on the IAV surface. Figure was taken and modified from [11]. B: Schematic 
illustration of one influenza A virion. The major glycoproteins HA and NA, together with M2, are embedded into 
the virus membrane. The M1 protein coats the inner layer of the virus particle and interacts with the NP protein. 
This protein encapsulates the 8 (-)ssRNA genome segments and forms together with the polymerase complex 
(PB1, PB2 and PA) the viral ribonucleoproteins (vRNPs). Figure was taken from [12].
Table 2-1: Influenza A virus genome segments, encoded proteins and their function [13] 
Segment Protein Description and Function 
1 PB2 Polymerase subunit, binds to 5` cap structure of cellular mRNA  
2 PB1 Catalytic subunit of polymerase complex, elongation of viral RNA  
 PB1-F2 Virulence factor, induces apoptosis  
 PB1-N40 Mediates balance between PB1 and PB1-F2  
3 PA Endonuclease activity, cap snatching  
4 HA Surface glycoprotein, receptor binding and membrane fusion  
5 NP RNA binding protein, major component vRNP, mediates nuclear 
import of vRNPs  
6 NA Surface glycoprotein, sialidase activity, virus release  
7 M1 Matrix protein, interaction with vRNPs, nuclear export and budding  
8 M2 Ion channel, important for uncoating and assembly  
NS1 Interferon antagonist and regulation of host gene expression  
 NEP  Nuclear export of synthesized vRNPs (earlier name: NS2) 
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2.1.2. Replication cycle of influenza A viruses 
The multistage IAV replication process includes binding, entry, fusion and uncoating, genome 
transcription, viral protein synthesis, assembly and finally egress/budding of progeny virions 
(Figure 2-2). Since transcription and replication of IAV take place in the nucleus, the viral RNPs 
have to be transported from the cell periphery to the nucleus of the cell for RNA synthesis.  
 
 
Figure 2-2: Schematic illustration of Influenza A virus replication cycle including the virion binding to the 
host cell via α2.3- or α2.6-linked sialic acid, the entry, fusion and uncoating as well as genome transcription, viral 
protein synthesis, assembly and finally egress/budding of progeny virions. Figure was taken and modified from 
literature [14]. 
The first step in IAV replication is the attachment of virions to the target cells [15] that is 
mediated by the binding of the homotrimeric virus surface glycoprotein HA to α2.3- or α2.6- 
linked terminal sialic acids on cellular host glycoproteins or glycolipids [16]. The virus is 
subsequently transported to the cell interior by endocytosis. The acidic pH within the 
endosomes triggers irreversible conformational changes in the HA causing the insertion of the 
HA2 subunit into the endosomal membrane 
[17]. Furthermore, the low pH activates the ion 
channel activity of viral M2 envelope proteins, resulting in the proton transport into the virion 
interior. This acidification leads to the release of viral RNP complexes and after the uncoating 
step to its transport into the nucleus that is mediated by nuclear localization signals on the 
nucleoprotein [18-20]. The negatively sensed genomic ssRNA segments are transcribed into 
mRNA by the heterotrimeric viral polymerase complex and translated in the cytoplasm by the 
host’s translation machinery. After being modified, the viral proteins NP, PA, PB1, and PB2 
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are transported back into the nucleus, where viral RNP complexes are formed and finally 
exported together with the M1 protein out to the cell surface. HA, NA and M2 are transported 
along the secretory pathway to the plasma membrane, where they wrap around the vRNP. 
Finally, virus progeny is released from cells by viral NA [13]. 
2.1.3. IAV pathology 
On the basis of molecular genetics and pathogenesis criteria, low pathogenic avian influenza 
viruses (LPAIV) and highly pathogenic avian influenza viruses (HPAIV) can be discriminated 
[21]. Whereas LPAIV usually induce no symptoms or only mild disease in birds, HPAIV cause 
severe disease with high mortality in poultry [22-24]. Generally, humans can be infected with 
both, HPAIV and LPAIV. However, infection with HPAIV usually requires direct contact with 
infected sick or dead birds. Zoonotic, non-human-adapted IAVs such as the HPAIV subtype 
H5N1 and H7N7 only occasionally infect humans but cause severe and frequently fatal 
diseases. Mild to severe, as well as fatal illness in humans have been also observed upon 
infection with the non-human adapted LPAIV virus H7N9 [25, 26]. Most of the known avian 
influenza viruses are classified as LPAIV. They are thought to be transmitted among non-
human mammals, such as animals from domestic poultry or swine [27]. Currently, only 3 HA 
subtypes (H1, H2 and H3) and 2 NA subtypes (N1 and N2) with mainly H1N1 and H3N2 are 
circulating in humans and cause the annual epidemics. As the main target for neutralizing 
antibodies, NA and particularly HA are under intense immune-mediated selection pressure. 
Two mechanisms, namely antigenic drift and antigenic shift allow the IAV to emerge host 
immunity. Antigenic drift describes the continuous acquisition of point mutations in the 
influenza surface proteins NA and HA that pass unnoticed since the viral RNA polymerase 
complex lacks a proofreading function. These small genetic changes can accumulate over time 
and result in antigenically distinct virus strains. The partial escape in host immunity by 
antigenic drift causes the yearly epidemic IAV infections. Due to the segmented nature of the 
influenza gene, entire genomic segments can be exchanged between different IAV strains of 
different hosts with the result of antigenically novel virus strains. These reassortment events 
are termed antigenic shift [12]. Since the population is immunologically naive against new 
strains, pandemics might be the consequence. Pandemics occur only every 10 to 50 years [28] 
but come with more severe consequences compared to the annual epidemics. The first 
documented pandemic was the 1918 Spanish flu, caused by the transmission of an avian H1N1 
virus to humans. The death of over 40 million people was the consequence [4]. Less severe 
pandemics were the Asian flu (H2N2) in 1957, the Hong Kong flu (H3N2) in 1968 [29] and the 
recent Swine flu (pH1N1) in 2009 [30]. 
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2.1.4. Prophylaxis and therapeutics 
The most efficient strategy to fight infectious diseases is vaccination. Although influenza 
vaccines are available since the 1930s [31, 32] the constant genetic changes entail a new vaccine 
composition on a yearly basis that is based on predictions. Besides of social distancing and a 
high personal hygienic standard, the yearly influenza vaccination is still the best option to 
prevent influenza infections and is highly recommended by the Centers for Disease Control and 
Prevention (CDC) and the World Health Organization (WHO) for high risk groups such as the 
elderly and children. Currently, trivalent and quadrivalent vaccines with either inactivated or 
live attenuated (i.e. less virulent) viruses are available. The recent influenza vaccines consist of 
two IAV strains (one pH1N1 and one H3N2 strain) and either one (trivalent) or two 
(quadrivalent) influenza B strains [33]. The vaccines are designed to stimulate the immune 
system to develop an adaptive response against viruses predicted to be circulating during the 
next influenza season. However, in case of a pandemic event, it will still take several months 
to develop a new effective vaccine, which rises the urgent need for novel and effective anti-
influenza drugs [13]. In theory, anti-influenza drug strategies can be directed against every step 
in the viral propagation cycle (see 2.1.1). At present, three classes of symptom-reducing 
antiviral medication are approved by the Food and Drug Administration (FDA), including M2 
ion channel inhibitors (Amantadine and Rimantadine), NA inhibitors (Oseltamivir, Zanamivir 
and Peramivir) and the very recently approved pro-drug baloxavir marboxil, an inhibitor of the 
endonuclease PA. These drugs are to be taken within 48 hours after the debut of influenza 
symptoms in order to reduce illness duration and severity [34]. The M2 ion channel inhibitors 
that only act on influenza A viruses are currently not recommended by CDC and WHO, since 
the latest H3N2 and pH1N1 swine flu strains showed amantadine and rimantadine resistance of 
92 % to 100 % respectively [35, 36]. Also, in the case of NA, specific mutations confer drug 
resistance against the present NA inhibitors [35, 37-39]. New strategies against influenza are 
required to face the emerging resistance. Researchers focus on the development of new 
derivatives of existing drugs and on new targets with HA being one of the most appealing 
targets. HA targeting approaches focus on antibody-based therapy where neutralizing 
monoclonal antibodies bind to reserved regions of HA [40] or on small molecules HA inhibitors. 
Depending on the HA maturation stage, those inhibitors target HA glycosylation, proteolytic 
activation, attachment to host cell receptors and HA-mediated membrane fusion [13, 41]. 
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2.2. IAV surface glycoprotein hemagglutinin 
Hemagglutinin is a type I transmembrane protein with an N-terminal signal peptide, a long 
ectodomain, a transmembrane region and a short cytoplasmic tail at the C-terminus (Figure 2-
3). HA is synthesized as a single chain zymogen consisting of 560 amino acids. This 
polypeptide has a molecular weight of 60 kDa that increases upon glycosylation [17].  
 
Figure 2-3: Genetic organization of hemagglutinin. A: HA is synthesized as the precursor HA0 protein of 
75 kDa (after modification) and consists of an N-terminal signal peptide (SP, red), the subunits HA1 (violet) and 
HA2 (orange) including the N-terminal fusion peptide (FP, green) as well as the C-terminal transmembrane domain 
(grey). B: Cleavage (arrow) after an arginine residue (or more rarely lysine) results in the introduction of a new 
C-terminus to the 55 kDa HA1 and an N-terminus to the 25 kDa HA2 subunit. The two subunits remain linked by 
a conserved disulfide bond (S-S) post cleavage. 
The HA ectodomain contains the HA1 subunit, a single arginine (or more rarely a lysine) 
connector residue, and the HA2 subunit 
[42]. During modifications in the ER, high mannose N-
glycans are added and HA homotrimers are formed. The position and number of N-
glycosylation sites, hence the size of the HA0
 precursor protein, can vary with different IAV 
isolates [43]. HA0 is cleaved by cellular proteases into the subunits HA1 and HA2, either in the 
trans-Golgi network (TGN), on the cell surface or in endosomes. Both subunits remain tightly 
associated post-cleavage through a conserved disulfide bond [44]. 
2.2.1. Three-dimensional structure of HA 
HA homotrimers have a cylindrical shape (Figure 2-4 A and B) with approximate dimensions 
of 135 Å (length) x 35-70 Å (radius) and can be detected via electron microscopy in form of 
spikes that project externally [45, 46]. Each HA monomer has a globular head domain and a stalk-
like stem domain (see Figure 2-4 C). The globular head is formed by the HA1 residues 116 – 
261, which are folded into a jelly-roll motif of eight stranded antiparallel β-sheets and sit on top 
of the triple-stranded coiled-coil of α-helices of the stem region [47, 48]. HA1 contains the 
receptor-binding site and the major antigenic epitopes. Amino acid changes at these antigenic 
sites during infection are associated with antigenic change [17]. The stalk is composed of the N- 
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and C-terminus of HA1, the proteolytic cleavage site on the surface loop (Figure 2-4 D), and 
the HA2 subunit containing the fusion protein that mediates the fusion of viral and endosomal 
host membranes during virus uptake [49]. The fusion peptide is a highly conserved region among 
all HA subtypes at the N-terminus of HA2 and is only presented after proteolytic cleavage of 
the precursor HA0 
[50]. 
 
Figure 2-4: The structure of uncleaved influenza A virus hemagglutinin subtype H1. Homotrimeric structure 
from the side (A) or the top view (B) orientation as well as the HA monomer (C) are color-coded as followed: 
HA1 subunit in violet, HA2 subunit in wheat with the fusion peptide in green. The globular head region contains 
the receptor-binding site (RBS) and is indicated by the star symbol. The stalk-like domain mainly consisting of 
HA2, the N- plus C- terminus of HA1 and harbors the active cleavage site (D). Cleavage occurs after an arginine 
residue and is indicated with an arrowhead. Figure was made with PyMol on the basis of the protein data bank 
(PDB) code: 1RD8. 
The proteolytic cleavage of HA0 into the subunits HA1 and HA2 is an essential step in the 
hemagglutinin-mediated virus uptake and thus virus spread and infectivity [51, 52]. Major 
consequences of the activation cleavage are the generation of an HA1 C-terminus and an HA2 
N-terminus, the latter containing the fusion peptide [53]. Post cleavage, the fusion peptide is 
hidden within the hemagglutinin homotrimers (see Figure 2-5 B). For HA fusion potential, 
several irreversible structural rearrangements of the HA, as a result of acidification, are 
required. At a pH of 5.0 – 6.0 (depending on the virus strain) the fusion peptide residues are 
relocated to the same end as the C-terminal end of the polypeptide chains close to the membrane 
* 
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anchor domain [54]. This rod-like low pH structure is considered to be the most stable HA 
conformation. 
 
Figure 2-5: Homotrimeric structure of HA3 of A/Aichi/2/68 virus (H3N2 subtype). A: Uncleaved H3-HA0 
with the cleavage loops in red and green sticks. Arrows indicating the cleavage site. B: Insertion of the HA2 N-
terminus into the trimer interior post cleavage. The HA1 subunits are shown in blue and HA2 subunits in gray. 
Figure was taken from literature [54].  
Depending on the cleavage motif of the respective HA strain and the host organism, different 
host proteases can catalyze the HA0 activation cleavage. In general, the number of basic amino 
acid residues, namely arginine and lysine, and the cleavage site sequence determine the 
pathogenicity of the virus [42, 49, 55]. HAs of LPAIVs, including H1 (as in H1N1) and H3 (as in 
H3N2) have monobasic cleavage sites. In contrast, HPAIVs such as certain H5- and H7-HA 
possess multibasic cleavage sites. HAs with multibasic cleavage sites of R-X-R/K-R↓G-L-F or 
R-X-X-R↓G-L-F with X as a non-basic amino acid can be proteolytically activated by 
ubiquitous present furin and furin-like proteases. Since these proteases are found throughout 
the host body they contribute to severe systemic infections [49]. Host cell proteases that activate 
LPAIV are mainly trypsin-like serine proteases including soluble serine proteases such as 
tryptase Clara [56] or plasmin [57] and membrane-anchored serine proteases, including the 
transmembrane serine S1 member 2 (TMPRSS2) [58-62] and matriptase [63, 64]. The epidemic 
annual infections from LPAIV are restricted to the aerodigestive tract. Viral spread is therefore 
limited to these organs, which makes it easier to be controlled by the immune system.  
2.3. Trypsin-like serine proteases 
Proteases catalyze the hydrolytic cleavage of peptide bonds. Almost one third of these proteases 
have a nucleophilic serine residue (along with histidine and aspartate) at the active site and are 
therefore classified as serine proteases. Trypsin-like serine proteases represent the largest 
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family of serine proteases and play essential roles in many important biological processes 
including blood coagulation (thrombin and factor Xa), food digestion (trypsin), fibrinolysis 
(uPA, tPA, and plasmin) or immunity (tryptase). Due to their high structural similarities, the 
amino acid residue numbering of the respective SPD follows the chymotrypsinogen numbering, 
since the catalytic mechanism was elucidated by the X-ray structure of chymotrypsin in 1985 
[65]. 
2.3.1. Characteristics of trypsin-like serine proteases 
As mentioned above, members of the trypsin-like serine protease family share high structural 
similarities. They have two six-stranded asymmetrically arranged β-barrels that host the 
conserved catalytic triad of His57, Asp102 and Ser195 at their interface (Figure 2-6). Peptide 
bonds are preferentially cleaved from these proteases following the amino acid residues 
arginine or lysine, mainly caused by the presence of the negatively charged Asp189 at the 
bottom of the S1 pocket [66]. 
 
 
Figure 2-6: Superimposition of three serine proteases of the S1A fold. Chymotrypsin (red), thrombin (blue) 
and matriptase (wheat) share a high structural similarity. The catalytic triad of chymotrypsin (consisting of the 
residues H57, D102 and S195) is highlighted in sticks with green carbon atoms. Figure was made with PyMol on 
the basis PDB codes: 1CBW (chymotrypsin) 2GV6 (matriptase) and 3EQ0 (thrombin). 
Trypsin-like serine proteases (and also chymotrypsin) are principally expressed as inactive 
zymogens that require catalytic activation by other proteases or by an autocatalytic manner. 
After cleavage of the peptide bond between residue 15 and 16 (Arg15 and Ile16 for 
chymotrypsinogen), the active enzyme form is stabilized by polar interactions between the new 
amino-terminal group of residues 16 and the conserved residue Asp194 (in the interior of the 
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molecule). Since trypsin-like serine proteases control many physiological processes, the 
expression as inactive zymogen prevents uncontrolled proteolytic degradation and allows tight 
control of enzyme activity. In addition, zymogens can be stored in larger quantities and the cell 
can rapidly provide high amounts of active protease when required. The presence of 
endogenous inhibitor proteins, such as protease inhibiting serpins, including antithrombin and 
antitrypsin, and Kunitz-type serine protease inhibitors tightly control the enzyme activity. Due 
to the inactive zymogen form and inhibitor-bound enzymes, the protease activity does therefore 
not necessarily correlate with its expression level.  
Many well-characterized members of the trypsin-like serine proteases, including trypsin itself, 
are soluble proteases that are secreted into the extracellular space. More recently, a subgroup 
of trypsin-like serine proteases had been identified that are anchored in the cell membrane by a 
transmembrane domain either on the C- (type I) or near the N-terminus (type II) or via a 
glycosylphosphatidylinositol (GPI) linkage. 
2.3.2. Type-II transmembrane serine proteases  
With 17 members in humans, the type II transmembrane serine proteases (TTSPs) represent the 
largest group of membrane-anchored serine proteases [67, 68]. All TTSPs share the structural 
organization of an N-terminal cytoplasmic domain, a transmembrane domain and an 
extracellular domain comprising of a variable stem region of 1 – 11 protein domains of six 
different types and a serine protease domain (SPD) of the chymotrypsin-like S1A fold at the C-
terminus. Based on similarities of the domain structures and amino acid sequences, the TTSPs 
have been divided into four subfamilies: the hepsin/TMPRSS, the matriptase, the corin and the 
HAT/DESC subfamily (Figure 2-7). 
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Figure 2-7: Schematic overview of the TTSP subfamilies. All TTSPs consist of an N-terminal cytosolic portion, 
a membrane anchoring domain and a variable stem region with the SPD at the C-terminus. Based on similarities 
of the extracellular portion, TTSPs are divided into 4 subfamilies: corin, HAT/DESC, hepsin/TMPRSS and the 
matriptase subfamily. 
Hepsin/TMPRSS subfamily 
With seven members, including enteropeptidase, hepsin, TMPRSS2, TMPRSS3, TMPRSS4, 
TMPRSS5 and MSPL (mosaic serine protease large-form, also TMPRSS13) the 
hepsin/TMPRSS subfamily is the biggest representative. All members of the subfamily contain 
a group A scavenger receptor cysteine-rich (SRCR) domain upstream the SPD and almost all, 
except hepsin and TMPRSS5, have an additional low-density lipoprotein receptor A (LDLRA) 
domain. Enteropeptidase (also named enterokinase or EK) is the most prominent TTSP and is 
well-studied because of its essential role in food digestion. It possesses a more diverse stem 
region of seven domains including a single sea urchin sperm protein, enterokinase, and agrin 
(SEA) domain, two LDLRA domains, two C1r/s, urchin embryonic growth factor and bone 
morphogenetic protein 1 (CUB) domains, one meprin, A-5 protein, and receptor protein-
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tyrosine phosphatase mu (MAM) domain as well as the family characteristic SRCR domain 
upstream the protease domain. Proteases of the hepsin/TMPRSS family are predominantly 
expressed in fetal liver and kidney, prostate, lung as well as in the respiratory and parts of the 
gastrointestinal tracts.  
 
HAT/DESC subfamily 
The HAT/DESC subfamily comprises of five members, which exhibit the simplest modular 
stem region structure of only one SEA domain. Compared to the wider distribution of the 
hepsin/TMPRSS subfamily, the expression of HAT/DESC family members is limited to the 
upper respiratory tract [68, 69]. 
 
Matriptase subfamily 
The matriptase subfamily contains three highly homologous proteases, namely matriptase-1 (or 
simply matriptase), matriptase-2 and matriptase-3 as well as polyserase-1 with a rather atypical 
structure. Matriptase, matriptase-2 and matriptase-3 have very similar stem regions with one 
SEA domain, two CUB domains and three (for matriptase-2 and matriptase-3) or four (for 
matriptase) LDLRA domains. Polyserase-1 has a unique structure with three tandem serine 
protease domains and the ability to generate three independent serine proteases (i.e. Serase-1, -
2 and -3) the third of which is enzymatically inactive due to the lack of the catalytic serine 
residue [70]. Such as EK, matriptase is a very well-studied TTSP and was found to be broadly 
expressed by epithelial tissues in all organs examined [71, 72] and to be involved in several 
physiological processes as well as disorders and diseases. Expression of the other members is 
more restricted. 
 
Corin subfamily 
The smallest TTSP subfamily is the corin subfamily with corin as the single member so far. 
The stem region is composed of 11 domains, including two frizzled domains, eight LDLRA 
domains and one SRCR domain. Corin is mainly expressed in the heart and associated with 
hypertensis, heart and renal diseases [73]. 
2.3.3. Modulation of TTSPs activity 
The membrane anchoring of TTSPs contributes to cellular localization and trafficking. 
Membrane polarity and the epithelial to mesenchymal transition (EMT) influence the 
pericellular distribution. In polarized epithelial monolayers, plasma membranes are separated 
into apical and basolateral surfaces. Whereas matriptase is present on basolateral membranes 
[74, 75], TMPRSS2 is localized to apical membranes [76, 77]. The loss of membrane polarity, as it 
occurs in tumor cells, is thereby associated with mislocation. Due to ectodomain shedding [78], 
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also several soluble TTSPs, including EK [79], matriptase [80, 81] and human airway trypsin-like 
protease (HAT) [82] have been detected. 
Not only the SPD, but also extracellular domains (stem region) were found to affect protease 
activity. In case of matriptase, and potentially other similar members, zymogen activation is not 
only dependent on the activation cleavage after the respective arginine residue but also requires 
proteolytic processing at a conserved glycine residue in the SEA domain. In addition, mutations 
or deletions within the LDLRA domain, as well as lacking PTMs such as N-linked 
glycosylation in the CUB domain were found to restrict matriptase activation [72, 83]. Another 
example represents corin: a single nucleotide polymorphism in the frizzled domain [84] as well 
as the glycosylation status of the SPD were found to affect zymogen activation [85, 86]. 
Crystallographic characterization of a hepsin variant containing the complete extracellular 
domain revealed that the SRCR domain was rigidly bound to the back of the SPD [87]. It has 
been discussed that the stem region is an interacting partner of the exposed SPD surface and 
contributes to an appropriate orientation of the active site cleft [88].  
Each stem domain seems to contribute uniquely to the respective TTSP cellular localization, 
activation and inhibition and plays an important, yet not fully identified, role in the regulation 
of TTSP mediated pericellular proteolysis. Profound insight into different TTSPs is given in 
several comprehensive reviews [68, 78, 89-91]. Although much work has been done since the EK 
structure has been identified as the first TTSP in 1994, and several TTSP members are already 
very well characterized, still little is known about other members such as TMPRSS2.  
2.3.4. The role of TTSPs in biological regulation 
As most of the trypsin-like serine proteases, also zymogens of the TTSPs require proteolytic 
cleavage to achieve proteolytic activity. This zymogen activation produces a prompt and 
irreversible response to a physiological stimulus and initiates new physiological functions. 
Single-step activation reaction or a consecutive series (i.e. cascade) is possible. For the latter, 
at least two consecutive proteolytic reactions occur with one protease zymogen being the 
substrate of another previously activated protease. The involvement of serine proteases in 
zymogen cascades has been demonstrated quite early with the most prominent example EK. 
The protease is located in the duodenum and catalyzes the crucial conversion of trypsinogen to 
trypsin [92] which is essential for normal digestion and nutritional well-being [93]. Trypsin, in 
turn, initiates a cascade of proteolytic reactions in order to activate additional pancreatic 
zymogens such as chymotrypsinogen. In vitro, trypsin is able to cleave nearly every serine 
protease zymogen at the respective activation cleavage site, since it cleaves exclusively C-
terminal to an arginine or lysine residue [94, 95]. However, in vivo activation is most likely 
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catalyzed by specific proteases or is a result of auto-activation, whereas the protease activities 
are often regulated by endogenous inhibitors. In the case of many TTSPs, these specific 
endogenous activating proteases are still unknown. Figure 2-8 gives an example of the 
involvement of some TTSPs (red) in the blood coagulation (factor VII activation by hepsin [96]), 
extravascular fibrinolysis (pro-uPA activation by matriptase [81]) and the metalloproteinase 
pathways (pro-MMP3 activation by matriptase [97]). 
 
 
Figure 2-8: Membrane anchored serine proteases participate in zymogen cascades. In vitro and in vivo data 
suggest that TTSPs intersect the blood coagulation cascade (factor VII activation), fibrinolysis (pro-uPA 
activation) and the metalloproteinase pathways (pro-MMP3 activation). Red: TTSPs, green GPI anchored serine 
proteases, blue: non-membrane anchored serine proteases Figure was taken and modified from literature [89]. 
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3. Preparation and characterization of recombinant matriptase 
SPDs 
3.1. Introduction to matriptase preparation and characterization 
The membrane-anchored trypsin-like serine protease matriptase-1 belongs to the matriptase 
subfamily of TTSPs (Figure 2-7). Other names for matriptase-1 are membrane-type-serine-
protease 1 (MT-SP1), tumor-associated differentially expressed gene-15 (TADG-15), 
TMPRSS14, suppression of tumorigenicity 14 protein and epithin for the mouse analogue. The 
gene designation is suppression of tumorigenicity 14 (ST14). On protein level, the name 
matriptase will be used for sake of simplicity in this thesis.  
3.1.1. ST14 gene organization and expression 
Matriptase is a glycoprotein of 855 amino acids (aa) that consists of a short N-terminal 
cytoplasmic tail (aa residues 1-54), a transmembrane domain (aa 55-77) and a C-terminal 
extracellular portion (aa 78-855) (see Figure 3-1). 
 
 
Figure 3-1: Schematic overview of the mosaic protein structure of matriptase. Matriptase comprises of an N-
terminal cytoplasmic tail, a transmembrane domain and a C-terminal extracellular portion that includes one SEA 
domain, two CUB domains, four LDLRA domains and the peptidase domain (SPD). Matriptase is expressed as a 
zymogen that requires two activation cleavages. Cleavage sites are indicated with an arrow (↓). 
The extracellular portion comprises one SEA domain (residues 86-203), two CUB domains (aa 
214-334 and aa 340-447), four LDLRA domains (residues 452-486, 487-523, 524-561, and 
566-603) and the C-terminal trypsin-fold S1 SPD (residues 615-855) possessing the catalytic 
triad of His656, Asp711, and Ser805 (His57, Asp102 and Ser195 in chymotrypsinogen 
numbering). The non-catalytic modules appear to play an essential role in the cellular 
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localization, activation, endogenous inhibition and likely the specificity of matriptase against 
natural substrates [98]. The stem region also contains four putative asparagine-linked 
glycosylation sites and a potential integrin-binding RGD motif in the first CUB domain 
(UniProtKB - Q9Y5Y6). Matriptase is synthesized as a single-chain 95 kDa zymogen that 
requires physiological activation. The complex maturation process involves two sequential 
proteolytic cleavages as well as interactions with hepatocyte growth factor activator inhibitors 
(HAI-I and HAI-II). The first proteolytic processing occurs after the glycine residue Gly149 of 
the SEA domain within the endoplasmic reticulum (ER) or the Golgi apparatus. Hydrolysis of 
the peptide bond is thought to be of a conformation driven non-enzymatic and spontaneous 
manner as it has been shown for human MUC1 transmembrane mucin [99]. The SEA-cleaved 
70 kDa zymogen remains attached to the membrane by non-covalent interactions [100] and is 
associated with HAI-I. This matriptase/HAI-I complex is translocated to the cell surface where 
the second proteolytic cleavage event occurs between Arg614 and Val615 within a highly 
conserved activation cleavage site of RQAR↓VVGG (for schematic representation see Figure 
3-1 and Figure 3-2).  
 
Figure 3-2: Schematic representation of matriptase activation, inhibition and possible shedding from the 
cell surface. During activation, matriptase is first cleaved after Gly149 in the SEA domain before being 
translocated to the cell membrane. After the autocatalytic activation cleavage after Arg614, a 120 kDa complex 
with HAI-1 will be simultaneously formed. Due to shedding, this inactive matriptase/HAI-1 complex can be 
released from the membrane to the extracellular space [98]. 
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Mutation of any catalytic triad residue prevents the activation of the SPD indicating an intrinsic 
autoproteolytic activation mechanism of matriptase [72]. The disulfide-linked two-chain fully 
active matriptase is subsequently inhibited by HAI-1 but can be shed from the cell surface [98]. 
Due to ectodomain shedding, inactive matriptase/HAI-I or HAI-II complexes were also found 
as soluble complexes in milk [101, 102].  
The auto-activation cleavage seems to be influenced by the stem region, posttranslational 
modifications, the cellular localization of the protease and matriptase zymogen activity [103, 104]. 
Even though trypsin-like serine proteases are classically synthesized as inactive zymogens 
some exceptions exist. This includes pro-tPA, which has a significant zymogen catalytic 
activity due to special structural features [105]. Zymogen activity of matriptase has been 
discussed in the literature and was investigated by enzyme kinetic studies with a Biotin-Arg-
Gln-Arg-Arg chloromethyl ketone (CMK) and a transgenic mouse model [104, 106, 107]. The 
difference in activity between a pseudozymogen (imitating the SEA-cleaved 70 kDa zymogen 
form) and the 27 kDa activated SPD (R614 cleaved) of rat-matriptase has been shown to be 
unusually small with only a 27-fold higher activity of the SPD using a synthetic peptide 
substrate [108, 109]. A more recent study of TAMBERG and colleagues confirmed these results: a 
zymogen-locked (R614A mutated) matriptase form possessed 3 % of matriptase-SPD activity 
(zymogenicity factor of 33-fold). Both matriptase forms were recombinantly expressed in P. 
pastoris (zymogen) or E. coli (SPD) and measured in enzyme kinetic experiments using a 
chromogenic peptide substrate [110]. The matriptase zymogen has been shown to possess 
adequate levels of catalytic activity to not only facilitate autoactivation (in order to achieve full 
activity) but also to carry out its endogenous function including the activation of other zymogen 
forms in proteolytic cascades. 
3.1.2. Physiological function of matriptase 
Matriptase was first isolated in 1993 as a secreted gelatinase expressed by cultured human 
breast cancer cells [111]. Since then, matriptase expression has been found in many vertebrates. 
However, unlike most other TTSPs, matriptase is widely expressed in epithelial compartments 
of many embryonic and adult tissues. These include several organs such as skin, breast, 
pancreas, lung, intestine, reproductive and glandular epithelia [72, 103] as well as immune cells 
like monocytes, macrophages and lymphocytes [103, 112, 113]. More recently, matriptase mRNA 
has been detected in several regions of the brain with an enrichment in neurons and at higher 
levels in younger compared to older individuals [114]. The essential role of matriptase in the 
epithelia was initially discovered in matriptase null mice which revealed aberrant skin 
development resulting in death shortly after birth due to dehydration from compromised skin 
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integrity [115]. These mice are unable to process pro-filaggrin, an important protein in the 
arrangement of keratin filaments in the skin [116]. Furthermore, matriptase-deficient mice 
exhibited a defect in the formation of lamellar granules. These specialized secretory vesicles 
contain lipid material which is required for the formation of extracellular lipid lamellae within 
the cornified layer. Last, the mice displayed impaired formation of epidermal tight junctions 
within the granular layer [117, 118]. 
3.1.3. Endogenous matriptase inhibitors  
On protein level, matriptase activity is tightly regulated by the cognate cell surface Kunitz-type 
serine protease inhibitors HAI-I and HAI-II. The dysregulation of matriptase is associated with 
several diseases including osteoarthritis [119, 120], ichthyosis and various kinds of epidermal 
cancer [121-124]. A mutation of the glycine residue Gly827 (216 after chymotrypsin numbering) 
to arginine (G827R) within the active site of the SPD, which is involved in the binding of the 
P3 residue of substrates and substrate-analogue inhibitors, led to significant reduction of 
matriptase activity in vitro and has been found in individuals diagnosed with autosomal 
recessive ichthyosis with hypotrichosis (ARIH). Characteristics of ARIH include thickened, 
scaly and shiny skin with follicular hypoplasia [71, 125, 126]. Hypomorphic mice show high 
similarities to the phenotype of patients with ARIH, but in contrast to matriptase null mice, they 
have a normal survival [71]. Besides HAIs, the secreted serpins antithrombin, alpha1-antitrypsin 
and alpha2-antiplasmin complexes were reported to inhibit matriptase activity especially in 
cells with low expression levels of HAIs, such as leukocytes [102]. 
3.1.4. Substrate specificity 
The substrate specificity of matriptase was determined by the topology of the binding pocket 
based on several crystal structures by using a positional scanning-synthetic combinatorial 
library (PS-SCL) and by substrate phage techniques. The preferred cleavage sequences were 
found to be P4(Arg/Lys)-P3(Xaa)-P2(Ser/Ala)-P1(Arg)↓P1’(Ala) and P4(Xaa)-P3(Arg/Lys)-
P2(Ser/Ala)-P1(Arg)↓P1’(Ala), with Xaa being a non-basic amino acid [81, 127-129]. Thus, in 
contrast to trypsin, matriptase does not indiscriminately cleave protein or peptide substrates 
after lysine or arginine residues but prefers recognition of additional basic residues especially 
in P4 or P3 position. Based on predictions, the first matriptase substrates were identified in 
vitro, including the pro-form of urokinase-type plasminogen activator (pro-uPA), the pro form 
of hepatocyte growth factor (pro-HGF) and the protease-activated receptor 2 (PAR-2). All these 
extracellular surface proteins contain the preferred P4-P1’ matriptase cleavage site of PRFK↓I, 
KQLR↓V and SKGR↓S for pro-uPA, pro-HGF and PAR-2 respectively [130]. 
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3.1.5. Matriptase and cancer 
Over the last decade, several substrates had been shown to be activated by matriptase in vitro 
of which many are linked to cancer progression. Examples include the previously mentioned 
substrates pro-HGF [131], pro-uPA [81, 131, 132] and PAR-2 [81, 133], but also the pro macrophage-
stimulating protein (pro-MSP-1) [112], the matrix metalloproteinase-3 (MMP-3) [97] and the 
epidermal growth factor receptor (EGFR) [134]. For the latter, matriptase has shown to cleave 
the EGFR extracellular domain in FT-293 cells at the same sites it is cleaved by prostasin. 
Matriptase and prostasin can activate the pro-forms of each other, respectively (Figure 2-8). By 
this cleavage, the ligand-binding domains are hampering e.g. mAB drugs (such as Erbitux) to 
be effective. EGFR dysregulation in either way (up- or down-regulation) is causative for many 
different types of solid tumors. A significant induction of matriptase expression was however 
not observed in FT-293 cells [134]. 
The dysregulation of matriptase has been associated to a wide range of benign and malignant 
tumors of epithelial origin such as breast cancer [80, 111], prostate carcinoma [135], ovarian cancer 
[136], cervical cancer [124], gastrointestinal cancers and kidney tumors [103, 137]. For most cancers 
(e.g. breast, cervical, ovarian and prostate cancer), matriptase overexpression at mRNA or 
protein level has been linked with tumor progression [121-124, 135, 136, 138]. In contrast, other studies 
on breast, gastric, and colorectal cancer [139-141] reported a significant down-regulation of 
matriptase expression levels. In total, approximately 85 % of all cancers originate from 
epithelial cells. This indicates the potential value of matriptase as a prognostic marker and as a 
possible therapeutic target for cancer treatment. Most proteases involved in carcinogenesis are 
expressed by the connective tissue, supporting the epithelia. Unlike them, matriptase is 
expressed by the transformed epithelial cells themselves [142]. A recently published review of 
the LIST group gives a more detailed summary of the role of matriptase in cancer [143]. Besides 
its relevance in cancer, matriptase has been identified as a critical driver for other diseases, 
including osteoarthritis [144] and virus infections such as the influenza viruses H1N1 and H9N2 
[63, 145] and the human immunodeficiency virus (HIV) [146]. 
3.1.6. Matriptase in direct and indirect IAV activation 
Matriptase is able to cleave the hemagglutinins of certain influenza viruses directly or 
potentially contributes to virus infections by proteolytical activation of other proteases, which 
subsequently can cleave hemagglutinin [64]. For virus infectivity, the influenza virus 
hemagglutinin must undergo proteolytic activation either in the TGN (secretory pathway), at 
the cell surface, in the extracellular space or within endosomes. The HA-activation is a 
prerequisite that the virus achieves fusion competence. Matriptase was detected in human 
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bronchial epithelial cells and was characterized as a potential protease for proteolytic activation 
of hemagglutinin in the human respiratory tract [145]. In addition, soluble matriptase was found 
in nasal wash samples of healthy human donors. Based on the ability to be shed from basolateral 
and apical faces of polarized epithelial cells, matriptase may also serve as a functional 
extracellular protease [64]. Since the influenza virus infects from the apical surface and the 
membrane-bound form of matriptase primarily resides on the basolateral face of epithelial cells, 
it has been suggested that the shedded active matriptase form is more likely to be involved in 
HA cleavage in intact epithelia.  
Several studies demonstrated that matriptase efficiently cleaves HA subtypes H1 and H9 (of 
H1N1 and H9N2) but also shows low activity towards H2- and H3-HA (of H2N2 and H3N2) 
[63, 64, 145]. The knockdown of matriptase in Calu-3 cells (lung cells) led to reduced growth of 
H1N1 strains [145]. Virus replication of H9N2 was demonstrated in the kidney of chickens, 
where matriptase is highly expressed, and associated to increased mortality [147]. BARON and 
colleagues data support H9-HA activation in two kidney cell lines (MDCK-II and chicken 
embryo kidney (CEK) cells) of some H9N2 strains and additionally gave evidence of a possible 
matriptase involvement in H9-HA cleavage: Overexpressed H9-HA with R-S-S-R or R-S-R-R 
motif was cleaved by recombinant matriptase SPD in vitro [63]. Virus replication of some H9N2 
strains was also detected in the brain of mice [148] which is compatible with matriptase 
expression in neural progenitor cells and neurons [149]. In a more recent study, matriptase, 
among seven other serine proteases, was investigated for cleavage of various peptides 
mimicking the cleavage motifs of distinct HA subtypes in vitro. Only matriptase (besides the 
ubiquitously cleaving trypsin) showed cleavage activity towards H10-HA subtype (H10N8) 
[150]. Whereas matriptase cleavage activity towards H10 was only weak, another study showed 
80 % HA0 cleavage in H10 expressing cells by TMPRSS2 
[151]. In accordance with the latter 
study, recent in vivo data even suggest a TMPRSS2 dependency of H10-HA cleavage [152]. 
Besides H9N2, H7 and H5-HA of H7N9 and H5N1 HPAIV strains containing the multibasic 
cleavage motif R-K-K-R were efficiently cleaved by matriptase in the study of STRAUS and 
WHITTAKER. H7N9 and H5N1 are highly infectious IAV types causing systemic infections in 
birds. H7- and H5-HA were thought to be mainly activated by furin and furin-like proprotein 
convertases [153] and are only rarely transmitted to humans so far. However, if transmitted, the 
resulting infections lead to severe disease exhibiting a mortality rate of 60 % in the case of 
H5N1. The H5N1 is one of the most critically observed influenza strains by the authorities and 
is discussed as a possible elicitor for the next influenza pandemic [154, 155]. Whereas H7N9 was 
suggested to be also mainly activated by TMPRSS2 in vivo, HPAIV H5N1 was still successfully 
activated in TMPRSS2 deficient mice lungs resulting in animal death [61]. The first H9N2 
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lineage that caused human infection showed genetic relations to isolates from H5N1 IAV [156]. 
This, and the fact, that H9N2 isolates had shown dual or human-like sialic acid receptor 
specificity classify H9N2 as a strain with a high potential to infect humans [157]. Thus, cleavage 
activity of matriptase towards the discussed HA subtypes makes matriptase also an interesting 
target for influenza drug development not only to reduce mortality in poultry but also to be 
prepared for a future pandemic outbreak in humans. 
Besides TTSPs, including matriptase, TMPRSS2, TMPRSS4 and HAT, extracellular soluble 
serine proteases such as tryptase clara [56] and extracellular thrombolytic proteases such as 
plasmin, uPA and plasma kallikrein were also detected to activate certain HAs in vitro. In 
addition, some of these proteases, were found in the respiratory tract when the tissue was 
damaged due to influenza virus infections [158]. Matriptase, in turn, has shown cleavage activity 
towards some of these zymogen forms in vitro [64, 131], underlining also an indirect impact on 
influenza virus activation. 
3.1.7. Recombinant production of matriptase in E. coli 
For in vitro investigations of enzyme activity, ligand binding, crystallization, protein 
interactions and other functions, it is crucial to produce sufficient amounts of pure matriptase. 
The isolation of enzymes from its natural source oftentimes suffers from low amounts of the 
protein, resulting in cost-intensive and laborious purification protocols with unsatisfying 
results. Hence, recombinant protein production (RPP) has become the method of choice. In the 
last years, various expression systems were developed based on different host organisms 
including prokaryotes, yeast, insect- or mammalian cells. Each system has advantages and 
disadvantages and no "golden" standard protocol is available.  
Recombinant production and purification of the matriptase SPD have been reported from 
different groups including the expression in E. coli [159-161], and the two yeast organisms 
Saccharomyces cerevisiae (S. cerevisiae) [162] and Pichia pastoris (P. pastoris) [163]. The protein 
expression in E. coli is, compared to higher organisms, inexpensive, offers rapid culture times 
and the ability to achieve high biomass and high protein yields. Furthermore, the system can be 
easily modified and many well-investigated expression systems are commercially available. In 
case of matriptase and many other eukaryotic proteins, the main advantage to choose yeast cells 
over E. coli is their ability to perform posttranslational modifications (PTMs), including 
disulfide-bond (DB) formation, a major PTM that dictates the correct fold of a protein, provides 
protein stability and biological activity. Among others, the lacking availability of disulfide bond 
formation of E. coli is one reason that the overproduction of matriptase leads to the formation 
of so-called inclusion bodies, particles of densely packed and denaturized, hence inactive 
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protein molecules that accumulate in the E. coli cytoplasm. The protein refolding from 
denaturized inclusion bodies into the bioactive form is a cumbersome procedure and often 
results in poor recovery of active protein or is even not possible at all. However, the successful 
recovery from E. coli inclusion bodies of several transmembrane serine proteases has been 
described in the past, including matriptase [159, 160].  
Various modified E. coli expression systems are nowadays available to overcome the initial 
drawbacks, such as inability to form DBs, for example by redirecting the proteins to the 
bacterial periplasm, an oxidizing compartment with enzymes catalyzing DB formation and their 
isomerization [164, 165]. However, this approach often results in very low protein amounts which 
require intensive optimization. In the interest of efficiency, it is advantageous to utilize the 
simplest system possible for protein production. In our laboratories, solely the recombinant 
protein production using E. coli as a host organism is established. Furthermore, active 
matriptase has already been successfully recovered and purified from inclusion bodies. As a 
consequence, E. coli was also the host of choice in this thesis. 
3.1.8. Aims for matriptase production and characterization 
Matriptase is one of the best investigated TTSPs and has been linked to many diseases including 
cancer and influenza virus infections. This chapter describes the recombinant production of 
different matriptase variants in E. coli, including the characterization and crystallization. 
 
In detail, the goals of this chapter are: 
▪ the preparation of wild-type matriptase SPD using an existing expression system and 
protocol [159], 
▪ the establishment of a novel more cost-efficient expression system of a C122S mutated 
matriptase SPD variant (collaboration with VIKTOR MAGDOLEN, TU Munich), 
▪ the adequate preparation of pure C122S-matriptase for further experiments,  
▪ the comparison of both matriptase variants using enzyme kinetic parameters, 
▪ and the establishment of C122S-matriptase crystallization in our facilities. 
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3.2. Results and discussion of matriptase preparation and characterization 
The heterologous production of recombinant proteins in E. coli is a common method to produce 
large quantities of the target protein, which is essential for its proper functional and structural 
characterization. So far, all protocols for the preparation of matriptase using E. coli resulted in 
the formation of inclusion bodies. As a result, an additional refolding step is required. Even 
though protocols for isolation, purification and refolding of matriptase exist, such protocols 
need to be established and optimized in each laboratory independently. In this chapter, two 
different matriptase constructs were used for protein production in combination with two 
different commercially available E. coli expression systems. In both cases, a tag of six histidines 
was added N-terminally to the SPD domain for purification purposes. As a TTSPs, matriptase 
needs a free N-terminus of the amino acid residue 16 (chymotrypsinogen numbering) for proper 
folding of the active site and hence activity. Therefore, the following purification and refolding 
as inactive form, matriptase was activated by removing all amino acid residues upstream of 
residue Val615, which corresponds Val16 according to the chymotrypsinogen numbering. In 
doing so, also the six histidines (6His-tag) were removed after initial affinity purification. 
3.2.1. Production of wild-type (wt) matriptase  
For the expression of wt-matriptase using the pET/BL21 expression system (Merck, 
Darmstadt), a glycerol stock from 2008 was used. The cloning of the expression plasmid and a 
protocol for the preparation of the recombinant protein had been described earlier [159]. In the 
course of this thesis, matriptase was isolated, purified, refolded and activated based on this 
protocol with only slight modifications as described in the experimental part (Chapter 7). For 
an overview, the workflow is summarized in Figure 3-3. General activity of the prepared wt-
matriptase was visually monitored using the chromogenic substrate Mes-DCha-Gly-Arg-pNA 
(synthesized in-house). Since the protocol has already been established in our lab and the 
production of wt-matriptase did not show any deviations from earlier documented procedures, 
the individual preparation steps are not shown in detail. Following the last chromatographic gel 
filtration step, active wt-matriptase was flash-frozen in liquid nitrogen at a protein concentration 
of 0.3 mg/ml and stored at -80 °C. 
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Figure 3-3: Workflow of the wt-matriptase production. Wt-matriptase producing E. coli was cultivated from a 
glycerol stock and purified from inclusion bodies, refolded, concentrated and activated following instructions as 
described earlier [159]. After final gel filtration, wt-matriptase was stored longterm at -80 °C until it was used in 
further experiments. TFF: Tangential flow filtration. 
The wt-matriptase batch prepared within this thesis was applied in various experiments for the 
HA activation of certain influenza strains by DR. KORNELIA HARDES from our group and the 
group of PROF. FRIEBERTSHÄUSER (Institute of Virology, Department of Medicine, Philipps 
Universität Marburg). Furthermore, in the group of PROF. GÜTSCHOW (University Bonn) wt-
matriptase was used to demonstrate the efficacy of a fluorescent-labeled phosphono 
bisbenzguanidine as an activity-based probe for matriptase by electrophoresis and fluorescence 
detection in HPLC [166]. These experiments verified the activity and high purity of the prepared 
wt-matriptase. 
3.2.2. Production and characterization of C122S-matriptase  
For the expression of C122S-matriptase SPD, M15[PREP4] E. coli cells were transformed with 
the respective pQE-30_C122S_matriptase expression plasmid (kindly prepared and provided 
by VIKTOR MAGDOLEN, TU Munich). C122S-matriptase was isolated, purified, refolded and 
activated following a newly established protocol (see Chapter 7). Figure 3-4 A gives a brief 
overview of all steps of the C122S-matriptase preparation process including the in process 
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monitoring in form of SDS-PAGE (Figure 3-4 B) and the analysis of the final product by 
western blotting (Figure 3-4 C). A typical gel-filtration chromatogram as the final step in 
C122S-matriptase preparation is shown in Figure 3-5. 
 
Figure 3-4: Description of the C122S-matriptase production process and its monitoring. A: Workflow of the 
C122S-matriptase preparation process including all main steps: creation of the expression plasmid, the upstream 
process (transformation and cultivation) and the downstream process including the purification, refolding and 
activation. B: SDS-PAGE-analysis to monitor C122S-matriptase production. Samples were taken during every 
matriptase preparation step, separated in a 15 % SDS gel and stained with 1x Roti®Blue solution overnight. The 
photo was taken after 30 min incubation in the destaining solution. Lane 1-8: 1: cell lysate (8 M urea); 2: flow 
through after 1st nickel column; 3: elution peak of 1st nickel column; 4: after refolding via step wise dialysis (urea 
free); 5: activation with 5xHis-tagged enteropeptidase; 6: flow through of 2nd nickel column (active matriptase; 
reverse IMAC); 7: 1st peak of gel filtration chromatography (120 ml); 8: 2nd peak of gel filtration chromatography 
containing active matriptase (after 215 ml; immediate yellow staining by turnover of substrate Mes-DCha-Gly-
Arg-pNA). Green arrow: non-activated 6xHis-tagged matriptase (calculated size: 28.4 kDa); pink arrow: after 
removal of 6xHis-tag (activated form; calculated size: 26.4 kDa). M: PageRuler Prestained 10-180 kDa marker. 
C: Western Blot Analysis. After manufacturing, 10 µl of variable concentrations (50, 25, 10 and 5 µg/ml) of the 
final C122S-matriptase product were separated in a 12 % SDS Gel and blotted to a PDFV membrane. After 
incubation with a monoclonal α-matriptase primary and HRP-conjugated secondary antibody, matriptase was 
visualized using the substrate SuperSignal™West Dura in the ChemiDocTM Imaging System. One single 
concentration-dependent signal appeared at approximately 26-27 kDa. 
CHAPTER 3: PREPARATION AND CHARACTERIZATION OF RECOMBINANT MATRIPTASE SPDS 
_________________________________________________________________________________________________________________ 
 
 
28 
 
Figure 3-5: Gel filtration chromatogram of purified, refolded and activated C122S-matriptase using a 
Superdex75 prep grade column. Blue: UV absorption at 254 nm; red: conductivity; pink: pH; light blue: 
temperature; brown: pressure. The x-axis is given in ml, the y-axis shows UV absorption in mAU. The sample was 
separated into six peaks (P1-P6). Peak 2 (P2) was visually identified as the peak with the highest matriptase activity 
using the Mes-DCha-Gly-Arg-pNA substrate. Peak 3 showed low matriptase activity, and no activity was detected 
in fractions of peaks 1, 4, 5 and 6. 
The SDS-gel (Figure 3-4 B) shows that C122S-matriptase was successfully prepared following 
the above-mentioned workflow (Figure 3-4 A). The denaturated 6xHis-tagged protein can be 
isolated from the crude cell lysate by IMAC (lane 1-3), refolded by stepwise dialysis (lane 4) 
and activated by incubation with recombinant 5xHis-tagged enteropeptidase (lane 5). The 
activated protein was separable from the non-activated portion by reverse IMAC (lane 6) and 
finally be cleared up by gel filtration from misfolded or digested protein pieces as a result of 
the activation step (lane 7-8). The gel filtration chromatogram (Figure 3-5) shows six different 
peaks, with the first and largest peak after 120 ml (P1) and several non-completely separated 
multiple peaks at 215 ml (P2), 230 ml (P3), 245 ml (P4), 262 ml (P5) and 278 ml (P6). All 
peaks were collected separately and tested for activity by incubation with the substrate Mes-
DCha-Gly-Arg-pNA. The faster the initial colorless solution turns yellow, the more catalytically 
active matriptase is expected to be in the sample. The fractions containing peak 2 (peak 
maximum at 215 ml) showed immediate yellow staining, indicating the highest concentration 
of active matriptase. Fractions covering peak 3 stained light yellow after several seconds. 
Fractions of peak 1, 4, 5 and 6 did not show yellow staining after incubation with the 
chromogenic substrate, implying that these fractions do not contain active matriptase. The first 
peak (P1) is the by far largest one and therefore expected to be composed of molecules of the 
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largest size. However, after SDS-PAGE analysis, the peak was identified as a mixture of several 
smaller protein fragments between 10 kDa and 15 kDa (Figure 3-4 B, lane 7). A possible 
explanation for the early elution is the aggregation of these small protein fragments and hence 
the “imitation” of a larger molecule in the gel filtration chromatogram.  
The single protein band in lane 8 of Figure 3-4 B represents peak 2 after gel filtration. It was 
finally verified as matriptase in western blot experiments using a specific monoclonal α-
matriptase primary antibody (Figure 3-4 C). Only a single concentration-dependent signal is 
visible at the same height of approximately 27 kDa. This final C122S-matriptase product was 
further analyzed via positive electrospray ionization time-of-flight mass spectrometry (TOF MS 
ES+). The analysis was performed using C122S-matriptase in a concentration of 1 mg/ml in 
storage buffer by employees of the bioanalytic service division of the chemistry department at 
Marburg University. As shown in Figure 3-6, the most prominent peak of 26415 m/z exactly 
matches the expected calculated mass of 26421 Da, based on the C122S-matriptase primary 
amino acid sequence under consideration of the formation of three disulfide bridges within the 
protease domain (- 6 m/z).  
 
 
Figure 3-6: TOF MS ES+ spectrum of C122S-matriptase. Purified C122S-matriptase was used to perform a 
mass TOF MS ES+ spectrometry by the MarMass bioanalytic service division of the chemistry department at 
Marburg University. The most prominent peak represents matriptase with a mass of 26.415 kDa. The exact mass 
matches the calculated mass of 26.421 kDa (based on the amino acid sequence using ExPASy ProtParam) under 
consideration of the three essential disulfide bridges within the matriptase peptidase domain (- 6 m/z). 
3.2.3. Comparison of wt-matriptase and C122S-matriptase production efficiency 
Both matriptase variants were produced according to their respective protocols. During the 
process, protein concentration was monitored by UV/Vis spectroscopy at reasonable steps to 
compare the final yields and to reveal "weak" spots of each procedure. Since the C122S-
matriptase production cycle was performed several times during this thesis, only one 
representative cycle has been chosen for comparison. 
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Production of wt-matriptase started from 6 liters E. coli culture, leading to approximately 
150 mg protein after a first IMAC purification step with Ni-NTA. During the following steps, 
including the refolding, desalting and activation, accompanied by filtration, concentration or 
dialysis steps around two-thirds of precipitated protein were removed. In a second reverse 
IMAC step again using Ni-NTA as resin, the properly refolded and active wt-matriptase without 
the N-terminal 6xHis tag was separated from the non-activated protein still containing the six 
histidines N-terminally. Only approximately one-tenth of the starting protein concentration 
could be recovered in this step. After a final gel filtration chromatography step using a SEC75 
column, possibly aggregated or multimerized protein molecules as well as other impurities were 
removed and monomeric wt-matriptase molecules were collected in 1 x PBS. In total, 6 mg of 
pure and active wt-matriptase was prepared from 6 liters initial bacterial culture. This 
corresponds to a protein recovery of 4 % (Table 3-1).  
Table 3-1: Monitoring of protein yields during the wt-matriptase workflow 
Process step 
*6 liters E. coli culture 
Total protein 
[mg] 
Overall yield [%] 
After IMAC (1st nickel column) 150 100 
After Refolding and concentration 133 89 
After desalting and filtration 48 32 
After activation and filtration 43 29 
After 2nd nickel column and concentration 14.5 10 
After gel filtration (SEC75) 6 4 
 
In the case of C122S-matriptase, approximately 180 mg protein had been isolated via IMAC, 
starting from 12 liters bacterial culture. After the separation of activated and non-activated 
C122S-matriptase, 55 % (circa 100 mg) of the initial protein quantity was recovered by reverse 
IMAC. Following the final gel filtration step, the fractions with active C122S-matriptase 
(detected using Mes-DCha-Gly-Arg-pNA as substrate) were pooled. Starting from 180 mg 
protein, 3.5 mg monodispersed and active C122S-matriptase could be recovered in a standard 
purification cycle, representing 2 % of the initial starting protein concentration (Table 3-2) 
Table 3-2: Monitoring of protein yields during the C122S-matriptase workflow. 
Process step 
*12 liters E. coli culture  
Total protein 
(mg) 
Overall yield (%) 
After IMAC (1st nickel column) 180 100 
After dialysis and filtration (refolding) 170 94 
After activation and 2nd nickel 100 56 
After gel filtration (Sec 75) 3.5 2 
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The production of the wt-matriptase from the pET-BL21(DE3) expression system in 
combination with the rapid dilution refolding strategy was, with a 4 % recovery, more fruitful 
than the production of C122S-matriptase using the pQ30E-M15 expression system and the 
stepwise dialysis strategy for refolding (2 % recovery). In addition, the total protein amount per 
liter bacterial culture was higher in the case of the pET-BL21 system.  
The main difference between the two expression systems is the promoter, a short nucleic acid 
sequence upstream of the target gene, controlling the attachment of the RNA-polymerase to the 
DNA. The promoter directly controls the amount of generated transcript. In pQE-30 plasmids 
(C122S-matriptase), gene expression is under control of the IPTG inducible T5 promoter, 
which is recognized by E. coli RNA polymerase of any strain. In pET vectors, gene expression 
is under control of the IPTG inducible T7 promoter that is only recognized by the T7 RNA 
polymerase but not the E. coli RNA polymerase. The T7 polymerase needs to be provided in 
another plasmid and is commonly placed in the λDE3 genome, such as in case of all BL21(DE3) 
bacterial strains from Novagen (Merck, Darmstadt). The T7 polymerase is highly active and 
exclusively dedicated to the production of target gene transcripts, while the T5 promoter 
competes with other host promoters [167]. Up to 50 % of the total cell protein has been reported 
to be represented by the target protein when using the T7 promoter - T7 RNA polymerase 
system [168, 169], making it a popular system for recombinant protein production. Nevertheless, 
it is also possible that very high transcription levels can direct energy fluxes towards mRNA 
production and away from protein expression [170, 171]. Surely, the promoter could be one 
possible explanation for higher wt-matriptase yields. However, also age, fitness and colony-to-
colony variations are considerable reasons. Other bacterial strains, such as BL21(DE3)Gold and 
BL21(DE3)RIPL cells were tested briefly as an expression host for C122S-matriptase and 
showed more promising results regarding isolated quantity per liter bacterial culture than the 
M15 cells. For future expression experiments it is therefore recommended to screen for an 
appropriate E. coli strain in order to increase the protein production and reduce expression costs 
for C122S-matriptase. In the end, both expression systems deliver sufficient protein to start 
purification and the main optimization focus should address the recovery yield after refolding 
of the inclusion bodies. Many different factors can influence the refolding success rate, 
including protein concentration, refolding temperature, pH and the chosen refolding method 
including the refolding buffer composition. The main cause of low yields of properly refolded 
proteins is non-specific aggregations, which derive from interactions of hydrophobic cores 
between proteins during the refolding process. Regarding protein concentration, it is generally 
accepted that the lower the final protein concentration, the greater the refolding efficiency. In 
addition, it has been found that protein aggregation predominantly occurs at medium 
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concentrations of denaturants due to the formation of an unstable intermediate form, which is 
more likely to result in misfolded or aggregated protein. In Figure 3-7 A and B, the standard 
refolding methods rapid-dilution (orange) and stepwise dialysis (blue) are graphically 
described.  
 
 
Figure 3-7: Graphic description of one-step rapid-dilution and stepwise dialysis protein refolding methods. 
A: In rapid dilution approaches, the denaturant is removed rapidly by diluting the denaturized protein sample 
usually 1:50 - 1:100 in a denaturant free buffer. Parallel to the denaturant concentration, the protein concentration 
decreases equally. B: In stepwise dialysis refolding approaches, the denaturant is removed stepwise by multiple 
buffer exchanges. After each buffer exchange, the protein solution is allowed to equilibrate. During the procedure, 
protein concentration remains constant and buffer components are either removed or introduced.  
In rapid-dilution, the concentrated and denaturized protein is introduced rapidly into a 
denaturant free refolding buffer creating only a brief aggregation-promoting environment in the 
beginning. In contrast, during stepwise dialysis the denaturant concentration is lowered slowly 
resulting in a longer phase with critical middle denaturant concentration. However, the stepwise 
buffer exchange allows control over the conditions and timepoint when protein is exposed to 
the critical environment. Especially the composition of the refolding buffer is a key step in 
protein refolding that has been discussed thoroughly in literature [172-174]. Solvent conditions 
modulate various properties of proteins in aqueous solutions, including solubility, stability and 
the potential interaction with other molecules. In general, two main types of additives can be 
classified: folding enhancers (i.g. kosmotropes as protein stabilizers) and aggregation 
suppressors (chaotropes as aggregation inhibitors), with folding enhancer enhancing protein-
protein interactions, and aggregation suppressors reducing side-chain interactions [75, 175]. Table 
3-3 gives detailed information about the buffer compositions used for wt-matriptase in the 
rapid-dilution method and C122S-matriptase during the stepwise refolding. The main 
differences are a gradual introduction of L-arginine (Buffer 1 and 2) during stepwise dialysis in 
the case of C122S-matriptase refolding and the regulation of the redox-state to arrange proper 
conditions for correct DB formation. 
A B 
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Table 3-3: Buffer compositions for wt-matriptase and C122S-matriptase refolding. 
 
L-arginine is customarily used as low molecular chaotrope that has shown to inhibit 
intermolecular hydrophobic interactions leading to subsequent precipitation [172, 176] and to 
increase protein solubility. Typically used L-arginine concentrations in refolding buffers are 
0.5 M-2 M. For both matriptase variants, the minimum recommended concentration of 0.5 M 
L-arginine was used. In the case of C122S-matriptase L-arginine was adjusted to 0.5 M to 
stabilize the protein when denaturant concentration was lowered.  
The redox-state of the refolding solution is regulated by the addition of folding enhancers and 
is a critical step during refolding for correct disulfide bond formation. The mechanism of 
disulfide bond formation in proteins involves a series of thiol/disulfide exchange reactions. The 
DB formation can only occur when the thiol groups (SH) of two cysteine residues are positioned 
in a correct steric conformation to enable the thiol-disulfide exchange [177]. Once formed, they 
restrict the number of possible folding conformations for a given protein, resulting in a 
decreased entropy and increased thermostability [178]. In vivo, the disulfide bond formation is 
mediated by specialized enzymes, including the protein disulfide isomerase (PDI) in the ER. 
During in vitro renaturation, the DB formation is standardly mediated using redox shuffling 
systems to not only drive the formation by creating an oxidizing environment but also to enable 
wrongly formed disulfide bonds to be reduced again with the goal to achieve the most stable 
form over the kinetically favored folding form. Commonly used redox shuffling systems 
include reduced and oxidized glutathione (GSH/GSSG) or cysteine/cystine which are combined 
in a molar ratio from 1:1 to 10:1 in concentrations between 1-15 mM [179]. In the case of 
matriptase recovery, the GSH/GSSG redox shuffling system as used for C122S-matriptase does 
Refolding buffer Wt- matriptase C122S-matriptase 
  Buffer 1 Buffer 2 Buffer 3 
Urea --- 4 M 2 M 1 M 
Tris-HCl 0.05 M 0.05 M 0.05 M 0.05 M 
L-arginine 0.5 M 0.25 M 0.5 M 0.5 M 
NaCl 0.1 M 0.1 M 0.1 M 0.1 M 
CaCl2 0.02 M 0.02 M 0.02 M 0.02 M 
EDTA 0.001 M 0.001 M 0.001 M 0.001 M 
Cysteine-HCl 0.0005 M --- --- --- 
GSH --- --- 0.0025 M 0.0015 M 
GSSG --- --- 0.00025 M 0.00015 M 
Tween-20 --- 0.005 % 0.005 % 0.005 % 
Refolding method Rapid dilution Stepwise dialysis 
Final buffer 
0.05 M Tris-HCl 
0.15 M NaCl 
 
0.05 M Tris-HCl 
0.1 M NaCl 
0.005 % Tween-20 
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not seem to be beneficial over simply cysteine (the electron donor from the cysteine/cystine 
redox shuffling system) and air oxygen as used for the wt-matriptase refolding process. No 
clear advantage of stepwise introduction and removal of buffer components during stepwise 
dialysis for matriptase recovery could be confirmed under the given parameters. However, 
plenty of further stabilizing additives are available including kosmotropes, such as glycerol or 
polyethylene glycols (PEGs). Glycerol stabilizes proteins by enhancing the hydrophobic 
interactions caused by an increase in the solvent ordering around the proteins. An increasing 
glycerol concentration correlates with an increase in protein stability. PEGs have a stabilizing 
effect by binding to the intermediate form during protein folding or interact with hydrophobic 
side chains of the denaturized protein [180, 181]. The identification of the optimal combination of 
refolding buffer and protein concentration is essential, but also very time-consuming as mostly 
achieved using trial and error approaches. To address this, high-throughput (HT) automated 
refolding screenings have been developed [182-184] allowing to screen multiple combinations of 
buffer and protein concentrations at the same time. However, success is often difficult to 
determine when quantified standardly by turbidity only. Both matriptase variants from this 
thesis require an additional activation step after successful refolding. Therefore, the HT-
approach, as a quick screening method, is difficult and would be more suitable for matriptase 
variants containing the autocatalytic cleavage site where protein activity in addition to turbidity 
can be used for quantification to identify suitable buffer components. In terms of production 
costs, the limiting factor for the wt-type matriptase production following the given protocol of 
[159] is the activating enzyme TAGZyme DAPase (QIAGEN, Hilden). To process 50 mg of 
recombinant protein, the usage of 2.5 U TAGZyme DAPase Enzyme (costs approximately 
500 € (2017)) is recommended. In the preparation run of wt-matriptase, around 50 mg protein 
remained after the refolding step and represented the base for the calculations of the activation-
mix formulation. With 500 € per 3.8 mg properly folded and processed active matriptase solely 
for the activation, the production costs of wild-type matriptase are significantly higher 
compared to the production of C122S-matriptase. The decisive factor of C122S-matriptase 
production costs is L-arginine with an average price of approximately 100 € per kg. Even 
though C122S-matriptase production requires circa 2.5 times more L-arginine (depending on 
buffer volume) than wt-matriptase manufacturing, the cost factor does not overcome costs for 
DAPase. The activating enzyme for C122S-matriptase (5xHis-tagged recombinant 
enteropeptidase) was kindly provided by Viktor Magdolen (TU Munich) but can also be 
produced in-house since the respective plasmid (Addgene) and a detailed manual are 
commercially available [185]. This do-it-yourself option is missing in the case of the TAGZyme 
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DAPase from QIAGEN. To sum up, the higher recovery rate of 4 % compared to the 2 % in 
case of C122S-matriptase does not compensate for immense activation costs of wt-matriptase.  
Ultimately, the functionality and quality of the prepared enzyme are vital. Therefore, both 
enzymes were characterized in enzyme kinetic measurements.  
3.2.4. Functional comparison of matriptase variants using enzyme kinetic parameters 
Both matriptase variants (wt and C122S-matriptase) were compared in enzyme kinetic 
measurements using six different fluorogenic AMC substrates (synthesized in our group) 
containing arginine in P1 position. At a constant enzyme concentration, the AMC release was 
determined at seven different substrate concentrations. In Figure 3-8, the steady-state velocities 
(Y-axis) were plotted versus the substrate concentrations (X-axis). The MICHAELIS-MENTEN 
equation was applied to determine the kinetic parameters KM and Vmax from the hyperbolic 
curves and the enzymatic efficiency is described by the ratio of Vmax/KM. The results are 
summarized in Table 3-4.  
Due to un-evaluable results in active site titration experiments using the fluorogenic substrate 
4-Methylumbelliferyl 4-guanidinobenzoate (MUGB), the determination of kcat was not possible 
for matriptase samples. As described for several other trypsin-like serine proteases [186-188], this 
method can generally be used to determine the active protein portion in a sample using a 4-
Methylumbelliferone calibration line. Since the method was successfully used under the same 
conditions for thrombin as an in-house positive control, general equipment or method failure 
can be excluded. The term Vmax/KM is proportional to the term kcat/KM and describes the enzyme 
efficiency with the highest value representing the best substrate for an enzyme. Due to an 
unsuccessful active site titration, the concentrations of both matriptase preparations used for 
kinetic measurements were adjusted to a final concentration of 0.2 nM based on the protein 
content (UV measurement at 280 nm). The two matriptase variants (C122S-matriptase in Figure 
3-8 A and wt-matriptase in Figure 3-8 B) show the same preferences for each tested substrate, 
respectively. For both, the lowest enzymatic efficiency was found for the substrate MI-1319 
and the highest Vmax/KM values were identified for MI-507. Although enzymatic efficiency for 
MI-508 is at the same level, substrate MI-507 (Mes-DArg-Pro-Arg-AMC) was chosen for 
further measurements, since it had been also used for matriptase testing in recent studies in our 
lab [128]. These kinetic results prove on the one hand, that the single site-mutation C122S does 
not affect the catalytic property of wt-matriptase and on the other hand that the two refolding 
strategies result in active enzyme of equal quality. Only marginal differences in performance 
can be observed and might be based on batch-to-batch variations or be caused by the different 
ages of both preparations. Whereas the slightly less active wild-type matriptase batch was 
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produced in 2014 at the beginning of the work, the C122S-matriptase batch used for the enzyme 
kinetic measurement was produced more recently.  
 
 
Figure 3-8: Determination of the enzyme kinetic parameters KM and Vmax for both matriptase variants with 
AMC substrates. Six different AMC substrates were measured at six concentrations using a constant amount of 
matriptase. The kinetic parameters KM and Vmax were determined using the MICHAELIS-MENTEN equation. 
Substrates MI-505(), MI-506 (), MI-1314 () and MI-1319 () were measured at 1.56 µM - 50 µM, whereas 
MI-507 (), MI-508 () were measured at a concentration between 3.13 µM - 100 µM. A: C122S matriptase, B: 
wt-matriptase. 
Table 3-4: Enzyme kinetic parameters of the tested AMC-substrates. 
 
KM  
(µM) 
Vmax  
(ΔRFU/s) 
Vmax /KM  
(RFU/µM*s) 
MI Sequence P4-P1’ C122S wt C122S wt C122S wt 
505 H-DArg-Pro-Arg-AMC 14.3 
(± 3.275) 
18.8 
(± 2.253) 
0.09 
(± 0.010) 
0.07 
(± 0.001) 
0.0062 0.0037 
506 H-DArg-Gly-Arg-AMC 7.7 
(± 0.844) 
11.2 
(± 0.101) 
0.05 
(± 0.007) 
0.04 
(± 0.000) 
0.0065 0.0036 
507 Mes-DArg-Pro-Arg-AMC 6.5 
(± 1.184) 
6.3 
(± 0.001) 
0.40 
(± 0.086) 
0.27 
(± 0.003) 
0.0620 0.0430 
508 Mes-DArg-Gly-Arg-AMC 6.8 
(± 1.048) 
7.1 
(± 0.383) 
0.40 
(± 0.065) 
0.27 
(± 0.001) 
0.0588 0.0380 
1314 Mes-DArg-Val-Arg-AMC 10.0 
(± 1.178) 
12.0 
(± 0.739) 
0.09 
(± 0.014) 
0.06 
(± 0.000) 
0.0090 0.0050 
1319 H-DhPhe-Pro-Arg-AMC 36.8 
(± 6.955) 
41.7 
(± 4.855) 
0.14 
(± 0.023) 
0.09 
(± 0.003) 
0.0038 0.0022 
 
 
3.2.5. Crystallization experiments using C122S-matriptase 
So far, binding modes of in-house matriptase inhibitors could only be investigated in complex 
with the serine proteases thrombin and trypsin since the availability of sufficient quantities of 
matriptase was limited. In order to establish matriptase crystallization in our facilities, C122S-
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matriptase was produced and concentrated to 5 – 10 mg/ml, incubated with either benzamidine 
or an inhibitor of the 3-amidinophenylalanine type (compound 17 in Table 4-1) and used in 
hanging drop crystallization experiments in combination with various crystallization buffers. 
Since properly purified monodispersed C122S-matriptase is still not superabundant for large 
screenings, first attempts included testing buffer conditions plus slight variations of already 
published matriptase crystallization conditions [159, 162, 189-192]. These screenings resulted mostly 
in drops being empty (Figure 3-9 A) or containing light (possibly crystalline, Figure 3-9 B) or 
dark precipitate (Figure 3-9 C). 
 
 
Figure 3-9: C122S-matriptase crystallization set up resulting in empty drop (A) or drop containing light 
precipitate (B), dark precipitate (C) or an overgrown protein crystal (D). C122S-matriptase at 5 mg/ml was 
subjected to crystallization experiments using the hanging drop vapor technique. Drops were monitored over time 
(up to 1 year) using a light microscope. Figures were taken 8 weeks after drop set up and incubation at 18 °C. 
Crystallization conditions for 5 mg/ml matriptase/10 mM benzamidine complex were described earlier including 
conditions used for A and B [159] as well as C [189]. For the crystallization experiment in D C122S-matriptase was 
incubated with 1 mM of the 3-amidinophenylalanine-derived inhibitor 17. Crystallization buffer composited of 
100 mM Tris-HCl (pH 8.0), 200 mM MgCl2 and 30 % (w/w) PEG 5000.  
Since polyethylene glycol (PEG) was used as precipitant in several earlier protocols for 
matriptase crystallization [159, 190-192] a self-made PEG screen (screening for PEG 3000 
(25/30/35 %), 5000 (25/30/35 %), 6000 (20/25/30 %) and 8000 (16/20/24 %) in combination 
with 200 mM MgCl2 or 200 mM Li2SO4) was used. Crystallization of the C122S-
matriptase/inhibitor complex resulted in one strongly overgrown protein crystal (Figure 3-9 D). 
As crystal growth was not repeatable at the very same and varying (pH and precipitant 
concentration) conditions, the overgrown crystal was used for subsequent seeding experiments. 
96 different crystallization buffers from two commercially available screens “The PEGs Suite” 
and “The PEGs II Suite” (QIAGEN) were chosen. Buffers with a pH of 6.5 (0.1 M MES), 7.5 
(0.1 M HEPES) and 8.5 (0.1 M Tris-HCl) containing precipitant only or precipitant plus a salt 
were selected. Crystallization drops composited of 4 mg/ml C122S-matriptase/1 mM inhibitor, 
crystallization buffer and seeding stock (undiluted) in a ratio 3:2:1 were prepared and 
monitored. Several conditions lead to drops containing crystalline materials in form of needles 
or small splitter like pieces ( Figure 3-10 A-C) but no conditions could be identified leading to 
single well-shaped protein crystals suitable for X-ray analysis.  
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Figure 3-10: Seeding experiments with C122S-matriptase resulting in needles and splitter like crystalline 
material. Seeding was performed as described in the literature [193] using the hanging drop vapor technique. Drops 
were monitored using a light microscope. Figures were taken 4 weeks after drop set up and incubation at 18 °C. 
A: 0.1 M MES (pH 6.5), 0.2 M MgCl2, 25 % (w/v) PEG 4000 B: 0.1 M Tris-HCl (pH 8.5), 0.8 M LiCl, 32 % (w/v) 
PEG 4000; C: 0.1 M MES (pH 6.5), 25 % (w/v) PEG 550 MME. 
Although these results were more promising, C122S-matriptase is still too limitedly available 
for larger in-house optimizations. Therefore, C122S-matriptase was also subjected to a high 
throughput nanodrop screening at the crystallization laboratory MarXtal (Marburg, Germany), 
where small amounts of protein are sufficient to screen against multiple different buffer 
compositions in a nanoscale. Using a crystallization robot, three commercially available kits 
containing 96 conditions each were screened for optimal crystallization conditions of C122S-
matriptase in combination with benzamidine or inhibitor. Each condition was photographed by 
the Rock Image system over time in order to monitor crystal growth. After one year of 
incubation at 18 °C, a single box-shaped C122S-matriptase/benzamidine crystal appeared that 
was suitable for X-ray analysis (Figure 3-11).  
 
 
Figure 3-11: Single box-shape C122S-matriptase crystal grown after 1-year incubation at 18 °C. 7 mg/ml 
C122S-matriptase/10 mM benzamidine was mixed in a ratio of 1:1 with the respective crystallization buffer. After 
incubation for 1 year a box shape single well-defined protein crystal appeared.  
After a much shorter incubation period of 7 days, walnut-like C122S-matriptase/benzamidine 
crystals appeared in several tested conditions (Figure 3-12). This crystal form is suitable for 
optimizations and was subjected to seeding experiments (described below). In addition, few 
optimization worthy C122S-matriptase/inhibitor crystallization conditions could be identified 
(Figure 3-13) but were not further followed. 
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Figure 3-12: Walnut like C122S-matriptase/benzamidine crystals grow after 5-7 days in high throughput 
nanodrop crystallization experiments. 7 mg/ml C122S-matriptase/10 mM benzamidine was mixed 1:1 with 
100 mM CAPS (pH 10.5), 200 mM Li2SO4, 1.2 M NaH2PO4 and 0.8 M K2HPO4 (No. 2 of JCSG Core IV screen 
(QIAGEN)) and incubated in a sitting-drop experimental set up over 41 days. Crystals of a walnut shape appear 
after 7 days. After 10 days the crystals stopped growing and no further changes were visible for the next 31 days 
of incubation. 
 
Figure 3-13: Crystallization conditions for C122S-matriptase/inhibitor complex that are suitable for 
optimization. 5 mg/ml C122S-matriptase/1 mM inhibitor was mixed 1:1 with respective crystallization buffers. 
A: Microcrystalline material visible using the crystallization buffer JCSG Core IV buffer No. 53 (3.6 M Sodium 
formate, 10 % Glycerol), B: Quasi-crystals in condition 33 of JCSG Core IV screen (0.1 M Tris-HCl (pH 8.0), 
1.6 M Ammonium sulfate), C: Mix of microcrystals and quasi crystals in condition 45 of JCSG Core IV screen 
(1.26 M Tri-sodium citrate, 0.09 M HEPES (pH 7.5) and 10 % Glycerol). 
To further improve matriptase crystallization, crystalline material from the first high throughput 
nanodrop screen was used for seeding experiments following the guide “Microseed Matrix 
Screening (MMS) for optimization in protein crystallization” that was published in 2014 [193]. 
Introduced crystalline particles can act as a nucleation site for crystal growth in the new 
experiment. Since optimal conditions for crystal nucleation are hypothesized to often differ 
from the optimal conditions for crystal growth, the hit rate is thought to be increased with this 
method. Furthermore, de novo nucleation is one of the most (if not the most) critical point in 
crystallization. In typical seeding experiments the same conditions are used as the seeding 
crystals grew in with simply lowering supersaturation (e.g. by a lower protein concentration) 
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[194]. The MMS approach from D’ARCY is based on the introduction of crystalline material from 
an initial experiment into a variety of new and often unrelated crystallization conditions, as 
initially published in 2004 [195], using a robotic liquid-handling device to seed into sparse-matrix 
screens [196]. Two different seed stocks were prepared using crystalline C122S/benzamidine 
material that was not of sufﬁcient quality for structure determination by X-ray diffraction. From 
one crystal out of 288 tested conditions, crystal quantity was thereby improved to 4 crystals out 
of 192 screened conditions by MMS. However, these C122S-matriptase crystals appeared again 
only after a long incubation period of several months.  
 
Figure 3-14: Improved C122S-matriptase/benzamidine crystal morphology by MMS. 6.4 mg/ml C122S-
matriptase /10 mM benzamidine solution was mixed 1:1 with a mixture of buffers No. 10 (JCSG Core Suite III 
screen) or No. 49 (JCSG Core Suite IV screen) and the respective seeding stock in a ratio of 2:1. Well plates were 
incubated in a sitting-drop experimental set up at 18 °C. Single protein crystals appeared between 126 and 225 
days of incubation.  
HT nanodrop screening is used to find suitable starting conditions for further optimizations in 
a larger drop scale, which is required since conditions are often not simply 1:1 transferrable in 
scale-up experiments. However, larger drops are favorable since the crystal quantity per drop, 
as well as the crystal size increases with the drop-size. Even though MMS led to nicely shaped 
single matriptase crystals, the long incubation time is not optimal for optimization experiments. 
In contrast to this very long incubation time, in two crystallization conditions appeared 
crystalline material in the MMS already after only 1 day (Figure 3-15). If these crystals are 
simply salt crystals or represent protein crystals has to be clarified. However, in case these drops 
contain protein crystals these conditions are very promising. 
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Figure 3-15: Improved matriptase/benzamidine crystal growth by MMS. 6.4 mg/ml C122S-
matriptase/10 mM benzamidine was mixed 1:1 with a mixture of buffers No. 92 and 93 (JCSG Core Suite III 
screen) and a seeding stock in a ratio 2:1. Well plates were incubated in a sitting-drop experimental set up at 18 
°C. Multiple differently shaped crystals appeared after 1 day of incubation and grew for the next 4 days.  
 
3.3. Summary of matriptase preparation and characterization 
In this chapter, the preparation of two active recombinant matriptase SPD variants from E. coli 
inclusion bodies using two different refolding approaches had been described. Wildtype 
matriptase was recovered successfully following an already established protocol including a 
rapid dilution refolding approach. A single site mutated C122S-matriptase variant, containing 
an EK cleavage site to allow directed activation, has been created and its preparation in E. coli 
could be established. For the refolding of C122S-matriptase a stepwise dialysis strategy had 
been applied. Both refolding approaches result in high quality and pure enzyme with equal 
catalytic performance after subsequent chromatographic steps. In terms of production 
efficiency, the rapid dilution refolding strategy applied for wt-matriptase resulted in a higher 
percental recovery yield. However, the total recovery yield was, with 2 % for C122S-matriptase 
and 4 % in the case of the wild-type variant, generally low and relatively inefficient for both 
enzymes. Besides the refolding method itself, the refolding buffer composition is critical for 
the success of protein recovery and various factors influence the recovery success of 
denaturized protein. Temperature, pH and different additives are known to inhibit protein 
aggregation or enhance protein folding and were discussed as explorable variables to further 
optimize the recovery yield of recombinant matriptase. Lower recovery yields aside, the C122S-
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matriptase production strategy is more favorable over the wt-matriptase production in terms of 
production costs. 
In the course of this thesis, adequate amounts of pure high-quality C122S-matriptase could be 
recovered and subjected to further experiments, one of which was protein crystallization. After 
initial unsuccessful in-house approaches based on already published conditions and intensive 
manual screening for suitable conditions, C122S-matriptase was subjected to high throughput 
nanodrop crystallization experiments using a robot device and commercially available buffer 
screens. After a long incubation time of one year a suitable crystal was available for structural 
analysis. By applying an MMS approach using a seeding stock (prepared from crystalline 
material from the first HP-nanodrop experiment that was not of sufﬁcient quality for structure 
determination by X-ray diffraction) four more excellent looking matriptase crystals could be 
found. However, also these crystals again grew only after a long incubation time. In 
combination with seeding, two buffer conditions were identified which showed promising 
results for further optimization since crystalline material appeared already after 1 day. 
Nevertheless, both conditions are very similar and the crystals are of a different shape than 
others, which might indicate that these are salt, but not protein crystals. Even though matriptase 
crystallization requires optimization, in total 5 matriptase crystals were found during this thesis 
and can be used to determine the crystallographic binding mode of in-house inhibitors.
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4. Computer assisted matriptase inhibitor design and their 
characterization 
4.1. Introduction to matriptase inhibitor design 
A comprehensive insight into matriptase, including its multidomain architecture, physiology 
and its endogenous regulation as well as patho-physiology has been given in the previous 
chapter 3. The strong involvement in cancer but also in the infectious disease influenza shapes 
matriptase into an interesting therapeutic target. In general, precise structural information such 
as amino acid composition, surface charge, and architecture of the binding pockets at sufficient 
resolution are essential for the rational structure-based design of efficient inhibitors. The first 
crystal structures of matriptase SPD in complex with benzamidine or the bovine pancreatic 
trypsin inhibitor aprotinin were published in 2002 [162]. Since then, several crystal structures of 
the matriptase SPD in complex with synthetic inhibitors [159, 189, 191, 197], fragment antigen-
binding (Fab) derived inhibitors E2 and S4 [190, 198] or with its endogenous inhibitor HAI-I [163] 
have been solved and contributed to a thorough structural characterization of matriptase. 
However, as being able to recognize and cleave numerous strongly basic and therefore, 
relatively polar substrates, matriptase represents a challenging target for potential drug 
development. Efficient and selective inhibitors, that additionally exhibit appropriate 
pharmaceutical properties such as bioavailability and prodrug potential, are in demand. 
Conventional as well as computational approaches led to a large selection of very potent hits 
that lend themselves as candidates for further hit to lead optimization. This chapter concentrates 
on the identification of synthetic monobasic matriptase inhibitors of the 3-
amidinophenylalanine type in order to obtain a fair selectivity profile against the serine 
proteases thrombin and fXa. In principle, such amidino compounds can be easily converted into 
nonbasic prodrugs, like hydroxyamidines, as known from the development of the orally 
available thrombin inhibitor ximelagatran [199] or the combined orally active uPA and matriptase 
inhibitor mesupron [200]. A computer assisted approach was applied to reasonably choose 
promising starting molecules that come with the best compromise of effort and costs. 
4.1.1. Structure of matriptase SPD 
Based on the similarities to other SPDs of trypsin-like serine proteases, the commonly used 
chymotrypsinogen amino acid numbering is used to describe and analyze the structure of 
matriptase. Matriptase shares typical characteristic features including the catalytic triad with, 
His57, Asp102 and Ser195, the oxyanion hole created by the main chain NH of Gly193 and
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 Ser195 and the S1 specificity pocket with the characteristic Asp189 at the bottom (Figure 4-
1 B and C).  
 
 
Figure 4-1: Surface binding pocket representation (A) and secondary structure (B) of matriptase with a 
close-up of the S1 binding site including the catalytic triad (C). Protein surface (A) and secondary structure in 
cartoon (B+C) are colored in grey with slightly visible surface. Important residues are given in sticks. Pictures 
were made with PyMol using PDB code 1EAX. The S1 binder benzamidine is shown in green. Dashed black lines 
in C indicate interactions between residues of the catalytic triad or between benzamidine and matriptase. 
The matriptase S1 pocket is bordered by segments Val213-Cys220, Ser190-Ser195, Pro225-
Tyr228 and the disulfide bridge between Cys191 and Cys220. Variations within this region 
between trypsin-like serine proteases were mainly found at position 217, 192 and 190, with an 
Asp217, Gln192 and Ser190 for matriptase. The hydrophobic S2 site is well suited for 
accommodating small to medium-sized P2-amino acids but has shown some flexibility to also 
accept larger amino acids. Although the small alanine was found to be a preferred P2 residue 
[128, 201], the potential space restricting Phe99 of the 90-loop possesses a rotatable side chain that 
allows matriptase to also efficiently cleave substrates with larger P2 amino acids such as Phe 
or Leu [103]. A unique characteristic of matriptase is the nine-residue 60-insertion loop on top of 
the S2 pocket (yellow in Figure 4-1 A). The averted orientation of this loop results in an 
accessible active site cleft and its conformational flexibility helps matriptase to adapt to 
different ligands by forming a number of additional favorable interactions [162, 163]. Another 
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characteristic of matriptase is the S3/4-binding site that is formed by the four amino acids Phe97 
on the top, Phe99 on the right side, Trp215 at the bottom, and Gln175 on the left (as shown 
below in Figure 4-5), which can accommodate both, hydrophobic and cationic residues. 
Presumably cation/-interactions, /-interactions and an overall negative potential formed by 
the carbonyl groups of amino acids 96-98 and the side chain carbonyl of Gln175 contribute to 
the preferred binding of basic amino acids to this binding site. In the case of non-substrate like 
analogues, these adjacent binding sites are also referred to as proximal (for S2) and distal (for 
S3/4) binding pockets. In the following S1, S2 and S3/4, as well as proximal and distal binding 
sites are used for matriptase areas as shown in Figure 4-1 A. 
4.1.2. Inhibitors of matriptase 
 
Natural inhibitors 
A wide variety of natural and synthetic matriptase inhibitors has been described in the literature. 
Besides the most discussed cognate and endogenous matriptase inhibitors HAI-1 and HAI-2 
[129, 163, 202], other natural inhibitors include ecotin [160], SFTI-1 [203] and its derivatives [204-207] as 
well as mABs [190, 208]. Highly efficient molecules were observed with Ki values of  9.8 pM for 
a double mutated (M84R/M85R) ecotin variant [160] or 920 pM for SFTI-1 [203]. Starting with 
affinities of 50 pM, mABs, more precisely chimeric proteins of two linked single-chain variable 
region fragments (scFv) comprising of heavy and light antibody chains, have also shown a high 
affinity to matriptase [208]. Due to their high selectivity and low toxicology, antibodies are well 
suited as therapeutic reagents but are large of size and have a restricted oral bioavailability. 
More recently, very potent HAI-1 derivatives were published. A soluble inhibitor with a Ki 
value of 70 pM has been identified, where the inactive Kunitz domain (KD) 2 of HAI-1 was 
replaced by a chimeric variant of KD2/KD1 and additionally fused to the crystallizable 
fragment (Fc) domain of an antibody. However, in contrast to antibodies, the resulting KD1-
KD2/1-Fc HAI-1 derivative lacks a strong selectivity profile as it also shows low nanomolar 
affinities to kallikrein 4 (Ki = 8.0 nM; selectivity: 110-fold) and hepsin (Ki = 1.5 nM; selectivity: 
20-fold) [129]. 
 
Synthetic small molecule matriptase inhibitors 
Different types of synthetic inhibitors have been developed, including non-peptidic molecules 
as well as substrate and non-substrate like peptidic inhibitors. Examples for different inhibitor 
types including their inhibition constant for matriptase are summarized in Table 4-1 but are not 
all discussed in detail. 
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Table 4-1: Structures and inhibitory potency of different matriptase inhibitor types. 
Inhibitor type Structure 
 
 
Non-peptidic inhibitors 
Benzamidine, 
p-aminobenzamidine 
(S1 binders) 
 
Bis-benzamidine 
derivatives 
 
 
 
Peptidic inhibitors 
Peptidic phosphonate-
derivatives 
(irreversible) 
 
 
Substrate analogue 
inhibitors 
 
CHAPTER 4: COMPUTER ASSISTED MATRIPTASE INHIBITOR DESIGN AND THEIR CHARACTERIZATION 
_________________________________________________________________________________________________________________ 
 
47 
Inhibitor type Structure 
Covalent substrate 
analogue inhibitors 
 
Tertiary amides of 
sulfonylated 
3-amidinophenyl-
alanine 
 
 
 
3 [209]; 4 [191]; 5 [210]; 6 [211]; 7 [189]; 8 [166], 9 [128]; 10 [212]; 11 [213]; 12 [214]; 13 [201]; 14 [215]; 15 [216]16 [217]; 17 and 18 [218] 
Simply benzamidine (compound 1) inhibits matriptase with a Ki value of 390 µM. Introducing 
an amino function in para-position (compound 2) results in a four times more potent compound 
(Ki
 = 90 µM). Both compounds solely occupy the S1 binding site. Bis-benzamidines can further 
improve Ki values to the nanomolar range (208 nM, compound 3). Since benzamidine perfectly 
fits into the S1 pocket of trypsin-like serine proteases, it is often used as an arginine mimetic in 
inhibitor design. In case of matriptase, it is sandwiched between the parallel peptide segments 
Trp215-Cys220 and Ser190-Gln192 while the amidino group forms two salt bridges with the 
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opposing Asp189 carboxylate and the sid-chain OH of Ser190 (Figure 4-1 C) and Gly219 (not 
visible in Figure 4-1 C) side chain on both sides at the bottom of the S1 pocket. However, due 
to the similar architecture of the S1 pockets in most trypsin-like serine proteases, the design of 
selective inhibitors is quite challenging. Matriptase, in contrast to trypsin, does not 
indiscriminately cleave after lysine or arginine residues but requires recognition of additional 
residues surrounding the scissile P1-P1’ peptide bond especially in the N-terminal direction for 
efficient cleavage. Potency, but also selectivity can be achieved for compounds that also address 
adjacent binding sites, including the S2 and S3/4 binding pocket above Trp215. Very potent 
inhibitors with a decent selectivity profile against other serine proteases were already developed 
and are discussed later on.  
The most potent compound for matriptase so far is an irreversible covalent binding substrate 
analogue inhibitor with a Ki value of 11 pM (compound 13 in Table 4-1) possessing an arginyl-
ketobenzothiazole group at the C-terminus [201]. A more detailed overview of various matriptase 
inhibitor types is given in a recently published review [219]. 
4.1.3. Synthetic inhibitors of the 3-amidinophenylalanine type 
The amino acid 3-amidinophenylalanine (19, Figure 4-2) is a well-suited starting scaffold for 
the design of trypsin-like serine protease inhibitors. The benzamidine-function fits perfectly 
into the S1 pocket and the scaffold offers two different vectors for further optimization: the 
amino and carboxyl groups. A noteworthy member of this inhibitor type is Mesupron, an orally 
bioavailable hydroxyamidino prodrug of the 3-amidinophenylalanine-derived serine protease 
inhibitor of the second generation (compound 15 in Table 4-1, in development by RedHill 
Biopharma (Tel-Aviv)). Mesupron represents the first synthetic inhibitor of trypsin-like serine 
proteases targeting pancreatic cancer and inflammatory gastrointestinal diseases, which reached 
clinical phase II development. After oral administration, Mesupron is converted to the active 
inhibitor WX-UK1 (compound 14), initially designed as an uPA inhibitor (Ki = 410 nM). 
However, WX-UK1 also inhibits several other serine proteases in the nanomolar range 
including matriptase and thrombin (Ki value of 370 nM and 490 nM, respectively) 
[220]. By 
introducing a C-terminal basic group and replacement of the N-terminal sulfonyl group, the 
potency could be improved for matriptase to a Ki value of 46 nM in case of compound 20 (CJ-
730 in Figure 4-2 from Curacyte Chemistry GmbH, Jena), with a  poor inhibitory potency 
against uPA (Ki = 1.3 µM) at the same time 
[159]. The crystal structure of this compound in 
complex with matriptase (PDB code: 2GV6) revealed a compact Y-shaped inhibitor 
conformation (Figure 4-2 A) that is consistent with similar compounds in complex with 
thrombin or trypsin [221, 222]. The benzamidine moiety is typically sandwiched between 
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fragments of the S1 site and forms the earlier described interactions with Asp189, Ser190, and 
Gly219 at the bottom of the S1 pocket. Moreover, the backbone NH and carbonyl of the P1 
residue form an antiparallel -sheet interaction with the matriptase residue Gly216 (Figure 4-
2 B). These interactions are typical for inhibitors of the 3-amidinophenylalanine type. The 
frequently used C-terminal piperidide ring extends to the proximal S2 binding site. The terminal 
guanidinoalkyl group is surrounded by several water molecules and does not form direct 
contacts with matriptase (Figure 4-2 A). Since the distal S3/4 binding pocket remains 
unoccupied by the N-terminal naphthylsulfonyl group of inhibitor 20 (CJ-730), further 
optimizations included its modification with aromatic and basic residues. The most potent 
matriptase inhibitor of the 3-amidinophenylalanine type to date is the tribasic inhibitor 16 
(Table 4-1) with a Ki value of 80 pM 
[217]. The N-terminal basic moiety probably targets the 
distal S3/4 pocket and is most likely involved in cation-π interactions to Trp215 and Phe99 of 
matriptase.  
 
 
Figure 4-2: Structures of 3-amidinophenylalanine (19) and the 3-amidinophenylalanine-derived inhibitor 
CJ-730 (20) including its binding mode in matriptase. A was taken from literature [223], B is showing polar 
contacts between the inhibitor and matriptase. Figure was taken and modified from PDB code: 2GV6. 
Between 2006 and 2009 numerous matriptase inhibitors based on sulfonylated 3-
amidinophenylalanine with modified N- and C-termini were developed at Curacyte Chemistry 
GmbH. Some candidates showed improved potencies and decent selectivity towards other 
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serine proteases, including thrombin and factor Xa [159, 217, 224]. However, the multibasic and 
strongly polar character of most compounds limited their bioavailability. Therefore, in 
subsequent works it was focused on the exploration of potent derivatives with lower basicity 
[218]. Optimization of the substitution pattern on the N-terminal sulfonylated biphenyl moiety 
resulted in the potent, but still dibasic inhibitor 17 (Table 4-1, internal ID: MI-432) with a Ki of 
2 nM. The monobasic analogue bearing a cyclohexyl urea as a replacement of the C-terminal 
amino group (compound 18) retained high matriptase affinity (Ki value of 5.1 nM). Both, the 
dibasic compound 17 and the monobasic analogue 18 were tested in cell culture experiments 
and did not show any cytotoxic effects but effectively reduced the propagation of various 
LPAIV strains in infected cells at a concentration of 50 µM [63].  
Due to insufficient matriptase amounts available, the binding mode of inhibitor 17 was only 
determined by crystallization in complex with thrombin (PDB: 4E7R). As expected, the 
biphenyl moiety directs towards the distal S3/4 binding site. It interacts with side chains of 
amino acid Trp215 and Asn98 (para-chlorine). The ortho-chlorine points towards Glu217 but 
has a distance of 3.7 Å suggesting only a very weak possible interaction. The modeling of 
inhibitor 17 into matriptase suggested similar polar contacts of the P1 residue and a possible 
additional interaction of the para-chlorine to Phe99. Notably, all dibasic compounds with a C-
terminal 4-(2-aminoethyl) piperidine possessed an approximately three to six-fold higher 
matriptase potency than their monobasic analogues containing a nonpolar C-terminal residue 
[218]. However, in contrast to monobasic amidino derivatives, which in principle can be easily 
converted into a single noncharged prodrug as described for Mesupron (15), this dibasic 
analogue would require a second prodrug approach to convert also the terminal amino group 
into an uncharged residue. Meanwhile, several strategies for the design of amine prodrugs are 
known [225] but have not been used for matriptase inhibitors so far. 
4.1.4. Selectivity of matriptase tailored inhibitors towards thrombin and fXa 
Due to high similarities between the active-site structures of various trypsin-like serine 
proteases, it is challenging to find inhibitors with a high potency towards only one target. Many 
matriptase inhibitors and also the uPA phase-II prodrug Mesupron (including the activated form 
WX-UK1) show similar affinities towards thrombin and fXa. These two soluble trypsin-like 
serine proteases play important roles in the blood coagulation cascade, where the fXa containing 
prothrombinase complex generates thrombin, which in turn activates fibrinogen. Fibrin is the 
insoluble clotting protein that finally closes wounds (Figure 4-3). Inhibiting one of these 
proteases would decelerate or prevent wound closure and therefore might lead to excessive 
bleeding with severe consequences even after small injuries. 
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Figure 4-3: The role of thrombin and fXa in the blood coagulation cascade. Factor Xa and thrombin are part 
of the common blood coagulation pathway. Factor X can be either activated to fXa by proteases of the intrinsic or 
extrinsic activation pathway (indicated by the orange and green box). Active fXa catalyzes the conversion of 
prothrombin to thrombin that in turn activates fibrinogen to the polymerizing fibrin (blue box, common pathway). 
Thrombin also generates the transglutaminase fXIIIa, which crosslinks and stabilizes fibrin clots. Clot degradation 
is mediated by plasmin. 
For the drug development of matriptase inhibitors it is therefore necessary to not only focus on 
potency and bioavailability but also on selectivity against the named proteases. For all published 
matriptase tailored 3-amidinophenylalanine derivatives and also some bis-benzamidine 
derivatives the selectivity towards thrombin and factor Xa had been analyzed [159, 210, 217, 218, 224]. 
Exemplary compounds showing a good selectivity profile are summarized in Table 4-2 and 
include compounds with a selectivity of matriptase over thrombin that ranges from 210 to 6750-
fold and over fXa from 52 to 5250-fold.  
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Table 4-2: Selectivity profile of multibasic matriptase inhibitors. 
3-amidinophenylalanine derivatives 
                                                 Ki [µM]            
No. R Mat Thr fXa  
 
 
Compounds 22 and 23 [159]; 21 [217] and 24 [218]  
21 
 
 
 
0.004 
 
27 
[6750] 
21 
[5250] 
22 
 
 
 
0.005 
 
13 
[2000] 
15 
[3000] 
23 
 
0.002 
 
6 
[3000] 
9.5 
[4750] 
24 
 
0.008 
36 
[4500] 
1.2 
[150] 
Bis-benzamidine derivatives 
                                                Ki [µM]            
  No. R Mat Thr fXa 
 
25 
 
 
 
0.003 
 
2.2 
[730] 
0.50 
[170] 
26 
 
 
 
0.01 
 
2.1 
[210] 
0.52 
[52] 
27 
 
 
 
0.02 
 
4.2 
[210] 
1.6 
[80] 
 
 
Compounds 25-28 [210]  
28 
 
- 
 
0.006 
 
2.7 
[450] 
1.1 
[180] 
Mat: matriptase, Thr: thrombin, fXa: factor Xa; selectivity ratios (Ki Thr/Ki Mat or Ki fXa/Ki Mat) are given in 
box brackets. 
  
Although highly selective and likewise very potent matriptase inhibitors of the 3-
amidinophenylalanine type have been identified, they share the drawback of a dibasic or even 
tribasic character that is connected to decreased bioavailability. Therefore, the development of 
monobasic amidine compounds, which are convertible into hydroxyamidino-prodrugs as shown 
for Mesupron, is highly intended. First monobasic inhibitors of the 3-amidinophenylalanine 
type with Ki values starting from 24 nM were published in 2009 
[224] (Table 4-3 upper part). 
HAMMAMI and colleagues developed further monobasic derivatives with improved potency (Ki 
= 900 pM – 5 nM; Table 4-3 lower part) [218]. However, all monobasic analogues have a limited 
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selectivity profile towards thrombin and/or fXa with some of them being even more potent 
thrombin inhibitors (including compounds 29, 30 and 32 - 34). The highest selectivity (410-
fold) towards thrombin was achieved by inhibitor 35 with a Ki of 1.23 µM whilst retaining high 
matriptase affinity (Ki = 3 nM). Anyhow, with a Ki value of 10 nM this compound is also a very 
potent fXa inhibitor. The highest matriptase selective over fXa shows compound 34 with a 32-
fold selectivity. However, this compound is an even stronger thrombin inhibitor with an 
inhibition constant of 0.2 nM.  
Table 4-3: Potency and selectivity profile of existing monobasic 3-amidinophenylalanine derivatives. 
                                               Ki [µM]            
Compound 29-32: [224] No.      R Mat Thr fXa 
 
29 
 
 
0.028 
0.006 
[0.02] 
0.64 
[0.64] 
30 
   
 
0.024 
0.004 
[0.17] 
0.37 
[15] 
31 
   
 
0.087 
2.05 
[24] 
0.83 
[9.5] 
32 
       
 
0.03 
0.001 
[0.03] 
0.70 
[23] 
                                                Ki [µM]            
Compounds 18, 33-35: [218] No. R R1 n Mat Thr fXa 
 
33 
  
 
 
 
 
2 
0.002 
 
0.0008 
[0.4] 
0.05 
[25] 
34 
    
 
 
 
 
 
 
2 
0.0009 
 
0.0002 
[0.22] 
0.03 
[33] 
35 
 
 
 
 
 
0 
0.003 
 
1.23 
[410] 
0.01 
[3] 
18 
      
       
 
 
 
 
 
0 
0.005 
 
0.63 
[126] 
0.02 
[4] 
Mat: matriptase, Thr: thrombin, fXa: factor Xa; selectivity ratios (Ki Thr/Ki Mat or Ki fXa/Ki Mat) are given in 
box brackets. 
 
 For all three enzymes, numerous crystal structures are available that enable the detailed 
comparison of the specific binding sites. Matriptase has a Ser190 adjacent to Asp189 at the 
bottom of the S1 pocket resulting in a more hydrophilic but narrower S1 pocket compared to 
proteases of the Ala190 type such as thrombin and factor Xa [226]. Thrombin and matriptase 
both possess a unique 60-insertion loop on top of the S2 binding site (highlighted yellow in 
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Figure 4-4). Whereas the segment Tyr60A-Pro60B-Pro60C-Trp60D of thrombin results in a 
well-formed but more restricted S2 binding site, the 60-insertion loop of matriptase has an 
averted orientation resulting in an open and accessible active site cleft (Figure 4-4 A). 
Therefore, the part of the compound addressing the proximal binding site (C-terminal residue 
of 3-amidinophenylalanine derivatives) is instrumental to achieve selectivity of matriptase 
inhibitors over thrombin. The proximal S2 binding site of fXa, which prefers Gly in P2 position, 
is rather unspecific and small due to the presence of the relatively bulky Tyr99 on the tip of the 
90-hairpin loop [227].  
 
Figure 4-4: Surface representation and multiple sequence alignment of different protease domains of the 
S1A-fold. A: Surface representations of matriptase (PDB code: 2GV6), thrombin (PDB code: 4E7R) and fXa 
(PDB code: 5K0H) in grey with colored binding sites: S1 pocket in green, proximal S2 pocket in wheat and the 
distal S3/4 binding site in light blue. The characteristic 60 loops of matriptase and thrombin are highlighted in 
yellow. B: Multiple sequence alignment of chymotrypsin, matriptase, thrombin and fXa SPDs. Important regions 
for matriptase are highlighted including the 60-loop (yellow box), the 90-loop (grey box) and the Gln175 (red 
box). Alignment was done with Clustal Omega using the amino acid sequence from merops codes S01.001, 
S01.302, S01.217 and S01.216, respectively. 
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The distal S3/4 binding site of all three serine proteases has a hydrophobic character. Whereas 
this cavity is well defined in the case of thrombin and fXa, it is more open on the western side 
in the case of matriptase (Figure 4-4 A and Figure 4-5). In fXa this pocket has a box-shaped 
hydrophobic/aromatic cavity lined by aromatic side chains of Tyr99, Phe174 and Trp215 
whereas in matriptase the distal binding site is formed by the three aromatic amino acids: Phe97 
on the top, Trp215 at the bottom surrounded by Phe99 on the right and Gln175 on the left side 
(Figure 4-5). Both, fXa and matriptase, accept also basic residues and substitutions of the N-
terminal aryl ring in ortho- and para-position and numerous inhibitors with such substitutions 
were identified to exert high affinities for both proteases [217, 218]. 
 
 
Figure 4-5: Amino acid residues of the distal (S3/4) binding pocket of matriptase and fXa. Protease structure 
is given in grey cartoon. Important amino acid residues forming the S3/4 binding sites are shown in sticks and 
colored in green for matriptase and purple for fXa. The picture was made with PyMol using PDB codes 2GV6 
(matriptase) and 5K0H (fXa). 
The 90-loop as well as the non-conserved Gln175 have been identified as reasonable structural 
targets to achieve selectivity of matriptase over fXa. GOSWAMI and colleagues successfully 
targeted the side chain carbonyl of Gln175 with a 4-aminocyclohexyl moiety or the amidines 
of bis-benzamidine inhibitor types, including compound 5 (cyan in Figure 4-6 A) and 
compound 36 (light green in Figure 4-6 B). Compared to compound 5 (structure given in Table 
4-1), the amidino function in para-position of compound 36 is with 3.6 Å more distant and 
might only allow a very weak hydrogen bond interaction with the Gln175. However, a strong 
H-bond interaction to the carbonyl of Phe97 on top of the distal S3/4 binding pocket is 
suggested by the proximity of 2.8 Å. The Gln175 of both structures (Figure 4-6 C) exhibits 
some flexibility and can adapt to the respective compound.  
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Figure 4-6: Crystallographic binding mode of bis-benzamidines in matriptase superimposed with the model 
of inhibitor 17 of the 3-amidinophenylalanine type. Compound 5 in cyan (A) and compound 36 [191] in light 
green (B) were crystallized in complex with matriptase (PDB codes 4O97 and 4JZ1, respectively). Black dashed 
lines indicate polar interactions in the S3/4 binding site. Their distances (in Å) are given in yellow boxes. Important 
matriptase residues Phe97, Phe99, Gln175 and Trp215 are labeled and shown as sticks. The Gln175 is highlighted 
in green with a zoom-in alignment from both structures in C. The structure of inhibitor 36 is shown in the lower 
right and the structures of compounds 5 and 17 in Table 4-1.Ki values for matriptase, thrombin and fXa are given 
in the lower left. 
Binding mode comparison of compounds 5 and 36 with that of compound 17 (pink in Figure 4-
6 A and B, respectively) suggests an amidino function in meta-position to be favorable in order 
to target the Gln175 side chain also in case of the 3-amidinophenylalanine inhibitor type. This 
additional interaction with the S3/4 binding site might be advantageous for matriptase potency 
and therefore increasing selectivity over fXa, where Phe174 is located in that position (Figure 
4-5). To achieve an improved bioavailability, a non-charged hydroxy group could be used 
instead of amino or amidino groups as hydrogen bond donors in case of monobasic compounds. 
4.1.5. Computer assisted matriptase inhibitor design for drug discovery 
The drug development process is cumbersome, time consuming and expensive. It typically 
takes more than 10 years to develop one drug and costs have been estimated to be > 2 billion 
USD. Figure 4-7 shows the different phases from the initial idea to a new drug on the market. 
Computer aided/assisted drug design (CADD) is one of the most effective new methods for 
facilitating and expediting this process, thereby saving time, money and resources [228]. 
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Figure 4-7: Workflow of drug discovery. The process of drug development can be divided in five major phases 
including the lead identification (green), its optimization (pink), the ADMET related optimization and testing 
(orange) and the clinical phase (blue) before the approval phase by the respective authorities (red). Figure was 
modified from www.enzolifesciences.com. 
Virtual screening is a key area in CADD and can be divided into two main categories: structure-
based and ligand-based virtual screening. Ligand-based techniques are suitable for quickly 
retrieving analogues (i.e. similar molecules) of known active ligands. Thus, these approaches 
are very helpful when no structural information about the target is known. The most common 
structure-based approach is docking, which aims at predicting the binding mode of a ligand 
within the binding site of a protein. These predictions are carefully evaluated and then lead to 
hits, as well as an approximate estimate of the free energy of binding from the resulting complex 
(included in the docking score). CADD is vital in order to make rapid, yet reasonable 
predictions of the binding mode. However, docking has limits, as its purpose is to find the best 
compromise between the speed of screening and its accuracy. It is regarded as time-efficient, 
but the prediction of the binding affinity is only a rough estimation that is solely used for ranking 
(i.e. prioritize which compounds are more likely to bind favorably).  
Before the first crystal structure of matriptase was available, docking was used to predict the 
binding of compounds based on matriptase models. In this way, ENYEDY and team discovered 
15 new bis-benzamidine inhibitors of matriptase by docking against a comparative model built 
using thrombin as a template (e.g. compound 3 in Table 4-1) [209]. The binding of benzamidine 
to the S1 pocket was confirmed with the first matriptase crystal structure in 2002 [162]. In 2006, 
STEINMETZER and team published the two first and only structures with inhibitors of the 3-
amindinophenylalanine type in complex with matriptase so far, including compound 20 (Figure 
4-2). Based on these crystal structures, GOSWAMI and colleagues used docking for the structure-
guided discovery of substituted benzenes and were able to confirm their docking results by 
crystallization [210] (e.g. compound 5 in Table 4-1 and Figure 4-6). In 2015, GOSWAMI made use 
of docking for applying a fragment-linking approach and discovered new P1 serine amides, 
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which were substituted with benzamidine on the Ser side chain [197]. Again, crystallization 
helped to evaluate these docking results. Docking was also used by COLOMBO [201] to discover 
new peptidomimetic matriptase inhibitors and by AVRUTINA [207] and FITTLER[206], where new 
SFTI-1 variants have been designed. In general, docking of large molecules containing many 
rotatable bonds, such as inhibitors of the 3-amidinophenylalanine type is challenging and the 
outcome needs to be evaluated carefully. For every rotor, the number of possible conformers 
increases yielding a combinatorial explosion problem. The more rotatable bonds a molecule 
has, the less likely it is that the docking software finds the best conformer and reliably places it 
within the binding site. In the case of compounds with established binding modes, including 3-
amidinophenylalanine derivatives, the docking results can be reasonably directed. Several 
docking applications allow to fix specific interactions, thereby reducing the present rotors of a 
molecule and significantly increasing the robustness of docking results.  
In this thesis, docking was integrated in the SAR study to rapidly suggest compatible 
replacements of a given template inhibitor that might improve affinity but more importantly 
selectivity of our matriptase ligands with a known binding mode. 
4.1.6. Goals of computer assisted matriptase inhibitor design 
In collaboration with a computational and synthetic chemist as well as crystallographers the 
main goal of the project was to identify new potent monobasic matriptase inhibitors of the 3-
amidinophenylalanine type that show an improved selectivity against thrombin and fXa. In 
detail, the goals of this project were: 
- Computer assisted lead optimization with a focus on selectivity and bioavailability 
including the feasibility, 
- a SAR analysis including compound synthesis and determination of inhibitory effect on 
the target proteases matriptase, thrombin and factor Xa, 
- the determination of the crystallographic binding mode of selected compounds in 
complex with matriptase and/or related serine proteases, 
- the testing of selected compounds in cell culture regarding cytotoxicity and inhibitory 
effect on H9N2 influenza virus propagation (collaboration with the group of PROF. DR. 
FRIEBERTSHÄUSER, Institute of Virology).  
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4.2.  Results and discussion of matriptase inhibitor design and 
characterization 
This project was part of an interdisciplinary collaboration between different colleagues of the 
pharmaceutical chemistry department of the Phillips University of Marburg. The computational 
part was carried out in collaboration with the computational chemist DR. FLORENT CHEVILLARD 
(group of PROF. DR. KOLB). The synthesis and analysis of the compounds were performed by 
OLIVER PILGRAM, who works on his doctoral thesis in the group of PROF. DR. STEINMETZER. 
DR. STEFAN MERKL from CrystalsFirst GmbH performed the inhibitor soaking and measuring 
of matriptase and trypsin crystals. The structure refinement was carried out by the scientists DR. 
JANIS MUELLER and DR. STEFAN MERKL of CrystalsFirst GmbH.  
4.2.1. Selection of compatible building blocks 
The crystal structure of matriptase in complex with compound 20 (PDB code 2GV6, Figure 4-
2) was used as starting point for docking studies. In order to target specific amino acids in the 
distal matriptase S3/4 binding pocket the naphthyl moiety of compound 20 was replaced with 
a substituted biphenyl moiety, which can be obtained by SUZUKI coupling of an iodo-benzene 
core with various phenylboronic acids (see also compounds 16-18, Table 4-1). As compound 
20 is too complex for rapid docking simply m-iodobenzene methylsulfone was used as a 
surrogate compound. The benzene ring and the sulfone group were sufficient to have a shape 
reference for visual inspection of the docking poses. Using PINGUI, commercially available 
boronic acids were filtered and merged with the surrogate m-iodobenzene methylsulfone. All 
2000 resulting virtual products were docked and the top 500 virtual product docking poses 
(based on the docking score) were visually inspected. For each pose, the main quality criterion 
was the overlap of the methylsulfone benzene group with the crystal structure of compound 20 
in complex with matriptase (Figure 4-8 A). Upon fulfillment of this criterion, it was assumed 
that the remaining part of the compound in the S1 and proximal pocket would not significantly 
change. Compounds interacting with Gln175 were highly prioritized as this residue was the 
main target of the optimization regarding matriptase selectivity over fXa. Additionally, 
compounds containing an amine or amidine moiety were initially discarded due to limited 
bioavailability issues. The chosen surrogate compounds were docked with fXa and thrombin in 
order to assure an either unfavorable binding mode or a poor docking score. An unfavorable 
binding mode was thought to penalize the compound affinity, thus improving the selectivity 
towards matriptase. Under consideration of the used libraries, eight products were found to 
respect all the criteria. After evaluating the price and availability, four boronic acids retained 
(compounds 37-40, Table 4-4) that were subsequently subjected to compound synthesis. 
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Table 4-4: Boronic acids subjected to inhibitor synthesis (based on docking results). 
Selected boronic acids 
 
 
 
  
The docking pose of the virtual product containing boronic acid 40 is shown for each receptor 
in Figure 4-8. Docking proposes an interaction between the compound’s terminal hydroxy 
group and the Gln175 side chain of matriptase (Figure 4-8 A). Under the giving orientation and 
shape, no polar interactions are predicted to occur in the case of fXa (Phe174, see Figure 4-8 
B) and thrombin (Ile174, Figure 4-8 C). Indeed, the polar hydroxyl group is pointing towards 
the hydrophobic residues in case of fXa and thrombin, which is energetically unfavorable 
mostly due to the cost of desolvation.  
 
  
Figure 4-8: Predicted binding mode of the virtual biphenyl product containing the substituted phenyl ring 
of boronic acid 40 in matriptase, fXa and thrombin. The virtual product (green C-atoms) was created using 
PINGUI and subsequently docked with the respective protease. A: Predicted binding mode of the virtual product 
in matriptase in superimposition with compound 20 (PDB code: 2GV6, carbons in pink). The overlap of the sulfone 
benzene (sulfur in yellow, oxygen in red, phenyl rings in pink and green, respectively) was the main quality 
criterion for compound selection. B: Docking of the virtual product with fXa (PDB code: 5K0H). C: Docking of 
the virtual product with thrombin (PDB code: 4E7R). Protease binding sites are shown in cartoon style and 
important amino acids as sticks. The cyan dashed lines indicate predicted polar interactions between the ligand 
and the proteases including the interaction of the compound with the NH of residue Gly219, which is present in 
all three proteases. 
37 38 39 40 
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4.2.2. Compound synthesis 
The synthesis of the 3-amidinophenylalanine derivatives has been established in our 
laboratories after methods as described before [159, 217, 218, 224]. In the first step, 3-
iodophenylsulfonylated 3-cyanophenylalanine (Figure 4-9) is prepared and serves as the initial 
scaffold that is subsequently modified N- and C-terminally. In the first series, different 
inhibitors with a cyclohexyl urea portion at the C-terminus were synthesized. The bulky 
cyclohexyl urea has shown to prevent proper binding below the 60-insertion loop of thrombin 
and resulted in decent matriptase selectivity of a monobasic derivative (410-fold, see compound 
35 in Table 4-3) against thrombin [218]. While keeping the C-terminus constant, the N-terminus 
was modified in order to achieve additional selectivity over fXa. As for earlier monobasic 
derivatives [218, 224] an additional variably substituted benzene ring was linked to the 
phenylsulfonamide of the initial scaffold. The resulting substituted biphenyl-3-sulfonyl moiety 
was obtained by SUZUKI coupling of the halide core molecule with varying phenylboronic acids. 
All building blocks contained a hydroxymethyl group that was predicted to act as hydrogen 
bond donor and to interact with the side-chain carbonyl of Gln175 on the left side of the distal 
binding pocket of matriptase, whereas the inhibitors’ terminal phenyl ring should bind to Phe99 
on the right side via hydrophobic contacts. 
 
 
Figure 4-9: Simplified synthesis route of 3-amidinophenylalanine derivatives. 
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4.2.3. First compounds 
Following the simplified synthesis workflow in Figure 4-9, four inhibitors (Table 4-5) were 
initially synthesized using the previously chosen boronic acids. All compounds showed only 
medium inhibition of matriptase with Ki values between 0.11 µM-0.37 µM and all four 
compounds are additionally more potent thrombin inhibitors (Ki values of 0.014 µM-
0.098 µM). 
Table 4-5: Inhibition of matriptase, thrombin and fXa by monobasic inhibitors with varying N-termini. 
 
 
        Ki [µM]  
No. R Mat Thr fXa  
41 
MI-479 
    
                     
0.21 
0.042 
[0.2] 
1.31 
[6.2] 
42 
MI-482 
   
0.29 
0.097 
[0.33] 
1.88 
[3.4] 
43 
MI-481 
 
 
0.11 
0.098 
[0.89] 
1.02 
[9.3] 
44 
MI-480 
     
            
0.37 
0.014 
[0.04] 
2.66 
[7.2] 
Mat: matriptase, Thr: thrombin, fXa: factor Xa; selectivity ratios (Ki Thr/Ki Mat or Ki 
fXa/Ki Mat) are given in box brackets. 
 
Low matriptase affinities probably result from an unfavorable combination of the additional 
ethylene spacer between the piperidine and the cyclohexylurea as well as suboptimal 
substituents on the aryl moiety. From these four compounds, inhibitor 43 containing the N-
terminal 3-hydroxymethyl-4-fluorophenyl group, represents the most potent matriptase 
inhibitor (Ki = 0.11 µM) and shows the highest selectivity over fXa (9.6-fold). Compared to 
compound 41, compound 43 contains an additional fluoride in para-position of the terminal 
phenyl ring resulting in an affinity boost. The incorporation of fluorine atoms is a standard 
strategy to enhance affinity, metabolic stability and/or selectivity in pharmaceuticals [229, 230] 
and had been shown to also successfully improve inhibitory potency of matriptase tailored 
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compounds before [218]. Due to their high electronegativity, some halogens and especially 
fluorine atoms can interact with electropositive regions of receptor sites and therefore 
strengthen protein-ligand binding [231]. In the case of matriptase, substitutions in ortho- or para-
position (compound 46, 48, 49 and 51) with either fluoride [218] or chloride [217] resulted in 
increased matriptase but also fXa affinity compared to the non-substituted analogue inhibitor 
45 (Table 4-6). Halogen substitutions in meta-position showed a slightly reduced matriptase 
affinity compared to the other substituted aryls but resulted in higher matriptase over fXa 
selectivity (circa 60-fold, each). Compared to fluorine, chlorine is slightly less electronegative 
and can form halogen/-interactions due to a positive electrostatic potential located at the tip of 
the chlorine atom, the so-called σ-hole [232]. This σ-hole is absent in fluoride substituents. 
Table 4-6: Inhibition of matriptase, thrombin and fXa by known dibasic inhibitors containing N-terminal 
halogen substitutions. 
 
  
Mat 0.110 µM 
Thr 0.056 µM 
 fXa      5.4 µM 
 
 
 Ki [µM]            
No. R Mat Thr fXa No. R Mat Thr fXa  
46 
MI-403 
   
0.023 0.04 0.081 49 
    
0.03 0.01 0.70 
47 
MI-404  
0.052 0.04 3.2 50 
 
0.09 0.05 5.6 
48 
MI-405  
0.033 0.005 1.12 51 
 
0.03 0.01 0.91 
Compounds 45,49-51 from [217] and compounds 46-48 from [218]. Mat: matriptase, Thr: thrombin, fXa: factor Xa               
 
The present effect of the fluoride on the slight gain in affinity in the case of compound 43 
compared to compound 41 cannot be clearly determined at this point. However, since fluoride 
substituents are known to be able to form a wide array of interactions with carbonyl carbons or 
CH groups [231], its para-position probably facilitates such interactions by moving the fluoride 
close towards the protein surface. In contrast, the additional chloride in ortho-position of 
compound 42 does not improve affinity compared to the halogen-free analogous compound 41 
(Table 4-5). As the cyclohexyl urea with the additional ethyl linker of compounds 41-44 is not 
restricting thrombin affinity, the C-terminus was subsequently optimized (Table 4-7). 
45 
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Compound 35 (Table 4-3) with 2,4-dimethoxy substituted phenyl on the N-terminus served as 
a reference compound. 
Table 4-7: Inhibition of matriptase, thrombin and fXa by monobasic inhibitors with variable C-termini. 
Enzyme kinetic data revealed 4-tert-butylureido-piperidide of compound 54 as a suitable C-
terminus. In combination with 2,4-dimethoxyphenyl at the N-terminus it shows a 575-fold 
higher matriptase affinity compared to thrombin and is even more selective than the analogous 
compound 35 (Ki Thr/Ki Mat: 410-fold). Even though matriptase (Ki = 4 nM) and fXa (Ki = 
2 nM) are inhibited equally by compound 54 the 4-tert-butylureido-piperidide was chosen for 
further optimizations of the N-terminus. Since 3-hydroxymethyl-4-fluoridophenyl, as also used 
in compound 43, was the most promising N-terminus of the initial four compounds containing 
the docking based selected boronic acids, it was now submitted to synthesis in combination 
with the aforementioned C-terminal 4-tert-butylureido-piperidide. However, based on a mix up 
of boronic acids by the vending company the following compound 55 (Table 4-8) had been 
identified to contain the hydroxymethyl substitution in para- but not as intended in meta-
position. This mix up was detected after synthesis by NMR characterization and by enzyme 
kinetic measurements with a resynthesized reference compound as well as during structure 
refinement following crystallization of the respective compound in complex with matriptase 
(shown and discussed in 4.2.4). 
 
 
 
 
  
 
 
 
  Ki [µM] 
No. R Mat Thr fXa 
52 
MI-483 
 
0.020 
 
0.085 
[4] 
0.017 
[0.9] 
53 
MI-484  
0.003 
 
0.273 
[91] 
0.003 
[1] 
54 
MI-485 
 
0.004 
 
2.3 
[575] 
0.002 
[0.5] 
Mat: matriptase, Thr: thrombin, fXa: factor Xa; selectivity ratios (Ki Thr/Ki Mat or Ki fXa/Ki Mat) are given in 
box brackets.  
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Table 4-8: Inhibitory effect including the selectivity profile of compound 55. 
Intended structure Actual structure of compound 55 
 
 
 
 
  Ki [µM] 
 No. Mat Thr fXa Try 
1st synthesis - 
0.015 
(± 0.002) 
23 
(± 3.031) 
0.19 
(± 0.029) 
0.0006 
(N.D.) 
2nd synthesis - 
0.014 
(± 0.0001) 
22 
(± 1.8) 
0.16 
(± 0.011) 
N.D. 
Mean 
55 
(MI-1904)  
0.015 
 
23 
[1533] 
0.18 
[12] 
N.D. 
Mat: matriptase, Thr: thrombin, fXa: factor Xa, Try: trypsin; standard deviations are given in round brackets; 
selectivity ratios (Ki Thr/Ki Mat or Ki fXa/Ki Mat) are given in box brackets 
 
After repeated synthesis of compound 55 using a 3-fluoro-4-(hydroxymethyl)benzene boronic 
acid from a different vendor and detailed comparative analysis (data not shown) the structure 
of compound 55 as shown in Table 4-8 was further confirmed. With only a slight decrease in 
matriptase affinity (Ki = 15 nM) compared to compound 54 and significantly decreased 
thrombin affinity by a factor of 10 (Ki = 23 µM) compound 55 has an excellent matriptase 
selectivity over thrombin (1533-fold). In addition, also fXa affinity could be decreased from a 
Ki value of 2 nM (compound 54) to 180 nM in the case of compound 55, resulting in a 12-times 
higher matriptase affinity compared to fXa. 
4.2.4. Binding mode of inhibitor 55 in complex with matriptase, thrombin and trypsin 
In the following the binding mode of the monobasic compound 55 was determined in complex 
with matriptase, thrombin and trypsin protein crystals. Whereas trypsin was directly co-
crystallized with the inhibitor, matriptase and thrombin (thrombin experiments conducted by 
the PhD student ANNA SANDNER) were co-crystallized with benzamidine each before being 
soaked with compound 55. Matriptase and trypsin structures were refined based on molecular 
replacement. Final structures are available under PDB codes 6T9T for matriptase and 6T9V for 
trypsin. The binding mode of compound 55 in thrombin could not be determined based on the 
given electron density since only the benzamidine moiety was clearly placeable in the S1 
pocket. In matriptase and trypsin, compound 55 shows the typical Y-shape binding mode of 
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arylsulfonylated 3-amidinophenylalanine derivatives containing a C-terminal cyclic tertiary 
amide residue. Moreover, the central 3-amidionophenylalanine forms the typical interactions in 
the S1 pocket including the polar contacts of the amidino function to Asp189, Ser190 and 
Gly219 as well as the interaction between the H-bond of the sulfonyl oxygen to the NH of 
Gly219 (Figure 4-10 A and B). The antiparallel β-sheet interaction between the 3-
amidinophenyl backbone to Gly216 is also present but not highlighted in these figures. The C-
terminal 4-tert-butyl urea moiety shows a distinct orientation that differs between the matriptase 
(Figure 4-10 A) and the trypsin (Figure 4-10 B) crystal structure. Whereas trypsin prefers the 
axial position, matriptase has a higher affinity to the equatorial position (Figure 4-10 C), which 
is expected for sterically demanding substituents. Hence, in trypsin, the urea substituent is 
positioned perpendicular to the piperidine ring, while in matriptase, it points towards the same 
direction as the piperidine ring. As a result of this parallel orientation relative to the piperidine 
ring, the terminal 4-tert-butyl group of compound 55 points towards matriptase’s cation cleft 
that is formed by the carbonyl groups of Ile60 and Asp60B from the 60-loop above of His57 
and the carbonyl of Asp96. In contrast to matriptase, trypsin lacks a specific 60-loop resulting 
in an open non-well-defined area above His57. Even though electron density might suggest a 
partial axial position of the 4-tert-butyl urea moiety in the case of matriptase it could not be 
reasonably confirmed during refinement. However, both isomers are always present in solution 
(in DMSO-D6), as proven by double signals in the NMR spectra of the inhibitor (data not 
shown). The N-terminal para-hydroxymethyl group of compound 55 interacts with the side 
chain of Gln175 of both proteases, as the 3-hydroxymethyl-4-(fluoro)benzene was predicted to 
do by docking (Figure 4-8). In addition, the matriptase structure (Figure 4-10 A) suggests a 
preference of the para-hydroxymethyl group to interact with the Gln175 on the left side of the 
distal binding pocket instead of interacting with the carbonyl of Phe97 on the top, which was 
suggested by the modeled binding mode of the related inhibitor 17 in Figure 4-6 B. The overlay 
of compound 55 from the matriptase and trypsin structures in Figure 4-10 C also shows a 
varying orientation of the N-terminal aryl ring, resulting in a slightly different exposition of the 
fluoride. However, the 4-hydroxymethyl has a similar distance to the Gln175 with 2.8 Å and 
3.0 Å for trypsin and matriptase, respectively. Since the availability of matriptase crystals is the 
limiting factor for detailed analysis of compound binding modes, similar proteases such as 
thrombin [218] and trypsin [128] have been used so far to investigate the binding mode of novel 
compounds in our group. With the focus of matriptase selective inhibitors against thrombin, 
only trypsin represents an alternative to matriptase for compounds with very weak thrombin 
affinity. In addition, trypsin also harbors the non-conserved Gln175 (Figure 4-10 B) that was 
targeted in the inhibitor design of this study.  
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Figure 4-10: Crystallographic binding mode of compound 55 in complex with matriptase (A, green carbon 
atoms) and trypsin (B, wheat carbon atoms) including an overlay of both ligand structures (C). The protease 
surfaces in A+B are shown in light grey, important amino acids are labeled and shown as sticks. Black dashed 
lines implicate interactions between the compound and the respective protease. The distances (in Å) of the polar 
interactions between the hydroxymethyl group to the Gln175 side chain are given in yellow boxes. * indicates the 
missing phenyl ring in A of the matriptase Phe97 (not visible in the electron density).  
Based on the findings so far, a second set of compounds was synthesized. To retain a weak 
inhibitory potency against thrombin these compounds had the C-terminal 4-tert-butylureido-
piperidide in common. Varying N-termini were used in order to improve fXa selectivity and to 
investigate the influence of the variously substituted terminal aryl rings. As basic groups, such 
as amidine moieties, are known to suit well into the distal S3/4 binding pocket of matriptase, 
four dibasic compounds were included to compare the influence of aryl substitutions in para- 
and meta-position. The results are summarized in Table 4-9. 
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Table 4-9: Inhibition of selected serine proteases by monobasic inhibitors with varying N-termini. 
 
  Ki [µM] 
No. R Mat Thr fXa Try 
56 
MI-490 
  
0.0007 
(± 0.0001) 
 
2.6 
(± 0.64) 
[3700] 
0.009 
(± 0.001) 
[12] 
0.005 
(N.D.) 
 
57 
MI-495 
 
0.0008 
(± 0.0001) 
 
0.45 
(± 0.07) 
[560] 
0.084 
(±0.003) 
[100] 
0.0007 
(N.D.) 
 
58 
MI-493 
       
0.001 
(± 0.0001) 
 
1.3 
(± 0.23) 
[1300] 
0.0001* 
(± 0.00001) 
[0.1] 
N.D. 
59 
MI-494 
  
0.004 
(± 0.0006) 
 
0.55 
(± 0.11) 
[137] 
0.010 
(± 0.0009) 
[2.5] 
0.009 
(N.D.) 
 
60 
MI-1902 
      
0.059 
(± 0.006) 
 
0.49 
(± 0.049) 
[8.3] 
0.033 
(± 0.004) 
[0.6] 
N.D. 
61 
MI-1903 
  
0.011 
(± 0.0004) 
 
12 
(±1.4) 
[1090] 
0.060 
(±0.010) 
[5.5] 
N.D. 
62 
MI-491 
  
0.041 
(0.005) 
 
0.90 
(0.023) 
[22] 
0.024 
(0.0004) 
[0.59] 
N.D. 
63 
MI-1905 
  
0.020 
(± 0.0008) 
 
0.009 
(± 0.0002) 
[0.45] 
0.10 
(± 0.008) 
[5] 
N.D. 
64 
MI-1906 
 
a,b     
0.008 
(± 0.00007) 
 
0.26 
(± 0.020) 
[27] 
0.005 
(± 0.0003) 
[0.5] 
N.D. 
65 
MI-1907 
 a      
0.014 
(± 0.0005) 
 
0.012 
(± 0.06) 
[0.7] 
0.79 
(± 0.0003) 
[56] 
N.D. 
Mat: matriptase, Thr: thrombin, fXa: factor Xa, Try: trypsin; standard deviations are given 
in round brackets, selectivity ratios (Ki Thr/Ki Mat or Ki fXa/Ki Mat) in box brackets.  
*: slow binder.  
a: dehydroxylated byproduct of compound 63 synthesis.  
b: exact constitution of the hydroxymethyl and methyl substituent not known. 
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As expected, the four dibasic compounds 56-59 possess strong affinities to matriptase with the 
two compounds containing an amidine moiety (compounds 56 and 57) inhibiting matriptase in 
the picomolar range (700 and 800 pM respectively). With a 3700-fold higher matriptase 
affinity, compound 56 represents the most matriptase selective inhibitor over thrombin of this 
thesis but has only moderate selectivity over fXa (12-fold). Compound 57 (amidine in para-
position) shows the highest matriptase selectivity over fXa (100-fold). In parallel to compound 
55 (Figure 4-10), the binding mode of compound 56 with the amidino substitution in meta-
position on the terminal aryl ring was crystallographically determined in complex with trypsin 
(Figure 4-11). 
 
 
Figure 4-11: Crystallographic binding mode of compound 56 in complex with trypsin (A, PDB code: 6T9U) 
and overlay with compound 55 from PDB structure 6T9V (B). Compound 56 is shown with green carbon 
atoms, compound 55 in wheat. The green star (circled in A) implies the three missing methyl groups of the C-
terminal 4-tert-butyl moiety of compound 56 (structure shown in Table 4-9) that were not visible in the electron 
density during structure refinement. Selected polar interactions are given as black dashed lines. The distances (in 
Å) of the polar interactions between the amidine (compound 56) or hydroxymethyl group (compound 55) to the 
Gln175 side chain are given in yellow boxes. The protease surface (in A) is shown in light grey and important 
amino acids are labeled and highlighted in sticks. 
Compound 56 shows the typical interactions with the residues Asp189, Ser190, Gly219, and 
Gly216 (the latter not shown in Figure 4-11 A). In addition, the 3-amidine group on the biphenyl 
moiety interacts with the side chain carbonyl of Gln175, as did the 4-hydroxymethyl substituent 
of compound 55 (PDB code: 6T9V) (Figure 4-11 B). This suggests that H-bond donors in meta- 
as well as para-position of the N-terminal aryl ring prefer to form a polar interaction with the 
Gln175 side chain on the left side instead of the carbonyl of residue Phe97 on top of the distal 
binding site. At the C-terminus, the three methyl groups of the tert-butyl group could not be 
refined by the given electron density (indicated by the star in Figure 4-11).  
The replacement of the amidines in compounds 56 and 57 by aminomethyl moieties in 
compounds 58 and 59 caused a slight affinity reduction for matriptase (Ki values of 1 nM and 
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4 nM, respectively). The analogous monobasic compounds 60 and 61 with a hydroxymethyl 
replacing the aminomethyl are both even less potent matriptase inhibitors. With a matriptase Ki 
value of 59 nM compound 60 containing a hydroxymethyl substituent in meta-position shows 
a significant drop in affinity. Based on docking, the 3-hydroxymethyl was also predicted to 
interact with the Gln175 side chain. However, SAR results suggest only a preference of 
matriptase for meta-substituted dibasic compounds, but a clear preference for compounds with 
a hydroxymethyl moiety in para- instead of the meta-position. In general, matriptase potency 
of compounds 56 - 61 can be ranked by their Ki values depending on the terminal moieties as 
amidine (picomolar) < aminomethyl (one-digit nanomolar) < hydroxymethyl (two-digit 
nanomolar). Thrombin Ki values of these compounds vary between 0.45 µM – 12 µM, however, 
the inhibitory potency for thrombin is relatively weak due to the presence of the C-terminal 
tert-butyl urea group which is strongly disfavored by thrombin in most cases. Dibasic 
compounds containing meta-substituted amidine or aminomethyl biphenyls (56 and 58) are less 
favored by thrombin, instead, it prefers a hydroxymethyl group in meta-position as in 
compounds 60 and 62 in case of monobasic compounds. Compound 61 with the hydroxymethyl 
in para-position (Ki = 12 µM) is a 24-times less potent thrombin inhibitor than the meta-
substituted compound 60 (Ki = 0.49 µM). The addition of a fluorine atom to hydroxymethyl 
substituted phenyls (as in compound 55 and 62) further decreased thombin affinities compared 
to the analogous compounds (61 and 60) regardless of their substitution pattern. Since the 
additional fluorine does not (or only marginally) affect matriptase affinities, fluorine-containing 
compounds have an increased matriptase selectivity against thrombin. The introduction of a 
second fluorine and the influences on thrombin affinity and matriptase selectivity are currently 
under investigation. As for matriptase, compounds 56-61 are also strong to medium fXa 
inhibitors (Ki values between 0.1 and 84 nM) with meta-substituted derivatives 58 and 60 
showing an even higher affinity to fXa than to matriptase. For the mono- as well as dibasic 
compounds of this series, fXa has a clear preference for N-terminal biphenyl residues with 
meta-substitutions. Whereas the introduction of a fluorine in meta-position (compound 55 in 
Table 4-8) resulted in decreased fXa affinity compared to compound 61 (Ki values of 60 nM 
(61) and 180 nM (55)), no such effect could be observed for compound 62 (containing the 
fluoride substituent in para- and the hydroxymethyl in meta-position) compared to the halogen-
free analogous compound 60 (Table 4-9). Compound 63 was designed with two hydroxymethyl 
groups (in para- and meta-position) and therefore thought to show improved matriptase affinity 
by interacting with Gln175 and Phe97. With a Ki value of 20 nM matriptase affinity was 
moderate and only a 5-fold selectivity over fXa could be determined. More surprising was the 
fact that compound 63 is also a relatively strong thrombin inhibitor. With a Ki value 9 nM for 
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thrombin, the earlier determined restricting effect of the C-terminal 4-tert-butylureido-
piperidine was completely abolished by the introduction of a second hydroxymethyl group on 
the N-terminal aryl ring. Compounds 64 and 65 were isolated as byproducts during the final 
hydrogenation for the synthesis of compound 63. Compound 65 possesses a 56-fold matriptase 
selectivity over fXa and represents the most selective monobasic inhibitor of the 3-
amidinophenylalanine type so far (regarding fXa). However, matriptase (Ki = 14 nM) and 
thrombin (Ki = 12 nM) are inhibited equally strong.  
Enzyme kinetic measurements have identified the 3-hydroxymethyl substitution at the terminal 
aryl ring as unsuitable for the design of matriptase inhibitors of the given 3-
amidinophenylalanine type containing N-terminal biphenyl-3-sulfonyl groups. Reduced 
matriptase affinity and selectivity against thrombin was observed. Also, these compounds were 
more affine to fXa than to matriptase. In contrast, the para-position hydroxyl group results in 
monobasic compounds with excellent matriptase selectivity over thrombin, which is further 
increased by the addition of a meta-fluorine to the terminal phenyl ring. CRAMER and 
colleagues’ recent review discusses the effect of a single hydroxy group addition to compounds 
[233]. The hydrogen bond including this hydroxy group can be either highly advantageous in 
terms of binding affinity and selectivity or deleterious if geometric requirements of the 
interactions are not met. In general, the addition, removal or modification of a single hydroxyl 
group can cause an affinity shift by several folds. In this thesis, no beneficial effect and only a 
slightly negative effect on matriptase affinity could be observed but selectivity against thrombin 
was strongly improved by the 4-hydroxymethyl group. For matriptase, the crystal structure in 
complex with compound 55 shows an interaction of the hydroxymethyl and the Gln175. Based 
on the alignment of the crystallographic binding mode of compound 55 and 56 (crystallized in 
complex with trypsin) also a 3-hydroxymethyl should be in the right distance for the H-bond 
formation with the side chain of Gln175 (Figure 4-11). To investigate such specific ligand-
protein interactions the crystallization of the target protein in complex with the compound of 
interest is vital. Also, as more structures of similar compounds become available, the quality of 
further modeling studies will improve.  
Figure 4-12 shows the alignment of N-termini from compound 17 (yellow), 20 (white) and 55 
(yellow), as well as the virtual biphenyl product (pink) that was generated by PINGUI. Whereas 
the binding mode of compound 17, 20 and 55 was crystallographically determined (20 and 55 
in matriptase and 17 in thrombin), the positioning of the virtual product was predicted by 
docking, where the naphthylsulfonyl of compound 20 was used as reference. The 4-hydroxy 
biphenylsulfonyl of compound 20 and the 2,4-dichloro substituted biphenyl sulfonyl (of 
compound 17) have an aligned position in the matriptase S3/4 binding site. However, the 
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terminal aryl ring shows a slightly varying orientation by what the meta-fluorine in case of 
compound 55 points away from the matriptase binding site. The new matriptase crystal structure 
from this thesis (6T9T) can serve as a starting point to further improve predictions made by 
docking with regard to the optimal distance and angle of the hydroxyl group to the protein. Two 
points that were discusses by CRAMER to be crucial for the affinity and selectivity boost caused 
by the addition of a single hydroxyl group [233]. 
 
 
Figure 4-12: Crystallographic binding mode alignment of different N-termini from 3-amidinophenylalanine 
derivatives in comparison to the virtual compound 40. Compound 20 (white C-atoms, PDB code 2GV6) and 
compound 55 (green C-atoms, PDB code 6T9T) were crystallized in matriptase. Compound 17 (yellow C-atoms, 
PDB code: 4E7R) was crystallized in thrombin. The virtual product 40 was docked into matriptase from PDB code 
2GV6. The Gln175 from the matriptase structure of (PDB: 6T9T) is shown in green sticks. The interaction between 
compound 55 and the Gln175 is shown in a black dashed line and the distance (in Å) is given in a yellow box. 
 
The crystal structures of inhibitors 55 and 56 in complex with matriptase and/or trypsin (Figure 
4-10 and Figure 4-11) confirmed the competitive reversible binding mode of these 3-
amidinophenylalanine-derived serine protease inhibitors. This binding mode was already 
determined before during the analysis of the enzyme kinetic measurements. Typical Dixon-
plots, indicating a competitive reversible inhibition mechanism, with all three proteases are 
shown in Figure 4-13.  
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Figure 4-13: Representative Dixon-plots of the inhibition of matriptase, thrombin and fXa by compound 
55. Measurements for matriptase and fXa were performed with the substrate Mes-dArg-Pro-Arg-AMC (MI-507) 
at concentrations of 14.3 µM (◼) and 7.2 µM () for matriptase and 50 µM (◼) and 25 µM () for fXa. 
Measurements with thrombin were performed with 10 µM (◼) and 5 µM () of substrate Tos-Gly-Pro-Arg-AMC 
(MI-109, Table 7-1). The parallel line to the X-axis represents the constant value for 1/Vmax that was determined 
in an independent measurement of the kinetic constants. 
4.2.5. Inhibition of H9N2 influenza virus propagation by matriptase inhibitors 
As highlighted in chapter 2, infectivity and replication of influenza virus A subtypes depend on 
the proper cleavage of its surface glycoprotein HA that mediates binding to sialic acid-
containing cell surface receptors and fusion of the viral envelope with the endosomal 
membrane. Since matriptase is known to cleave hemagglutinin subtype H9 [63] the more potent 
dibasic matriptase inhibitors 56-59 (MI-490, MI-493, MI-494 and MI-495) as well as the 
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monobasic compounds 54 (MI-485) and 55 (MI-1904) were examined for their inhibitory effect 
on the propagation of H9N2 influenza virus with the R-S-S-R↓ cleavage site in MDCK II cells. 
As shown in Figure 4-14, no or only a minimal cytotoxic effect of any tested inhibitor on 
MDCK-II was detected when these cells were treated at a concentration of 50 µM. A further 
reduced, negligible cytotoxicity on MDCK-II cells was observed for all analogues at an 
inhibitor concentration of 25 µM. Therefore, all inhibitors could be used to investigate their 
inhibitory effect on virus propagation (Figure 4-15).  
 
Figure 4-14: Determination of cytotoxic effects of selected inhibitors on MDCK-II cells. Cells were incubated 
48 h with inhibitor concentrations of 50 µM (blue) or 25 µM (red). Final DMSO concentration in wells after 
inhibitor treatment was 0.5 %. As control, cells were treated equally with 0.5 % DMSO only. Absolute 
luminescence is given on the Y-axis and was determined photometrically using the CellTiter Glo 2.0 kit (Promega) 
following manufacturer’s instructions. 
MDCK-II cells were infected with H9N2 (A/quail/Shantou/782/00) at a MOI of 0.005 resulting 
in moderate virus propagation of approximately 50 % (green box) and 100 % infection after the 
addition of 0.5 µg trypsin (orange box). DMSO at a concentration of 0.5 % has no inhibitory 
effect on virus propagation in contrast to all inhibitors, which all show a significant inhibition 
on virus propagation at all three applied concentrations (10, 25 and 50 µM). At an inhibitor 
concentration of 10 µM compound 56 with a meta-amidine substitution and the meta-
aminomethyl derivative 58 show the strongest inhibitory effect of the new compounds (Figure 
4-14 A), in consistency with their low Ki values of 700 pM and 1 nM for matriptase, 
respectively. In wells containing compounds 54, 55, 57 and 59 the virus propagation was 
inhibited to a lesser extent, but no clear differences are determinable even though compound 
55 with a Ki of 15 nM has been identified as an 18-times less potent matriptase inhibitor 
compared to compound 57 (Ki = 800 pM) in enzyme kinetic experiments. In an independent 
repetition of the experiment including the same inhibitors (54-59, see Figure 4-15 B) inhibitor 
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55 indeed showed lower inhibitory effect than the remaining tested inhibitors including a dose-
dependent effect. Whereas the concentration of 50 µM leads to circa 90 % inhibition, the 
concentration of 25 µM approximately only halves virus propagation (compared to control with 
or without DMSO (green box)). At 10 µM of inhibitor 55, only a slight inhibition of virus 
propagation is visible. The meta-aminomethyl substituted compound 58 results again in the 
strongest virus inhibition at all tested concentrations. More surprisingly, inhibitor 57 seems to 
only show medium inhibitory effect at 10 µM in both experimental set-ups even though a 
matriptase Ki value of 800 pM has been determined in enzyme kinetic experiments (Table 4-9). 
Also, compound 56 as the most potent matriptase inhibitor (Ki = 700 pM) did not completely 
inhibit virus propagation at 10 µM in the second set-up (Figure 4-15 B). However, all 
compounds have an inhibitory effect on virus propagation without showing cytotoxic effect on 
MDCK-II cells. Compound 17 (structure shown in Table 4-1) served as a positive control in 
Figure 4-15 A, since this inhibitor has been shown to inhibit H9N2 earlier [218]. 
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Figure 4-15: Inhibition of H9N2 influenza virus propagation by treatment with matriptase inhibitors in 
MDCK-II cells. (A) MDCK II cells were infected with the virus A/quail/Shantou/782/00 (H9N2) at a MOI of 
0.005 and incubated with the respective inhibitors at 37 °C. After 24 h the infected cells and comet-like spread of 
infection were fixed with 4 % paraformaldehyde in minimum essential medium. These cells were incubated with 
a specific primary antibody against the viral nucleoprotein (NP) of H9N2, followed by conjugation with an HRP-
coupled secondary antibody. Infected cells were immunostained using the TrueBlue™ Peroxidase substrate (KPL 
International Limited, India). *: Compound including the Ki value adopted from [218] (B) Independent repetition of 
experiment A. The experiments were conducted by HANNAH LIMBURG in the Institute of Virology (University 
Marburg). 
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4.3. Summary of matriptase inhibitor design and characterization 
In the course of this thesis, new inhibitors of the 3-amidinophenylalanine type were produced 
and investigated regarding their affinity to matriptase, thrombin and fXa in order to obtain 
potentially bioavailable affine matriptase inhibitors with negligible affinities to the enzymes 
fXa and thrombin. For the initial virtual screening of promising compounds, the experimental 
crystal structure of matriptase in complex with compound 20 (Figure 4-2) was used as a 
template. Based on experience, thrombin selectivity was achieved by using rather bulky C-
terminal residues that target the proximal S2 thrombin binding site, which accessibility is 
restricted by the thrombin specific 60-loop. With docking in combination with close analysis 
of the distal S3/4 binding sites of matriptase and fXa, a hydroxymethyl in meta-position on the 
terminal biphenyl-3-sulfonyl group was predicted to be in optimal distance and orientation to 
interact with the Gln175 side chain on the left side of the distal binding pocket of matriptase. 
This additional interaction in matriptase, was thought to result in an improved affinity in 
matriptase but not in fXa containing Phe174 in this position. Hence an increased matriptase 
selectivity over fXa was suggested.  
In total, 18 novels monobasic and 4 dibasic compounds, were subjected to SAR analysis. After 
identifying 4-tert-butylureido-piperidide as suitable C-terminal residue to achieve selectivity 
against thrombin (Table 4-7) 11 different substitution patterns on the N-terminal phenyl ring 
were investigated (Table 4-8 and Table 4-9). Thereby, meta- and para- phenyl-substitutions 
were compared, including also double substituted N-terminal phenyl rings. The main findings 
of this analysis were for 
Matriptase affinity: 
- Matriptase prefers dibasic inhibitors over monobasic compounds. 
- Matriptase prefers meta-positioned amidino- and aminomethyl-substitutions (dibasic 
compounds 56 and 58) on the N-terminal ring of its biphenyl-3-sulfonyl group. 
- Matriptase prefers para-positioned hydroxymethyl-groups (55 and 61) compared to 
meta-hydroxymethyl substitutions (60 and 62) in the case of monobasic compounds. 
- No improvement in matriptase affinity with double substituted aryl rings (compounds 
62-65) was found. 
- The bis-amidino compounds 56 and 57 show the highest matriptase affinity (700 – 
800 pM). 
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Matriptase selectivity over thrombin: 
- Higher selectivity with meta-positioned amidino- and aminomethyl-groups (dibasic 
compounds 56 and 58). 
- Higher selectivity with para-positioned hydroxymethyl-groups (monobasic compound 
61) that is further increased by an additional meta-positioned fluorine (compound 55). 
- Complete abolishment of selectivity with the introduction of a second hydroxymethyl 
group (compound 63) or two methyl groups in meta- and para-position (compound 65). 
- Dibasic compound 56 shows highest selectivity against thrombin (3700-fold). 
- Compound 55 is the most thrombin selective monobasic compound of this series (1533-
fold stronger matriptase inhibition). 
Matriptase selectivity over fXa: 
- Higher selectivity in the case of para-substituted aryl rings of dibasic as well as 
monobasic compounds (55, 57, 59 and 61). 
- Only low till moderate fXa selectivity was found with monobasic as well as dibasic 
compounds. 
- Dibasic compound 57 shows highest selectivity against fXa (100-fold). 
- Compound 65 is the most fXa selective monobasic compound (56-fold stronger 
matripatse affinity). 
The binding mode of two inhibitors (compounds 55 and 56) was crystallographically 
determined in matriptase and/or trypsin and showed the inhibitor typical interactions in both 
proteases. In addition, the amidine in meta- (56) and the hydroxymethyl in para-position (55) 
on the N-terminal biphenyl-3-sulfonyl group interact with the side chain of Gln175 that is 
present in matriptase and trypsin. However, the additional interaction in the distal binding site 
did not result in the predicted selectivity increase of matriptase against fXa.  
With compound 55 being investigated in complex with matriptase and trypsin, the comparison 
of the binding mode revealed that trypsin is a suitable substitute for matriptase when 
interactions of the compound within the distal S3/4 binding site of matriptase are in focus. In 
contrast, the C-terminal substituent on the piperidide moiety of compound 55 showed a slightly 
different orientation in the proximal binding site of the two proteases. The matriptase crystal 
structure of compound 55 is the first structure in complex with a compound of the 3-
amidinophenylalanine type since 2006 and the first in general with this inhibitor type where the 
S3/4 binding pocked is occupied by the compound’s biphenyl-3-sulfonyl moiety. So far, the 
orientation of the biphenyl-3-sulfonyl including possible interactions with amino acids of the 
distal matriptase binding site was predicted based on crystal structures in complex with the 
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related proteases thrombin or trypsin and subsequent modeling with matriptase. These models 
are reliable predictions with high accuracy, however as also shown in this thesis (comparison 
of binding mode of compound 55 in matriptase and trypsin) slight differences are present. Based 
on the present new matriptase crystal structure the binding modes of similar inhibitors can now 
be even better predicted and this new structure should improve the quality and precision of 
future docking studies.  
In addition, selected monobasic as well as dibasic compounds demonstrated strong suppression 
of H9N2 influenza virus replication in a matriptase-expressing MDCK II cell model. Especially 
the monobasic compounds are suitable for the application in further cell culture and animal 
studies as a potential prodrug, as it is well established for various benzamidino-drugs.  
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5. Characterization of truncated and mutated TMPRSS2 variants 
5.1. Introduction to TMPRSS2 characterization 
The type II transmembrane protease TMPRSS2 (Transmembrane protease serine S1 member 
2) is a member of the Hepsin/TMPRSS subfamily (Figure 2-7). The mouse analogue is known 
as epitheliasin, which is also recommended as the official name by the peptide database 
MEROPS (S01.247). In the following, TMPRSS2 is used to describe the gene (italic letters) as 
well as the protein (regular letters).  
5.1.1. TMPRSS2 gene organization and maturation  
The TMPRSS2 gene was first described in 1997 and is located on the smallest human 
chromosome number 21 [234]. The protein is synthesized as a single-chain 70 kDa inactive 
precursor protein of 492 aa with a short N-terminal cytoplasmic tail (residues 1-83), a 
transmembrane domain (aa 84-106) and a C-terminal extracellular portion (aa 107 - 492) 
(Figure 5-1 A). Besides the SPD (residues 256-492) with the catalytic triad of His296, Asp345 
and Ser441, the extracellular portion comprises of one LDLRA domain (aa 112-149) and one 
SRCR domain (aa 150-242). These two latter domains form the stem region. The process of 
TMPRSS2 maturation involves several posttranslational modifications and in order to be active, 
TMPRSS2 needs to be cleaved after the highly conserved arginine in position 255. Based on 
similarity, 18 cysteines have been identified to form nine disulfide bonds, three of which are 
located within the SPD and one that keeps the SPD connected to the stem region post cleavage 
after Arg255 (Figure 5-1 B and C). TMPRSS2 has an additional cysteine residue within the 
SPD at position 379. In hepsin, two additional cysteines were found, one which is discussed to 
form a fourth disulfide bond and another unpaired cysteine that was suggested to assist with 
protein or ligand interactions [235]. The function of the additional Cys379 of TMPRSS2 is 
unclear. Based on sequence analysis, TMPRSS2 harbors at least two N-glycosylation sites at 
residues N213 and N249 (Uniprot: O15393). The activation cleavage after residue R255 is a 
prerequisite for proteolytic TMPRSS2 activity and occurs to be autocatalytic since the single 
site mutagenesis of the active site serine to alanine (S441A) as well as the arginine 255 to 
glutamine (R255Q) in the cleavage site result both in the loss of cleavage capacity [76]. AFAR 
and colleagues investigated TMPRSS2 cleavage in western blot experiments using polyclonal 
α-TMPRSS2 primary antibodies. The wild-type TMPRSS2 showed an approximately 32 kDa 
signal in addition to the 70 kDa precursor but the S441A and R255Q mutated TMPRSS2 
samples did not show this 32 kDa protein signal, which was referred to as protease domain.
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More recent data suggest a slightly smaller size of the protease domain of approximately 27 kDa 
[236, 237] or 24 kDa [238]. The calculated size of the TMPRSS2 SPD is about approximately 27 kDa 
(calculated with ExPASyProtParam). Slight differences might result based on the usage of 
different antibodies or protein size markers. So far, no experimental structural data for 
TMPRSS2 is available. 
 
 
Figure 5-1: Schematic overview of the mosaic-like TMPRSS2 zymogen structure and its maturation. A: 
TMPRSS2 comprises of an N-terminal cytoplasmic tail, a transmembrane domain and a C-terminal extracellular 
portion including one LDLRA and one SRCR domain as well as the SPD. TMPRSS2 is expressed as inactive pro-
enzyme that requires cleavage for activation. The arrow (↓) indicates the autocatalytic cleavage site after arginine 
R255. B: Cleavage of TMPRSS2 zymogen. After the cleavage, the SPD remains linked to the stem region through 
a conserved disulfide bond. C: Disulfide pattern of TMPRSS2, which harbors 18 cysteine residues forming 9 
disulfide bonds including one linking the SPD to the stem region post cleavage (dashed line). Three disulfide bonds 
were identified by similarities within the LDLRA and SPD each and two within the SRCR. In addition, two N-
glycosylation sites were found by sequencing analysis (asparagine residues 213 and 249 ()). 
Human TMPRSS2 mRNA is mainly expressed in epithelial cells of several tissues including 
mainly the prostate and colon but also breast, kidney, small intestine, pancreas, ovary, salivary 
gland, stomach, and lung [77, 239-242]. The physiological function of TMPRSS2 is still unclear. 
Protease deficient mice do not show any phenotypical alterations in comparison to their wild 
type littermates, suggesting that TMPRSS2 functionality is not essential for mice vitality [243]. 
Functional expression studies in Xenopus oocytes demonstrated that TMPRSS2 might 
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contribute to the regulation of the airway surface liquid (ASL) volume by decreasing the levels 
of epithelial sodium channels (ENaCs) in the human airway epithelium through proteolytic 
cleavage [244]. In addition, cardiac myocytes have shown to express TMPRSS2, which might 
imply that TMPRSS2 contributes to influenza-associated myocarditis [245]. LUCAS and 
colleagues identified TMPRSS2 as a potential participant in proteolytic cascades with relevance 
in the physiological function of the prostate [246]. 
5.1.2. TMPRSS2 and cancer 
TMPRSS2 expression had been detected at higher levels in prostate cancer cells compared to 
healthy prostate cells. Unlike other TTSPs, the TMPRSS2 transcription in prostate cells is 
regulated by androgenic ligands and the androgen receptor (AR). In most cases, the AR-
regulated TMPRSS2 upstream region was fused with the oncogenic ETS-related gene (ERG), a 
member of the erythroblast transformation-specific (ETS) gene family [76, 247]. ERG 
overexpression, as an effect of gene fusion, was discussed to impact the AR-signaling and 
possibly contribute to the development of an androgen-independency in prostate cancer cells 
[248]. Based on this high expression in prostate cancer, TMPRSS2 was suggested to serve as a 
potential marker or therapeutic target for prostate cancer [249]. The TMPRSS2:ERG fusion is 
unlikely to result in proteolytic function as the product does not encode the SPD of TMPRSS2 
[250]. However, TMPRSS2 activity in soluble or membrane-anchored form can be linked to 
diseases, including cancer and others, by processing disease-related substrates. Cell-based 
expression studies revealed PAR-2 as potential TMPRSS2 substrate, although it might be also 
activated by other trypsin-like serine proteases including matriptase. PAR-2 is found to be up-
regulated in many tumor tissues including prostate [251]. Therefore, also TMPRSS2 activity is 
discussed as a potential candidate to modulate aspects of tumor cell growth and metastasis. 
CHUN-JUNG KO and colleagues discussed TMPRSS2 to promote prostate cancer growth and 
metastasis via matriptase activation and degradation of the extracellular matrix (ECM) proteins 
nidogen-1 and laminin β-1 [237]. In their study, TMPRSS2 expression correlated with higher 
levels of matriptase activation in prostate cancer tissues. TMPRSS2 was thereby shown to 
directly activate matriptase but also to possibly shed the endogenous matriptase inhibitor HAI-
1, and thus further enhancing matriptase activity. Since HAI-1 inhibits various serine proteases 
including, for example, hepsin and prostasin [252], the TMPRSS2 induced shedding may also 
cause activation of these pericellular proteases. In general, matriptase activity itself is linked to 
many forms of cancer and other diseases as already discussed in section 3.1 of this thesis. Alike 
matriptase, also TMPRSS2 had been identified as a potent activator of the hepatocyte growth 
factor zymogen pro-HGF as a result of positional scanning substrate combinatorial library (PS-
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SCL) [246]. HGF, also named as scatter factor, interacts with the c-Met receptor tyrosine kinase 
and therefore influences well-described developmental programs that are linked to pathological 
processes including carcinogenesis and metastasis [253]. In addition, the analysis revealed the 
tissue-type plasminogen activator (tPA) and kallikrein-2 (KLK-2) as potential TMPRSS2 
substrates [246]. Furthermore, TMPRSS2 activity had been connected to certain infectious 
diseases caused by influenza viruses [58, 62, 254], corona viruses [245, 255, 256], the parainfluenza virus 
[257], the human metapneumovirus [258] and the hepatitis C virus [259]. TMPRSS2, such as other 
host proteases, is involved in virus spread by activating the respective fusion proteins on the 
virus surface, which is an essential step in the virus replication cycle. 
5.1.3. The Role of TMPRSS2 in influenza virus activation 
Cleavage of the influenza-A-virus (IAV) surface glycoprotein HA by TMPRSS2 has been 
shown in several in vitro [58, 151, 236, 254, 260] and in vivo [60-62] studies. GALLOWAY and colleagues 
investigated TMPRSS2 cleavage activity regarding all 16 avian HA subtypes in vitro and found 
a broad cleavage activity for almost every HA subtype except for H8 and H12 [151]. This 
included also the HPAIV subtypes H5 and H7 that contain multibasic cleavage sites and are 
cleaved in vivo by furin or furin-like proprotein convertases within the TGN [153, 261]. Similar to 
furin, TMPRSS2 was found to cleave IAV HA exclusively in the intracellular space in vitro 
[262, 263]. In vivo studies including tmprss2 -/- knockout mice showed a TMPRSS2 dependency 
of influenza A subtype H1N1 virus spread and pathogenesis. Due to the lack of HA cleavage, 
tmprss2 -/- knockout mice were protected from viral spread and pathogenesis upon H1N1 
infection. Further studies confirmed these findings and reported also a TMPRSS2 dependency 
of H7N9 viruses [60-62]. In contrast to H1N1 and H3N2 that circulate in humans, the avian H7N9 
is only transmitted after direct contact with infected animals. However, over 1500 confirmed 
cases of severe influenza infections with a mortality rate of 39 % were reported [264]. Infection 
of tmprss2 -/- knockout mice with the H3N2 virus still resulted in an efficient virus spread into 
the pulmonary tissue implying the involvement of another protease in H3-HA activation of the 
mouse lung. Those mice succumbed to infection. In a recent study including H3N2 IAV, 
LIMBURG and colleagues identified TMPRSS2 as a major HA-activating protease in primary 
human airway cells. Efficient knockdown of TMPRSS2 prevented proteolytic activation and 
multiplication of H1N1pdm, H7N9 and H3N2 IAV in primary human bronchial epithelial cells 
(HBEC) and primary type II alveolar epithelial cells (AECII) suggesting that TMPRSS2 is 
essential for activation and multiplication of these IAV in the human lower respiratory tract 
[254]. Currently also H10N8 IAV is under surveillance by the WHO based on its potential to 
infect humans [265]. Since the first detection in humans 2013 [266], only three cases have been 
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reported, of which two had a lethal outcome. In the in vitro study of STRAUS and WHITTAKER, 
the H10-HA subtype was not or only poorly cleaved by the tested human respiratory tract 
proteases. Minor cleavage was only observed by matriptase in addition to full cleavage of 
trypsin [267]. TMPRSS2 was not included in this study. However, very recent investigations with 
tmprss2 -/- deficient mice implied that TMPRSS2 activity is also essential for in vivo replication 
and pathogenesis of H10 IAV, since knockout mice did not show viral replication and also 
reduced inflammatory lesions in the lung compared to wild-type mice [152]. H10-HA from 
H10N7 was investigated in the in vitro study of GALLOWAY and colleagues and showed an 
aberrant TMPRSS2-dependent cleavage profile compared to the cleavage by trypsin. Slightly 
smaller HA1 and HA2 subunits than expected and multiple cleavage products were observed 
in western blots. The authors discussed that TMPRSS2 might cleave at multiple sites or only a 
specific glycosylated H10-HA form [151]. TMPRSS2 is one of the most discussed TTSPs in IAV 
infections and therefore, represents an interesting target for anti-influenza drug development. 
However, besides TMPRSS2, a broad range of serine proteases represent potential candidates 
for activation of the IAV HA and cleavage of the precursor protein HA0 can take place at 
different stages of the replication cycle or even extracellularly [268, 269].  
Among many other serine proteases, also TMPRSS2 is likely to be involved in different 
activation cascades. For example, it has been shown that TMPRSS2 can activate matriptase 
[237]. As discussed in section 3.1.6, matriptase cleaves IAV H9N2 HA, resulting in efficient 
virus spread [63]. The involvement of TMPRSS2 in these protease cascades remains unclear 
since the availability of data on TMPRSS2 compared to other TTSPs is still rather low. 
Nevertheless, the cleavage activity towards matriptase implies also a possible indirect role in 
IAV activation. 
5.1.4. Subcellular TMPRSS2 localization 
Since TMPRSS2 mRNA transcription and gene expression is increased in prostate cancer [76, 
240, 242, 270], localization of TMPRSS2 has been mainly studied in normal and cancerogenic 
prostate cells. Based on immunohistochemistry (IHC) studies, LUCAS and colleagues reported 
TMPRSS2 mislocalization in high-grade cancer; TMPRSS2 loses membrane polarity and was 
prominently detected in the cytoplasm in contrast to normal prostate cells, where TMPRSS2 is 
expressed along the apical membrane of luminal secretory epithelial cells [270]. Nevertheless, 
these studies did not reveal a clear subcellular localization and the authors discussed that 
TMPRSS2 may be localized in intracellular vesicles or organelles of the secretory pathway. 
AFAR and colleagues detected shedded soluble TMPRSS2 in cell culture medium of androgen-
stimulated prostate cancer cells (LNCaP cells), in the prostate lumen and in seminal fluid [76]. 
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BÖTCHER-FRIEBERTSHÄUSER and colleagues studied subcellular localization of TMPRSS2 
expressing MDCK-H cells [262]. The TMPRSS2 zymogen, as well as the mature membrane-
bound TMPRSS2 were found on the surface of the plasma membrane and marginally as soluble 
form in the supernatant. However, only TMPRSS2 within the cell showed proteolytic activation 
of HA, suggesting that TMPRSS2 only supports the cleavage of newly synthesized HA. Indirect 
immunofluorescence (IF) with protease specific primary antibodies gave further evidence that 
TMPRSS2 is located on the cell surface of non-permeabilized MDCK cells (Figure 5-2 A, left 
panel) and is localized in the TGN of permeabilized MDCK cells (Figure 5-2 B, right panel). 
In addition, TMPRSS2 co-localization with furin, a TGN resident protease, was shown in Huh-
7 cells (Figure 5-2 B) [271]. 
 
 
 
Figure 5-2: Determination of subcellular localization by indirect immunofluorescence. Proteases were stained 
using protease-specific primary antibodies and cell nuclei were counterstained with DAPI. A: Subcellular 
TMPRSS2 localization on the cell surface (non-permeabilized cells; left panel) and within MDCK cells 
(permeabilized cells; right panels). TMPRSS2 (in green) was stained using a TMPRSS2-specific primary antibody 
and FITC-conjugated secondary antibody. B: Co-localization of TMPRSS2 and furin (in red) after transient 
expression in Huh-7 cells. Cells were permeabilized and stained using TMPRSS2- and furin-specific primary 
antibodies, respectively and FITC-(TMPRSS2) or TRITC-(furin) conjugated secondary antibodies. Figure is  taken 
and modified from literature [271]. 
5.1.5. Starting approach for isolation of active TMPRSS2 from mammalian cells 
TMPRSS2 is anchored in the plasma membrane even after proteolytic activation cleavage, due 
to a conserved disulfide bond that connects the SPD with the SRCR domain (Figure 5-1 B). 
Although shedding may occur, TMPRSS2 activity is thought to be limited to the intracellular 
space in the case of non-prostate cancer cells. The isolation of membrane-bound proteins from 
mammalian cells, more precisely from the TGN in case of TMPRSS2, is usually accomplished 
by adding detergent that solubilizes the biomembrane and forms a soluble complex with the 
membrane. The solubilization is one of the most critical steps and has to be carefully optimized 
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to avoid protein loss and inactivation. Protein denaturation and/or aggregation are frequently 
encountered. Earlier isolation attempts of TMPRSS2 from MDCK-TMPRSS2 cells were not 
successful in FRIEBERTSHÄUSER lab; only inactive TMPRSS2 could be purified. To circumvent 
the harsh treatment during solubilization, in this thesis truncated TMPRSS2 constructs without 
the transmembrane anchoring domain were designed in order to obtain soluble TMPRSS2. The 
transmembrane domain of Type-II transmembrane proteins also harbors a specific signal 
peptide, regulating the translocation of the newly transcribed protein into the secretory pathway, 
where essential post-translational modifications take place. Therefore, the removal of the 
transmembrane domain, including the signal peptide requires the introduction of an artificial 
signal peptide to cover the functional loss and mediate the translocation into the secretory 
pathway post translation.  
KNAPPE and colleagues designed soluble variants of the related TTSP corin, by cloning its 
extracellular portion into the pSecTag2 HygroB plasmid [84]. This plasmid possesses the murine 
Ig kappa secretion peptide (Igκ-SP) upstream of the multiple cloning site to facilitate the 
secretion of the fused protein [272]. Soluble and active recombinant 6xHis-tagged corin had been 
isolated from conditioned cell culture medium of transfected 293T cells. In addition to soluble 
wt-corin, they created a corin variant where the autocatalytic cleavage site was substituted with 
an EK cleavage site (DDDDK) to purify soluble EK-corin in a less sensible inactive form. 
Functional soluble corin could be recovered following an activation step under controlled 
conditions by adding recombinant EK. To study TMPRSS2 in prostate cancer, CHEN and 
colleagues generated a specific monoclonal TMPRSS2 antibody using a transmembrane 
domain truncated inactive Igκ-SP containing R255Q mutated TMPRSS2 variant. The 
TMPRSS2 gene was fused downstream to the Igκ-SP in the MCS of the pSecTag2 HygroB 
plasmid. Stably transfected 293T clones were cultivated and FLAG-R255Q-TMPRSS2-6xHIS 
was isolated from conditioned medium and purified via IMAC and gel filtration [273]. These data 
suggest that the Igκ-SP is generally suitable to produce soluble TTSPs from 293T cells and that 
proteins can be secreted to the cell culture medium. In this thesis, TMPRSS2 without its 
anchoring domain should be produced and tested for the applicability in large expression 
experiments.  
The stem region of TTSPs is continually discussed to play an important role in proteolytic 
activity. For example, removing the TMPRSS2 LDLRA domain using peptide-conjugated 
phosphorodiamidate morpholino oligomers (PPMOs) that interfere with TMPRSS2 pre-mRNA 
resulted in an inactive 63 kDa TMPRSS2 zymogen after expression in A549 or Calu-3 cells. 
Compared to the full-length TMPRSS2, no SPD signal at approximately 32 kDa was detected 
implying that the LDLRA domain is essential for the enzymatic activity of TMPRSS2 [236]. 
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Based on these data, various TMPRSS2 constructs with N-terminally truncated extracellular 
portions and the Igκ-SP at the N-terminus should be designed, produced and characterized. For 
purification purposes, a 6xHis-tag or a FLAG tag should be introduced C-terminally. Another 
approach included the single-site mutation of the cysteine residue C365 (C122 based on 
chymotrypsinogen numbering) within the full-length TMPRSS2 gene. This highly conserved 
cysteine among TTSPs is involved in the disulfide bond formation that keeps the SPD 
connected to the stem region after the autocatalytic activation cleavage (Figure 5-1 B). By 
removing this cysteine, hence hampering the disulfide bond formation, the proteolytic active 
SPD is thought to be isolable from cell lysates. Both strategies follow the goal to obtain 
membrane-unbound correctly processed soluble and active TMPRSS2 that can be purified from 
the cell interior or the cell culture medium. In parallel, a third approach focused on the isolation 
of the membrane-bound full-length TMPRSS2 from MDCK-TMPRSS2 cells by 
immunoprecipitation.  
5.1.6. Goals of TMPRSS2 characterization 
Since its discovery in 1997, TMPPRS2 has been identified as a potential marker for prostate 
cancer. In addition, TMPRSS2 is an interesting target of host factor directed drug discovery for 
influenza treatment, since TMPRSS2 is involved or even responsible for HA activation of 
several HA subtypes. Nevertheless, compared to other well-characterized TTSPs such as EK or 
matriptase, still little is known about TMPRSS2 including its physiological function. Up to date, 
no TMPRRS2 crystal structure is available, nor large substrate/ inhibitor studies were 
conducted by comparing enzyme kinetic parameters. To use the potential of TMPRSS2 as a 
target for drug discovery, a profound functional and structural characterization of the protease 
is vital. The main goal of this part was to obtain new details on TMPRSS2 functionality in order 
to identify and develop a system to isolate proper amounts of active recombinant TMPRSS2 
for functional (and structural) studies. In detail, these included the following steps: 
- the design and production of truncated and/or mutated TMPRSS2 constructs (plasmids), 
- the transient expression of these TMPRSS2 variants in mammalian cell culture including 
their functional characterization, 
- the subcellular localization of TMPRSS2 wild type compared to truncated variants, 
- and the isolation of functional TMPRSS2 for further studies. 
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5.2. Results and discussion of TMPRSS2 characterization 
Mammalian cell culture-based experiments were performed in the laboratories of PROF. 
FRIEBERTSHÄUSER in the institute of virology (department of medicine, University Marburg). 
The cloning and bacterial based work were performed in the laboratories of PROF. KLEBE as 
part of the institute of the pharmaceutical chemistry (department of pharmacy).  
5.2.1. TMPRSS2 expression in E. coli 
In parallel to C122S-matriptase (see chapter 3), a C122S-TMPRSS2 variant (numbering based 
on chymotrypsinogen) containing an EK cleavage site upstream of amino acid residue Ile16 
had been created and deployed in recombinant expression experiments using E. coli. In the case 
of TMPRSS2, the free cysteine residue C136 was additionally mutated to a serine (C136S). 
Although TMPRSS2 could generally be produced using E. coli cells, no soluble active 
TMPRSS2 could be recovered after the activation step with recombinant EK. Optimization 
attempts focused mainly on the refolding conditions, such as the refolding method, temperature, 
pH and buffer compositions, but also on the use of different TMPRSS2 constructs but did not 
result in active protein. Whereas for other TTSPs cloning of solely the SPD suffices to obtain 
functional protein, TMPRSS2 appears to be more challenging. Therefore, TMPRSS2 constructs 
containing one or two domains upstream the SPD were tested additionally (in collaboration 
with the group of VIKTOR MAGDOLEN, TU Munich) without success. No active TMPRSS2 
could be recovered from E. coli during this thesis (data not shown). Consequently, mammalian 
cell culture systems were chosen for further experiments and different TMPRSS2 variants were 
created and tested. In the following, chymotrypsinogen numbering will not apply, and amino 
acids will be numbered from 1-492 based on full-length TMPRSS2 (Figure 5-1). 
5.2.2. Cloning and transient expression of a first set of TMPRSS2 constructs 
In a first round, different truncated or mutated TMPRSS2 constructs were produced. The 
truncated TMPRSS2 gene was therefore amplified by PCR and subcloned into the pSecTag2 
Hygro B vector. In a second PCR-step, the final construct containing the Igκ-SP was amplified 
using the pSecTag2 HygroB-TMPRSS2 plasmid as a template. Finally, the respective Igκ-
TMPRSS2 gene was subcloned into the mammalian expression plasmid pCAGGS. Site-directed 
mutagenesis was applied to generate single residue substitutions in the TMPRSS2 gene. 
Confirmed by sequencing, positive constructs were then transiently transfected into 293T cells, 
and cell lysates were analyzed by SDS-PAGE and western blotting using specific primary and 
HRP-conjugated secondary antibodies 48 h post transfection. The results including the 
construct structure are given in Figure 5-3 A-D. 
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Figure 5-3: Autocatalytic activation of truncated or mutated TMPRSS2 variants. Different TMPRSS2 
constructs were expressed in 293T cells. Cell lysates (A+B) and cell culture medium (C) were analyzed via SDS-
PAGE and subsequent blotting to a PVDF membrane. Proteins were visualized with protein or tag specific primary 
antibodies and HRP-conjugated secondary antibodies. Samples showing a 27 kDa signal are considered as "active" 
(indicated by a green arrow). Igκ: murine Ig-kappa secretion peptide, TM: transmembrane domain, EK: 
enterokinase cleavage site (DDDDK), C365S: site-directed mutation of cysteine 365 to serine."+" implies 
transfection of cells with TMPRSS2 plasmids and "-" indicates non-transfected cells, x indicates empty gel slots. 
A: TMPRSS2 constructs containing a C-terminal FLAG-tag. TMPRSS2_FLAG represents the full-length 
TMPRSS2 without any modification in the TMPRSS2 gene and is considered as a positive control. Proteins were 
visualized using a polyclonal α-TMPRSS2 primary antibody and the respective secondary antibodies. B+C: 
TMPRSS2 constructs containing a C-terminal 6xHis-tag (HIS) were immunostained with a primary α-His 
antibody. D: Schematic construct overview. 
As shown in Figure 5-3 A-C, TMPRSS2 variants were successfully expressed in 293T cells after 
transient transfection with the respective plasmids. No TMPRSS2 was detectable in conditioned 
cell culture medium (Figure 5-3 C). The full-length TMPRSS2 with a C-terminal FLAG-tag 
((a) in Figure 5-3 A and D) served as a positive control since it has shown proteolytic cleavage 
of HA in co-expression experiments in vitro [58, 236, 262]. The appearance of a 27 kDa signal in 
addition to the zymogen form (65 kDa - 70 kDa in case of the full-length TMPRSS2) is linked 
to enzyme activity. Previous studies have shown, that intrinsic autocatalytic activity is required 
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for TMPRSS2 activity in expression experiments with 293T cells. A S441A mutated TMPRSS2 
did neither show a 27 kDa signal in western blot experiments nor a detectable cleavage of HA 
in co-expression experiments [58, 76]. In the following, the presence of a 27 kDa signal will be 
used as a marker to evaluate the different TMPRSS2 variants regarding their potential 
proteolytic activity.  
Besides the positive control, only the sample of Igκ_ΔTM_TMPRSS2_HIS shows a 27 kDa 
protein signal ((c) in Figure 5-3 B and C). No autocatalytic cleavage activity could be observed 
in the case of the constructs ΔTM_TMPRSS2_FLAG (b), Igκ_ΔTM_EK_TMPRSS2_HIS (d) and 
TMPRSS2_C365S_HIS (e). The presence of the 27 kDa signal in the case of construct 
Igκ_ΔTM_TMPRSS2_HIS paired with its absence in case of construct ΔTM_TMPRSS2_FLAG 
suggest that the entry into the secretory pathway is a decisive factor for TMPRSS2 activity. 
Without the Igκ-SP, TMPRSS2 maturation of truncated variants including the autocatalytic 
activation is not possible in 293T cells. Interestingly, the single site mutation of residue cysteine 
365 to serine results in the loss of TMPRSS2 autocatalytic activity (construct (e) in Figure 5-
3). Based on sequence alignment of TTSPs, this cysteine residue C365 is the conserved cysteine 
(C122 after chymotrypsinogen numbering) forming the disulfide bond between the SPD and 
the stem region of TMPRSS2. The loss of activity by replacing the cysteine residue with serine 
and hence inhibiting the formation of this disulfide bond might imply that this disulfide bond 
has a crucial structural function for TMPRSS2 activity. Nevertheless, one prominent 
background signal, caused by the used primary α-His antibody, overlaps with the calculated 
size of full-length TMPRSS2 and the general expressibility of the construct has to be further 
confirmed. In the case of Igκ_ΔTM_EK_TMPRSS2_HIS (d) no TMPRSS2 activity was 
expected. The autocatalytic cleavage site was altered to an EK cleavage site to create a secreted 
TMPRSS2 variant that can be activated upon EK addition under defined conditions.  
In order to isolate substantial TMPRSS2 amounts, scale-up experiments were performed with 
constructs Igκ_ΔTM_TMPRSS2_HIS (c) and Igκ_ΔTM_EK_TMPRSS2_HIS (d) (Figure 5-4 A 
and B). The respective plasmids were transiently expressed in 293T cells and protein was 
isolated via IMAC in batch purification experiments from crude cell lysates. Following standard 
purification protocols, proteins were eluted with imidazole. Figure 5-4 A shows that the 
purification of truncated TMPRSS2 from construct Igκ_ΔTM_TMPRSS2_HIS (c) was not 
successful. Even though a signal at 27 kDa is visible (green arrow), the elution fraction ‘e’ 
shows multiple bands with two non-TMPRSS2 related background signals at 60 kDa and 
37 kDa (red arrows) being the most prominent ones. The calculated size of both truncated 
TMPRSS2 variants is about 50 kDa, which is indicated by the blue arrow. Also, inactive 
TMPRSS2 with the EK cleavage site (Figure 5-4 B) could not be purified properly from the 
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cell lysate ‘l’. Although a strong TMPRSS2 signal at the expected size is visible in the cell 
pellet ‘p’, mainly the 60 kDa background protein was present in the elution fractions. This 
unspecific protein seems to interact stronger with the Ni-NTA resin than the 6xHis-tagged 
truncated TMPRSS2.  
 
Figure 5-4: Medium-scale expression and purification of truncated 6xHis-tagged TMPRSS2 variants. 
TMPRSS2 variants were transiently expressed in 293T cells and purified via IMAC using Nickel-NTA. Several 
samples were taken during the purification process and separated in SDS-PAGE. Proteins were blotted to a PVDF 
membrane and visualized with an α-His-tag primary and an HRP-conjugated secondary antibody. p: cell pellet, l: 
cell lysate, ft: flow through, w: washing step, e: elution step, ek: concentrated eluate. Red arrow: background 
60 kDa and 37 kDa signals, blue arrow: TMPRSS2 zymogen, green arrow: 27 kDa matriptase SPD. A: 
Igκ_ΔTM_TMPRSS2_HIS. B: Igκ_ΔTM_EK_TMPRSS2_HIS. 
 
The 293T cell line is a popular expression tool that has been extensively used in the last decades 
for recombinant protein production. The cells are easy to cultivate, show a high transfection 
efficiency and have a biochemical machinery providing most of the post-translational folding 
and processing that is often required to generate functional and mature proteins. However, the 
cell biochemical machinery also strongly produces non-target proteins, which obviously 
interferred with the Ni-NTA resin in our batch purification experiments. Certainly, 
optimizations including the transfection and the purification procedure are possible but the 
results of these first purification experiments at a medium-scale were not very promising. 
Additionally, the elution fraction also did not show proteolytic activity towards the pNA 
substrate Mes-DCha-Gly-Arg-pNA (described in chapter 3.2). Besides, the used transfection 
reagent Lipofectamine® 2000 is highly cost-intensive and not practicable for large scale 
experiments to produce required TMPRSS2 quantities. However, the purification experiments 
support the results that truncated TMPRSS2 from the construct Igκ_ΔTM_TMPRSS2_HIS ((c) 
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in Figure 5-3 D)  might result in functional TMPRSS2 since autocatalytic cleavage took place 
(27 kDa signal, Figure 5-3 B and Figure 5-4 A (green arrow)). With these first expression 
experiments it has been shown that TMPRSS2 does not need its transmembrane domain, but 
the Igκ-signal to maturate properly. In contrast to the similar experiments with the TTSP corin 
[274], no secreted soluble TMPRSS2 was detected in conditioned cell culture medium of 293T 
cells also at a medium expression scale (T75 cell culture flask, Figure 5-3 C). The experiments 
of CHEN and colleagues, where inactive truncated R255Q_TMPRSS2 was isolated from culture 
media of transfected 293T cells, could not be reproduced with the new TMPRSS2 variants 
during this thesis [273]. However, they used stably transfected cells allowing them to perform 
experiments at a much larger scale. Eventually, secreted TMPRSS2 concentration in the 
screened cell culture media was below the detection limit of the primary antibody and much 
larger cell numbers are required. Nevertheless, since TMPRSS2 was perfectly detectable in 
crude cell lysates it is suggested that truncated TMPRSS2 remains at least partly located 
somewhere in the cells despite the introduction of the artificial secretion peptide. 
5.2.3. Further preparation of TMPRSS2 variants with a C-terminal FLAG-tag 
Since the purification of 6xHis-tagged TMPRSS2 variants using IMAC at the present scale did 
not turn out as an appropriate method, further truncated and/or mutated TMPRSS2 constructs 
were designed containing a C-terminal FLAG-tag for purification and detection. All truncated 
TMPRSS2 variants have the Igκ-SP added to the N-terminus. Table 5-1 gives an overview of 
the produced and analyzed TMPRSS2 constructs including their expected calculated molecular 
weight. Molecular weights were determined solely based on the amino acid sequence without 
consideration of eventual PTMs using the ExPASy ProtParam tool (SIB Bioinformatics 
Resource Portal). In small scale expression experiments, TMPRSS2 variants were investigated 
regarding their autocatalytic cleavage activity upon transient expression in 293T cells by SDS-
PAGE and in western blot experiments using specific primary and HRP conjugated secondary 
antibodies. As specified before, samples showing a 27 kDa signal are considered as potentially 
‘active’.  
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Table 5-1: List and schematic overview of TMPRSS2 constructs containing a C-terminal FLAG tag. 
 
 
Nr. TMPRSS2 construct name Amino 
acid 
Description Size(calc) 
[kDa] a 
1 TMPRSS2_FLAG 1 - 492 Full-length TMPRSS2 (positive control) 54.9 
2 TMPRSS2_S441A_FLAG 1 - 492 Mutation of the catalytic serine (inactive)  54.9 
3 TMPRSS2_C244S_FLAG 1 - 492 
Mutation of cysteine 244 to serine as part of the 
inter chain disulfide bridge 
54.9 
4 TMPRSS2_C365S_FLAG 1 - 492 
Mutation of cysteine 365 to serine as part of the 
interchain disulfide bridge 
54.9 
5 TMPRSS2_C365S/C244S_FLAG 1 - 492 
Mutation of cysteine 365 and cysteine 244 to 
serines (interchain disulfide bridge) 
54.9 
6 TMPRSS2_V149I_FLAG 1 - 492 
Mutation of valine 149 to isoleucine (present 
mutation in PPMO altered constructs [236]) 
54.9 
7 TMPRSS2_V479I_FLAG 1 - 492 
Mutation of valine 479 to isoleucine (random 
mutation to proof concept of applied method 
creating mutations) 
54.9 
8 Igκ_ΔTM_TMPRSS2_FLAG 106 - 492 
Truncated by the cytosolic tail and the TM 
domain 
50.0 
9 
Igκ_ΔTM_TMPRSS2_S441A_ 
FLAG 
106 - 492 
Truncated by the cytosolic tail and the TM 
domain, mutation of the serine 441 to alanine 
50.0 
10 
Igκ_ΔTM_TMPRSS2_C365S 
_FLAG 
106 - 492 
Truncated by cytosolic tail and the TM domain, 
mutation of cysteine 365 to serine.  
50.0 
11 Igκ_ΔLDLRA_TMPRSS2_FLAG 149 - 492 
Truncated by cytosolic tail, TM domain and 
LDLRA domain. 
45.5 
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12 
Igκ_ΔLDLRA_TMPRSS2_C365S_
FLAG 
149 - 492 
Truncated by cytosolic tail, TM domain and 
LDLRA domain, mutation of cysteine 365 to 
serine. 
45.4 
13 Igκ_aa173-492_TMPRSS2_FLAG 173-492 
Truncated by amino acid 1-172 (including the 
cytosolic tail, TM & LDLRA domains and the 
first 22 residues of SRCR domain) 
42.6 
14 Igκ_aa186-492_TMPRSS2_FLAG 186-492 
Truncated by amino acid 1-185 (including the 
cytosolic tail, TM & LDLRA domains and the 
first 35 residues of SRCR domain) 
41.1 
15 Igκ_aa231-492_TMPRSS2_FLAG 231-492 
Truncated by amino acid 1-230 (including the 
cytosolic tail, TM & LDLRA domains and 80 
residues of SRCR domain) 
36.0 
16 Igκ_ΔSRCR_TMPRSS2_FLAG 243 - 492 
Truncated by cytosolic tail, TM, LDLRA and 
SRCR domain. 
34.8 
17 ΔTM_TMPRSS2_FLAG b 106 - 492 
Truncated by cytosolic tail and TM domain. 
Without artificial signal peptide N-terminally 
43.8 
a calculated protein size using ExPASyProtParam (https://web.expasy.org/protparam). PTMs are not considered. 
b
 truncated construct 17 without Igκ-SP ((d) in Figure 5-3 D) 
*
indicate single-site mutations 
 
 
Figure 5-5: Autocatalytic activation of truncated TMPRSS2 variants with C-terminal FLAG-tag. TMPRSS2 
variants were transiently expressed in 293T cells. Crude cell lysates were separated in SDS-PAGE and blotted to 
a PVDF membrane. TMPRSS2 was visualized using a specific α-TMPRSS2 primary antibody and an HRP-
conjugated secondary antibody. Blue arrows indicate the TMPRSS2 zymogens (if visible), the green arrow 
indicates the 27 kDa SPD. A: Constructs 1, 8 and 11. B: Constructs 13-16. The full-length construct (construct 1) 
containing a FLAG-tag was used as positive control.  
 
As already shown before in Figure 5-3, TMPRSS2 without the transmembrane domain can be 
autocatalytically processed in 293T cells also with a C-terminal FLAG tag (construct 8, Figure 
5-5 A) instead of a 6xHis-tag ((e) in Figure 5-3). In addition, the TMPRSS2 variant, lacking the 
transmembrane and the LDLRA domain (construct 11) also harbors autocatalytic cleavage 
activity. Besides the 27 kDa signal, signals of 50 kDa (Igκ_ΔTM_TMPRSS2_FLAG) and 
45 kDa (Igκ_ΔLDLRA_TMPRSS2_FLAG) are visible and match the expected calculated size of 
the truncated TMPRSS2 variants, respectively. Even further truncated TMPRSS2 variants do 
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not result in properly maturated protein. Samples from constructs 13-16 only show signals of 
the zymogens but no SPD related signal at 27 kDa (Figure 5-5 B). These results suggest that 
the SRCR domain, but not the LDLRA nor the transmembrane domain are important for 
protease activity, measured on the availability of the freshly synthesized TMPRSS2 
macromolecule to undergo autocatalytic activation. The SRCR domain comprises of amino acid 
150 - 242 and contains two disulfide bridges, one between cysteines 172 and 231 and another 
between cysteines 185 and 241 (UniProtKB - O15393). Not only the removal of the complete 
SRCR domain (construct 16), but already removing the first cysteine residue downstream of 
the LDLRA domain (C172; construct 13) results in the loss of activity. Whether hampering a 
crucial disulfide bond formation or removing another crucial residue by truncating for further 
22 amino acid compared to the construct 11 causes the loss of autocatalytic activity remains to 
be further investigated. In the case of hepsin, a crystal structure has shown that the SRCR 
domain was rigidly bound to the back of the SPD through the conserved linking disulfide bridge 
and a network of non-covalent interactions [87]. It could be well possible that also in case of 
TMPRSS2 the SRCR domain interacts with the SPD thereby contributing to its active 
conformation as discussed for other TTSPs [88].  
In a previous study, the deletion of nucleotides nt382 - nt501 (Δex5) resulted in a TMPRSS2 
variant without LDLRA domain, but still containing the transmembrane domain [236]. The 
deletion was in frame but caused a single site mutation of valine residue 149 to isoleucine 
(V149I). In vitro studies revealed that the Δex5_TMPRSS2 variant did not display autocatalytic 
cleavage activity and was also not able to cleave HA in co-expression experiments. The authors 
concluded that the LDLRA domain is essential for enzymatic activity. However, the new results 
from this work imply that the LDLRA domain is not a limiting factor for at least TMPRSS2 
autocatalytic cleavage activity. The main differences between the LDLRA depleted TMPRSS2 
variants include the V149I mutation in the case of the exon 5 silenced inactive variant (Δex5) 
and the transmembrane domain that is removed additionally in case of the ‘active’ 
Igκ_ΔLDLRA_TMPRSS2_FLAG variant (construct 11) from this work. A negative impact of 
the V149I mutation on TMPRSS2 activity can be excluded since a full-length TMPRSS2 
variant harboring this exact amino acid substitution (construct 6, TMPRSS2_V149I_FLAG) 
shows autocatalytic cleavage activity (Figure 5-6 C). If activity loss of the Δex5_TMPRSS2 
occurs due to possible interactions between the remaining extracellular portion and the 
transmembrane domain or a general structural rearrangement occurs remains highly 
speculative. Here, only a crystal structure of this TMPRSS2 variant could reveal more detail. 
The LDLRA domain itself is in any event not a limiting factor for TMPRSS2 activity (see 
construct 11 in Figure 5-6 A and B). 
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In Figure 5-6, truncated and/or mutated TMPRSS2 variants were visualized using three 
different primary antibodies: two polyclonal α-TMPRSS2 (isolated from rat or mouse) and one 
α-FLAG primary antibody. In consistency with the previous results truncated TMPRSS2 
variants (construct 11 and weaker also in construct 8) yet again showed autocatalytic cleavage 
activity when detected with the rat α-TMPRSS2 primary antibody (Figure 5-6 A) and α-FLAG-
tag antibody (Figure 5-6 B). As expected, no autocatalytic cleavage activity was observed in 
the case of the negative control (construct 2). In parallel, the S441A mutation results also in 
activity loss of the transmembrane truncated TMPRSS2 (construct 9 in Figure 5-6 A and B). 
The results shown in Figure 5-6 yet again support that the disulfide bond connecting the SPD 
to the stem region post activation cleavage is crucial for TMPRSS2 activity. The mutation of 
either one of the involved cysteine residues (C244 or C365) or both (constructs 3,4 and 5 
respectively) caused the loss of autocatalytic cleavage activity. In addition, the lacking 27 kDa 
signal for construct 4 containing the FLAG-tag confirms the previous results, where no cleavage 
activity was observed for TMPRSS2_C365S with a 6xHis-tag C-terminally ((e) in Figure 5-3). 
Both membranes in Figure 5-6 A and B reveal difficulties in the detection of precursor 
TMPRSS2 forms. Precursor proteins of all constructs are only vaguely visible and required the 
loading of high amounts of 293T cell lysates. Due to gel overloading, smeary signals are the 
consequence. Nevertheless, the protease domain is clearly visible, if present.  
In Figure 5-6 C, TMPRSS2 variants were detected by using a different polyclonal α-TMPRSS2 
primary antibody (produced in mice, kindly provided by CHENG-YONG LIN (Georgetown 
University) to the group of PROF. FRIEBERTSHÄUSER) than in Figure 5-6 A. This antibody has a 
higher sensitivity towards the precursor proteins and shows several cleavage products, but is 
not able to detect the 27 kDa SPD signal as highlighted in Figure 5-6 D. Unfavorably, the more 
sensitive mouse-derived antibody results in a background signal of approximately 28-29 kDa 
that is slightly above the potential 27 kDa SPD signal. Only the extra incubation step with the 
α-FLAG primary antibody (additional to incubation with the mouse-derived α-TMPRSS2 
antibody) shows the SPD-signal in the respective samples (Figure 5-6 D, right). 
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Figure 5-6: Autocatalytic activation of truncated and/or mutated TMPRSS2 variants with C-terminal 
FLAG-tag. TMPRSS2 constructs were transiently expressed in 293T cells. Crude cell lysates were separated via 
SDS-PAGE and immunostained after blotting to a PVDF membrane. +: 293T cell lysates were transfected with 
respective TMPRSS2 constructs, -: transfection with empty pCAGGs vector. In A and B the same samples were 
visualized using two different primary antibodies in combination with the respective HRP-conjugated secondary 
antibody. A: Rat-derived α-TMPRSS2 primary antibody, B: α-FLAG primary antibody. Blue arrows indicate the 
respective TMPRSS2 pro-enzymes and the green arrows indicate the 27 kDa SPD. C: Proteins in cell lysates 
containing constructs 1-3, 6-8 and 10-12 were visualized using a second mouse-derived α-TMPRSS2 primary 
antibody (kindly provided by CHENG-YONG LIN to the lab of PROF. DR. BÖTTCHER-FRIEBERTSHÄUSER) which 
recognizes the precursor proteins and additional cleavage products but not the 27 kDa SPD. D: The identical PVDF 
membrane containing respective proteins was first incubated with the primary mouse α-TMPRSS2 antibody (left) 
and then with the primary α-FLAG primary antibody as well as species-specific HRP-conjugated secondary 
antibodies (right). A background signal of approximately 29 kDa (red arrow) is present in all cell lysates including 
the empty vector control. Only after incubation with the α-FLAG antibody, the 27 kDa SPD appears (green arrow). 
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Yet, different TMPRSS2 variants can be compared and evaluated for autocatalytic cleavage 
activity based on their cleavage pattern in reference to the positive (construct 1) and negative 
control (construct 2). The positive control shows two strong bands: one of approximately 
40 kDa and a weaker signal at approximately 24 kDa. The S441A mutant only reveals two weak 
signals at circa 45 kDa and 42 kDa. With the knowledge that the positive control possesses 
proteolytic activity, the 40 kDa and 24 kDa signal can be considered as a marker for 
autocatalytic TMPRSS2 cleavage activity when using the mouse-derived primary α-TMPRSS2 
antibody. Whereas C365S_TMPRSS2 has the same cleavage pattern as the negative control, 
the V149I and V479I mutated TMPRSS2 variants are matching the cleavage pattern of the 
positive control suggesting autocatalytic cleavage activity of V149I_TMPRSS2 and 
V497I_TMPRSS2. Therefore, the applied method to create the single site mutated TMPRSS2 
variants has no negative impact on TMPRSS2 activity itself. Again, results support a C365S 
mutation dependent TMPRSS2 activity loss. Since the same result was observed when mutating 
residue C244 to serine, it indicates that not the residue C365 itself is essential, but rather the 
formation of the corresponding disulfide bond. Besides linking the SPD to the stem region after 
the activation cleavage, this disulfide bond seems to impact TMPRSS2 maturation in general. 
The proofed autocatalytic cleavage activity of V149I_TMPRSS2 (from construct 6) also 
excludes a V149I-related activity loss of the LDLRA lacking TMPRSS2 variant (construct 
TMPRSS2_Δex5_FLAG in Figure 5-6 C) from the PPMO-studies [236]. No clear conclusions can 
be drawn for the truncated TMPRSS2 constructs, since they show an aberrant cleavage pattern. 
Instead of the antibody-dependent activity related 24 kDa signal of the full-length TMPRSS2 
variants, truncated TMPRSS2 from construct 8 and 11 (Igκ_ΔTM_TMPRSS2_FLAG and 
Igκ_ΔLDLRA_TMPRSS2_FLAG, respectively) possess a very weak signal clearly below 
20 kDa (Figure 5-6 C) which might represent cleavage products from autocatalytic cleavage. 
Ultimately, the detection of different TMPRSS2 variants in western blot experiments was not 
straightforwardly possible with only one antibody, but the combination of three different 
primary antibodies led to conclusive results. The more sensitive mouse α-TMPRSS2 antibody 
thereby allows detection of precursor proteins but is not suitable to evaluate activation cleavage 
of truncated TMPRSS2. In contrast, the other two used antibodies can recognize the 27 kDa 
SPD signal of full-length and truncated TMPRSS2 variants, if present. 
5.2.4. Co-expression experiments of TMPRSS2 constructs with H1-HA or H3-HA  
So far, different TMPRSS2 variants were investigated for autocatalytic cleavage activity in 
western blot experiments. Depending on the used primary antibody, the appearance of the 
27 kDa SPD signal or a specific cleavage pattern had been associated with a proteolytic active 
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protease. To further evaluate protease activity, in vitro TMPRSS2 cleavage activity towards 
H1-HA or H3-HA was investigated in co-expression experiments. Proteolytic active TMPRSS2 
cleaves the precursor HA0 into the subunits HA1 and HA2 
[58, 236, 262]. Different TMPRSS2 
variants were therefore co-transfected with H1- or H3-HA in 293T cells. The respective cell 
lysates were separated by SDS-PAGE, blotted to membranes and immunostained using primary 
α-H1N1 or α-H3N2 antibodies, respectively. The appearance of an HA1- (55 kDa) or HA2-
(25 kDa) related signals suggest HA0 (75 kDa) cleavage, thus TMPRSS2 activity. Results are 
shown in Figure 5-7, Figure 5-8 and Figure 5-9.  
 
Figure 5-7: Proteolytic cleavage activity of mutated full-length TMPRSS2 variants towards H1-HA. 293T 
cells were transiently co-transfected with plasmids encoding H1-HA and different TMPRSS2 variants (+) or an 
empty vector as a negative control. Cleavage of H1-HA0 was detected in crude cell lysates 48 h post transfection 
by western blot analysis using a primary α-H1N1 and an HRP-conjugated secondary antibody. TMPRSS2 activity 
is indicated by the appearance of the HA2 signal at 25 kDa. 
Figure 5-7 supports proteolytic activity of the V149I and V479I mutated full-length TMPRSS2. 
Both TMPRSS2 variants were able to cleave the precursor HA0 of the H1-HA subtype. As for 
the positive control, a clear signal for the HA2 subunit at 25 kDa could be detected. In contrast, 
no cleavage activity towards HA0 was observed in the case of the TMPRSS2_C365S variant in 
consistency with the negative control (TMPRSS2_S441A). These results confirm that the 
appearance of the 27 kDa SPD signal correlates with proteolytic activity in the case of full-
length TMPRSS2 variants. Also, by implication, the lack of the SPD signal is associated with 
TMPRSS2 inactivity. The disulfide bond including the cysteine residue C365 has been 
identified as a crucial factor for TMPRSS2 maturation. Disulfide cross-links are known to have 
a substantial increase in the stability of proteins. In the case of TMPRSS2 the loss of this 
stabilizing disulfide bond might hamper structural proximity, required for autocatalytic 
activation as a prerequisite for protease activity and /or simply destabilize the molecule during 
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maturation. What exactly causes the activity loss of the TMPRSS2_C365S variant remains 
unclear at this point.  
 
Figure 5-8: Proteolytic cleavage activity of mutated full-length and truncated TMPRSS2 variants towards 
H3-HA. 293T cells were transiently co-transfected with plasmids encoding H3-HA and different TMPRSS2 
variants (+) or with an empty vector as negative control. Cells solely transfected with H3-HA plasmid (-) served 
as additional control. Cleavage of H3-HA0 was detected in crude cell lysates 48 h post transfection by western 
blotting using two different primary α-H3N2 antibodies and the respective HRP-conjugated secondary antibody. 
A: α-H3N2 primary antibody (isolated from goat), B: α-H3N2 primary antibody (isolated from rabbit). The 
appearance of the 55 kDa HA1 signal implies TMPRSS2 activity. 
In Figure 5-8 A and Figure 5-8 B the same constructs were investigated for TMPRSS2 
catalyzed H3-HA cleavage using two different α-H3N2 primary antibodies. Only the positive 
control shows clear cleavage activity towards HA0 (HA1 associated 55 kDa cleavage product) 
in both cases. In consistency with the lacking 27 kDa SPD signal in the previous experiments, 
no cleavage activity was observed in case of H3-HA co-expression with constructs 2 and 4 as 
well as the constructs 9, 10 and 16. Results for constructs 8 (Igκ_ΔTM_TMPRSS2_FLAG) and 
11 (Igκ_ΔLDLRA_TMPRSS2_FLAG) are rather distinct. No clear cleavage product of H3-HA 
as for the positive control is visible. However, as shown in Figure 5-8 B the co-expression with 
construct 11 in particular results in a slightly more intense and broader 55 kDa signal compared 
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to the negative control sample, where only H3-HA was transfected. In addition, the precursor 
HA0 signals are less intense for the samples of constructs 8 and 11 compared to those of the 
other constructs (2, 4, 9, 10 and 16). As shown for the positive control, HA cleavage results in 
a less distinct signal for the precursor protein HA0. Therefore, already weaker precursor signals 
might imply marginal cleavage activity by the two discussed truncated TMPRSS2 forms. 
Qualitative western blot experiments, as performed in this thesis, are generally prone to 
different band intensities caused by experimental parameters, such as differences in sample 
loading, transfer of proteins to the membrane or the time-sensitive enhanced 
chemiluminescence (ECL) detection method. Quantification of proteins is generally possible 
but requires certain preconditions including antibody titration and internal loading controls. 
These parameters were not fulfilled in the given experiments. However, without clear HA1 
cleavage product, H3-HA cleavage by these two TMPRSS2 variants can not be ultimately 
evaluated. In the following, 293T cells were co-transfected with H3-HA and various amounts 
of plasmid DNA harboring the construct 11 (Figure 5-9).  
 
 
Figure 5-9: Proteolytic cleavage of H3-HA in a dose-dependent manner by truncated and full-length 
TMPRSS2. 293T cells were transiently co-transfected with plasmids encoding HA of the H3 subtype and different 
amounts of full-length TMPRSS2 plasmid (construct 1: TMPRSS2_FLAG) or truncated TMPRSS2 containing 
plasmid (construct 11: Igκ_ΔLDLRA_TMPRSS2_FLAG) of different quantities. Cells transfected with an empty 
vector or solely plasmids encoding for H3-HA (-) served as negative controls. Cleavage of HA0 was detected in 
crude cell lysates 48 h post transfection by western blotting using a primary α-H3N2 and an HRP-conjugated 
secondary antibody. The red arrow indicates an antibody-specific background signal and the green arrow the HA1 
cleavage product at 55 kDa indicating TMPRSS2 activity. 
The crude cell lysates were analyzed for H3-HA signals using the more sensitive rabbit derived 
primary α-H3N2 antibody (also used in Figure 5-8 B). Results suggest an HA expression-
dependency on the quantity of co-transfected TMPRSS2 construct. The higher the introduced 
TMPRSS2 plasmid DNA amount, the less intense appeared the HA0 and HA1 signals. H3-HA 
signals from co-transfection with 5 ng TMPRSS2_FLAG plasmid-DNA (positive control) are 
stronger than from the 10 ng TMPRSS2_FLAG plasmid DNA sample. However, the weaker 
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55 kDa HA1 signal of the latter 10 ng sample in co-expression with the H3-HA allows 
distinguishing two different signals of very similar molecular weights. The slightly lower signal 
(red arrow) is referred to as background signal since it appears in all samples, including the 
negative control sample that was solely transfected with H3-HA plasmid DNA (lane 2 (-) in 
Figure 5-9). In consistency with the findings in Figure 5-8 B, a slightly more intense and 
broader 55 kDa signal is visible when HA-H3 was co-transfected with construct 11 in 
comparison to the negative control. A weak HA1 signal (green arrow) in addition to the 
background signal (red arrow) is visible. Notwithstanding the signals are very flimsily, the 
additional signal at 55 kDa implies cleavage of HA0 and hence indicate proteolytic activity of 
the truncated TMPRSS2 variant as it has been suggested from previous experiments where 
autocatalytic cleavage activity was observed with construct 11 (Figure 5-5 A, Figure 5-6 A and 
Figure 5-6 B). Even though autocatalytic cleavage activity of truncated TMPRSS2 (from 
construct 11) and of the full-length TMPRSS2 (construct 1) was comparable, only very weak 
H3-HA cleavage could be determined by the truncated TMPRSS2. It is conceivable that 
TMPRSS2 activity of truncated variants might simply not be adequately detectable in the given 
experimental setup. TMPRSS2 and HA are both membrane-anchored proteins. The removal of 
the TMPRSS2 anchoring domain could result in the unapproachability of the membrane-bound 
substrate hemagglutinin due to TMPRSS2 dislocation. When TMPRSS2 cannot spatially reach 
HA, HA0 cannot be proteolytically cleaved. TMPRSS2 has been suggested to exclusively 
activate HA within the TGN or possibly in endosomes, which might indicate a local 
environmental dependency of proteolytic activity. Also, truncated TMPRSS2 might maturate 
properly to be autocatalytically processed but could subsequently be identified as foreign by 
the cell recycling system resulting in the activation of its recycling. However, all TMPRSS2 
variants were detectable in western blot experiments and did not show any signs of degradation. 
Altogether, HA0 cleavage by co-expressing H3-HA and truncated TMPRSS2 variants is not a 
very suitable system to evaluate proteolytic TMPRSS2 activity. So far, no other activity tests 
are available for TMPRSS2 in cell culture experiments that could be used to further investigate 
and determine the specific activity of truncated TMPRSS2. 
5.2.5. Subcellular localization of TMPRSS2  
For a deeper insight into the subcellular localization of TMPRSS2, cell compartments of stably 
TMPRSS2 expressing MDCK-H cells (MDCK-TMPRSS2 cells) were separated and analyzed. 
In addition, different TMPRSS2 variants were investigated in indirect immunofluoresccnce 
experiments for subcellular localization within Huh-7 cells after transient expression in order 
to detect possible dislocation of truncated TMPRSS2 variants. 
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Cell compartmentation 
TMPRSS2 expression in MDCK-H cells was induced by the addition of doxycycline (Figure 5-
10 A). Proteins were isolated from different cell compartments, including the cytosol (C-
fraction), membrane-bound organelles (M-fraction) and the cell nucleus (N-fraction) and 
separated via SDS-PAGE before being analyzed in western blot experiments with the α-FLAG 
primary antibody (Figure 5-10 B and C). Precipitated proteins during isolation as well as the 
cell debris are summarized as insoluble fraction (I). Two different methods were applied for 
compartmentation. In Figure 5-10 B, the C- and M-fraction were isolated together by the 
ProteoJET™ Kit components and separated from the N-fraction and the I-fraction. By using 
the second method [275], proteins from C- und M-fractions could be isolated separately (Figure 
5-10 C). In this case, N- and I-fractions were isolated together for simplicity since no TMPRSS2 
was suspected and found in the N-fraction before (Figure 5-10 B). 
 
Figure 5-10: Doxycycline induced TMPRSS2 expression (A) and subcellular localization of full-length 
TMPRSS2 by cell compartmentation (B+C). MDCK-TMPRSS2 cells were grown in T75 cell culture flasks in 
the absence (-) or presence (+) of doxycycline for 48 h. Cell compartments were isolated in B using the Fermentas 
ProteoJET™ Kit by following manufacturer's instructions or in C based on a protocol from [275]. TMPRSS2 was 
detected by western blot analysis using α-FLAG primary antibody and HRP-conjugated secondary antibody. 
Proteins from different cell compartments are indicated with C for cytosolic, M for membrane-bound organelles, 
N for nucleic and I for insoluble protein fractions. Since no TMPRSS2 was found in the nucleic protein fraction 
in B, only C- and M- protein fractions were separated in the following compartmentation experiments as indicated 
in C. Blue arrow: glycosylated TMPRSS2 zymogen, green arrow: TMPRSS2-SPD. 
 
Active full-length TMPRSS2 was only detectable upon doxycycline induction in MDCK-
TMPRSS2 crude cell lysates (see 27 kDa SPD signal in Figure 5-10 A). After cell 
compartmentation using the ProteoJET™ Kit, TMPRSS2 was found in the C/M fraction and 
the I-fraction. In the latter insoluble fraction, TMPRSS2 related signals are most likely a result 
of precipitated proteins due to the detergent-based isolation method. The separation of C- and 
M-fractions (Figure 5-10 C) shows a TMPRSS2 signal at approximately 55 kDa in the C-
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fraction matching the calculated size of the non-glycosylated zymogen form of TMPRSS2 (see 
also Table 5-1, construct 1). Maturated active TMPRSS2 possessing the 27 kDa SPD was only 
detected in the M-fraction and again in the portion containing insoluble or precipitated proteins 
plus the nucleic proteins (N/I). The TMPRSS2 precursor in the M-fraction is, with 
approximately 65 - 70 kDa, of a slightly bigger than calculated size and matches the predicted 
size of glycosylated TMPRSS2 [76]. Indeed, this result is not surprising, since membrane-bound 
organelles (M-fraction) include the endoplasmic reticulum where PTMs take place. Therefore, 
compartmentation results confirm the presence of possibly active TMPRSS2 exclusively in 
membrane-bound organelles but not as soluble protein in the cytoplasm nor in the cell nucleus. 
Crude MDCK-H and MDCK-TMPRSS2 cells lysates as well as the respective isolated C- and 
M-fractions were tested for proteolytic activity by incubation with the Mes-DCha-Gly-Arg-
pNA substrate and visually analyzed. All samples showed a color turnover after incubation 
overnight at RT with the strongest yellow staining in the crude cell lysate of MDCK-H cells 
and MDCK-TMPRSS2 cells, but no visible difference between the C- and M-fraction. Since a 
wide range of serine proteases cleave substrates after monobasic amino acid residues, the 
yellow staining gives no evidence of TMPRSS2 specific proteolytic activity. 
With a major objective in the head to create an appropriate system to isolate active TMPRSS2 
for functional testing, TMPRSS2 was also isolated via immunoprecipitation from MDCK-
TMPRSS2 cell lysates using ANTI-FLAG® M2 Affinity Gel (Sigma-Aldrich) that allows 
isolation of FLAG-tagged proteins. Although TMPRSS2 was captured successfully (see Figure 
5-11 A) no proteolytic cleavage activity could be detected of these samples using the 
aforementioned Mes-DCha-Gly-Arg-pNA substrate. In addition, the C- and M-fractions, as well 
as the eluate from the immunoprecipitation experiments were incubated with 293T cells that 
were previously transfected with the H1-HA plasmid in order to investigate proteolytic 
TMPRSS2 specific HA cleavage activity. After 3 h incubation at 37 °C, H3-HA cleavage was 
only observed in case of the positive control containing externally added trypsin (see Figure 5-
11 B) but not in samples where the C-, M- or eluate fractions were externally added. No 
TMPRSS2 activity could be detected outside the cell. 
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Figure 5-11: Isolated full-length TMPRSS2 does not possess catalytic cleavage activity towards H1-HA. A: 
TMPRSS2 was isolated from doxycycline induced MDCK-TMPRSS2 crude cell lysate by immunoprecipitation 
using the ANTI-FLAG M2 antibody (Sigma-Aldrich). Bound protein was eluted by incubation with glycine-HCl 
at pH 3.0 and directly neutralized using 10x TBS. Blue arrow indicates TMPRSS2 zymogen and the green arrow 
indicates the 27 kDa SPD. B: 293T cells were transiently transfected with an H1-HA encoding plasmid. After 48 h, 
cells were harvested by centrifugation and incubated with trypsin (1 h at 37 °C) or portions from cell 
compartmentation (C- and M-fractions of MDCK-TMPRSS2 cells) or the eluate from immunoprecipitation for 3 h 
at 37 °C. Cleavage of hemagglutinin is indicated by the appearance of a 25 kDa HA2 signal. Color Prestained 
Protein Standard, Broad Range (11–245 kDa; NEB) was used as a marker in B. 
To see if the removal of the anchoring system results in TMPRSS2 dislocation, MDCK-H cells 
were transiently transfected with the construct Igκ_ΔLDLRA_TMPRSS2_FLAG (construct 11) 
and cell compartmentation experiments were performed (Figure 5-12). Truncated 
autocatalytically processed TMPRSS2 was exclusively found in the N/I-fraction that includes 
the nucleic and insoluble protein portions. Neither in the C- nor in the M-fraction was any 
TMPRSS2 signal detectable and TMPRSS2 repeated to precipitate completely during the 
separation of the different cell fractions. This might suggest an incompatibility with the buffer 
components that contain detergents that are standardly used to form stabilizing complexes with 
membrane proteins during isolation. Without the membrane anchoring domain, the detergents 
might have a rather destructive character. Also, aberrant protein stability might be the result of 
truncation by losing important interactions or by forming unfavored new ones. Also, a negative 
effect of the transfection method itself could be plausible. MDCK-H cells were transiently 
transfected with construct 11 using the strong transfection reagent Lipofectamine 2000. Full-
length TMPRSS2 was isolated from stably transfected cells where expression was induced upon 
doxycycline addition. Although precipitation due to general protein overload is not excludable, 
only a partly precipitation would have been expected in this case. Ultimately, the localization 
of truncated TMPRSS2 within the cells by compartmentation was not possible in the given 
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experimental setup. The reason for experimental failure remains speculative. Nevertheless, yet 
again, autoproteolytic cleavage activity of truncated TMPRSS2 using construct 11 has been 
confirmed (green arrow in Figure 5-12), which is generally associated with TMPRSS2 activity. 
 
 
Figure 5-12: Subcellular localization of truncated TMPRSS2 by cell compartmentation. MDCK-H cells were 
transiently transfected with truncated TMPRSS2 (Igκ_ΔLDLRA_TMPRSS2_FLAG). Cell compartments were 
separated 48 h after transfection based on a protocol from [275]. TMPRSS2 was detected by western blotting using 
α-FLAG primary and HRP-conjugated secondary antibodies. Proteins from different cell compartments are 
indicated with C for cytosolic, M for membrane-bound organelles, N for nucleus and I for insoluble protein 
fractions. Blue arrow: zymogen form, green arrow: SPD, red arrow: cleavage product/background signal. 
 
Indirect immunofluorescence 
Huh-7 cells were transiently transfected with different TMPRSS2 constructs and proteins were 
visualized using the α-TMPRSS2 primary antibody and an Alexa Fluor® 488-conjugated 
secondary antibody (Figure 5-13 A-D). TMPRSS2 is detected as a green signal under the 
fluorescence microscope. Cell nuclei were visualized in blue following incubation with the 
dsDNA stain DAPI.  
 
Figure 5-13: Subcellular localization of truncated TMPRSS2 variants by indirect immunofluorescence. 
Huh-7 cells were transiently transfected with the respective plasmids encoding for TMPRSS2 variants. TMPRSS2 
was visualized 24 h post transfection using an α-TMPRSS2 primary and Alexa Fluor® 488-conjugated secondary 
antibody. Cell nuclei were counterstained with DAPI during incubation of the secondary antibody. A: 
Igκ_ΔTM_TMPRSS2_FLAG, B: Igκ_ΔLDLRA_TMPRSS2_FLAG and C: Igκ_ΔSRCR_TMPRSS2_FLAG. Cell 
nuclei are blue, TMPRSS2 emerges in green. Yellow bars: 10 µM (magnitude 20x). 
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No aberrant location of truncated TMPRSS2, compared to the full-length TMPRSS2 (Figure 5-
13 A) was detectable in Huh-7 cells. Full-length TMPRSS2 (construct 1) and the truncated 
TMPRSS2 variants from construct 8 (Igκ_ΔTM_TMPRSS2_FLAG, Figure 5-13 B), construct 
11 (Igκ_ΔLDLRA_TMPRSS2_FLAG, Figure 5-13 C), as well as construct 16 
(Igκ_ΔSRCR_TMPRSS2_FLAG, Figure 5-13 D) are all located in cell compartments 
surrounding the cell nucleus, such as the ER and TGN. The removal of the anchoring TM 
domain does not seem to result in protein accumulation in the cytoplasm in which case the cell 
shape would have been indicated by the green color. However, at least a localization change 
within the single cell compartment is most likely since the protease variants can not be 
physically attached to the plasma membranes by the anchoring domain anymore. The applied 
technique and the optical magnification (20x) of the used microscope are not suitable to 
determine the precise location within a single cell compartment by microscoping. For a deeper 
insight, more experiments are necessary with different equipment. This could include the co-
staining of TMPRSS2 and organelle protein-specific primary antibodies including, for example, 
α-calnexin or α-calreticulin for the ER, α-GM130 for the Golgi-apparatus and α-Rab4 for 
endosomes.  
5.2.6. Matriptase catalyzed activation of TMPRSS2 
Androgen-induced TMPRSS2 has been shown to activate matriptase in vitro [237]. In Figure 5-
14, 293T cells were harvested 48 h post transfection with different TMPRSS2 constructs 
(constructs 1, 2 and 17 of Table 5-1) and treated with recombinant matriptase or trypsin 
afterwards. Whereas the untreated full-length TMPRSS2 sample (construct 1) shows 
autocatalytic cleavage activity, only zymogen forms of the proteolytical inactive constructs 2 
and 17 are present in the untreated samples. Upon treatment with either trypsin or matriptase 
(wt-matriptase from chapter 3) the SPD related 27 kDa signal additionally appears in samples 
of the constructs 2 and 17 (green arrow in Figure 5-14). Samples incubated with externally 
added trypsin thereby show (almost) complete cleavage of the inactive zymogen forms (no or 
only weak signal present after treatment, blue arrow) including also a strong cleavage product 
of approximately 15 kDa that is standardly present when using the α-FLAG primary antibody 
(see Figure 5-6 B, Figure 5-10, Figure 5-11 and Figure 5-12). This 15 kDa signal is only 
vaguely visible for samples treated with matriptase, which is known to not cleave 
indiscriminately after nearly every arginine or lysine such as trypsin. These data suggest, that 
not only TMPRSS2 can activate matriptase, but also that TMPRSS2 is a possible matriptase 
substrate.  
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Figure 5-14: Post expression proteolytic TMPRSS2 zymogen cleavage by externally added matriptase and 
trypsin in vitro. 293T cells were transiently transfected with TMPRSS2 variants (constructs 1,2 and 17 in Table 
5-1). Cells were harvested 48 h post transfection and treated with trypsin (T) for 1 h or wt-matriptase (M) for 3 h 
at 37 °C. Φ: cell lysates without additional protease treatment. The blue arrows indicate TMPRSS2 zymogen 
forms, green arrow indicates the 27 kDa SPD. 
 
5.3. Summary of TMPRSS2 characterization 
In total, 17 different TMPRSS2 variants with a FLAG-tag were investigated during this thesis. 
This includes 15 new mutated and/or truncated variants that were tested for their autocatalytic 
cleavage activity, proteolytic activity towards influenza HA, and partly for their subcellular 
localization. In the following, the results will be summarized and the characterization of 
TMPRSS2 will be further discussed. For an overview see Table 5-2. 
Table 5-2: Characterization of TMPRSS2 variants with FLAG-tags. 
Nr. TMPRSS2 construct name Amino 
acid 
residues 
Autocatalytic 
cleavage activity 
Proteolytic 
cleavage activity 
towards HA0 
1 TMPRSS2_FLAG (positive control) 1 - 492 YES YES 
2 TMPRSS2_S441A_FLAG (negative control) 1 - 492 NO NO 
3 TMPRSS2_C244S_FLAG 1 - 492 NO NO 
4 TMPRSS2_C365S_FLAG 1 - 492 NO NO 
5 TMPRSS2_C365S/C244S_FLAG 1 - 492 NO NO 
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Nr. TMPRSS2 construct name Amino 
acid 
residues 
Autocatalytic 
cleavage activity 
Proteolytic 
cleavage activity 
towards HA0 
6 TMPRSS2_V149I_FLAG 1 - 492 YES YES 
7 TMPRSS2_V479I_FLAG 1 - 492 YES YES 
8 Igκ_ΔTM_TMPRSS2_FLAG  106 - 492 YES UNCLEAR 
9 Igκ_ΔTM_TMPRSS2_S441A_FLAG  106 - 492 NO NO 
10 Igκ_ΔTM_TMPRSS2_C365S_FLAG  106 - 492 NO NO 
11 Igκ_ΔLDLRA_TMPRSS2_FLAG 149 - 492 YES YES 
12 Igκ_ΔLDLRA_TMPRSS2_C365S_FLAG  149 - 492 NO NO 
13 Igκ_aa173-492_TMPRSS2_FLAG  173-492 NO NO 
14 Igκ_aa186-492_TMPRSS2_FLAG  186-492 NO NO 
15 Igκ_aa231-492_TMPRSS2_FLAG  231-492 NO NO 
16 Igκ_ΔSRCR_TMPRSS2_FLAG  243 - 492 NO NO 
17 ΔTM_TMPRSS2_FLAG 106 - 492 NO NO 
 
5.3.1. Autocatalytic cleavage activity of different TMPRSS2 variants 
In a first round, TMPRSS2 variants containing a C-terminal 6xHis-tag were characterized in 
cell culture experiments. A TMPRSS2 variant without transmembrane domain but with the Ig-
SP instead (construct (c) in Figure 5-3) had been identified to maturate properly, indicated by 
autocatalytic cleavage activity. A 27 kDa signal of the SPD is visible in the respective samples. 
In contrast, the single-site mutation of C365S (construct (e)) caused the loss of autocatalytic 
TMPRSS2 cleavage activity. 
In a second set up, TMPRSS2 variants with C-terminal FLAG-tag were investigated (Table 5-
1). Initial results could be confirmed: C365S mutated full-length TMPRSS2 (construct 4) is not 
able to mature properly. The cysteine residue C365 (as well as C244) have been identified as 
crucial for TMPRSS2 maturation, possibly due to a stabilizing disulfide bond that is normally 
formed between those two cysteine residues.  
By analyzing truncated TMPRSS2 variants, the cytosolic part, the transmembrane domain and 
the LDLRA domain have been identified as not being essential for autocatalytic processing. 
Truncated variants of constructs 8 and 11 show the activity associated 27 kDa-SPD signal in 
the respective cell lysates. In contrast, further removal of 22 amino acid residues downstream 
the LDLRA domain resulted in the loss of TMPRSS2 autocatalytic activity. All four cysteine 
residues of the SRCR domain, that form two disulfide bonds, seem to be important in the 
maturation process. The single-site mutation of cysteine residue C365 also resulted in the loss 
of autocatalytic cleavage activity in the case of all truncated TMPRSS2 variants (constructs 10 
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and 12) compared to the analogous truncated variants without the mutation (constructs 8 and 
11, respectively). However random mutations in the TMPRSS2 gene at position V149 and V479 
(constructs 6 and 7 with each valine residue being substituted with an isoleucine) gave evidence 
that the applied mutating technique itself did not cause the loss of autocatalytic cleavage activity 
since these TMPRSS2 variants showed both, autocatalytic cleavage activity as well as 
proteolytic cleavage activity towards HA. Furthermore, a positive control (full-length 
TMPRSS2, construct 1 in Table 5-1) was included in every experiment to support the credibility 
of the results and to exclude general experimental failure. 
5.3.2. Cleavage activity towards H1- and H3-HA 
In the case of full-length TMPRSS2, autocatalytic cleavage activity was identified as an 
indicator for proteolytic cleavage activity towards influenza HA of the subtypes H1 and H3 in 
co-expression experiments. Whereas the mutated TMPRSS2 variants TMPRSS2_V149I and 
TMPRSS2_V479I showed cleavage activity in parallel to the positive control, the 
TMPRSS2_C365S variant was not able to cleave HA0 of subtype H1 (in parallel to the inactive 
negative control: TMPRSS2_S441A). Altering the cysteine residue C365, hence hampering the 
respective disulfide bond formation, led to the loss of TMPRSS2 activity. In contrast, the 
method was not perfectly suitable for truncated TMPRSS2 variants. Only marginal HA0 
cleavage was observed in the case of the truncated TMPRSS2 (from construct 11) even though 
strong autocatalytic cleavage activity occurred. If the truncated TMPRSS2 variants are only 
partly active after maturation or are simply not able to spatially interact adequately with the 
also membrane-bound hemagglutinin due to an altered intracellular location remains to be 
determined. A different activity test applicable to detect possible TMPRSS2 activity of non-
membrane-bound TMPRSS2 within the cell would be helpful. 
5.3.3. Localization of TMPRSS2 
Compartmentation experiments of MDCK-TMPRSS2 cells revealed that autocatalytically 
cleaved TMPRSS2 is exclusively present in membrane-bound organelles. Only the non-
glycosylated inactive TMPRSS2 zymogen could be detected in very little amounts in the 
cytosol and no TMPRSS2 is present in the cell nucleus. These experiments support previous 
suggestions that TMPRSS2 is active within the TGN. Compartmentation was not applicable for 
cells that were transiently transfected with truncated TMPRSS2. Truncated TMPRSS2 
precipitated repeatedly during isolation. In addition, results from indirect immunofluorescence 
experiments did not show any obvious differences between the localization of truncated 
TMPRSS2 variants in comparison to the membrane-anchored full-length TMPRSS2. Truncated 
TMPRSS2 localization seems also limited to cell organelles surrounding the cell nucleus.  
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5.3.4. Isolation of recombinant active TMPRSS2 for functional studies 
Three different approaches were investigated during this thesis in order to develop an 
appropriate system for the isolation of active TMPRSS2. 
First, truncated TMPRSS2 without the anchoring TM domain was used with the aim to isolate 
soluble active protein from the cell cytosol or in secreted form from cell culture medium. Even 
though truncated TMPRSS2 showed autoactivation activity, proteolytic activity could not be 
ultimately confirmed. The cell lysis with the detergents digitonin and igepal led to protein 
precipitation. Also, no truncated TMPRSS2 was detectable as a secreted form in conditioned 
cell culture medium nor in the cytoplasm. Truncated TMPRSS2 did not show any obvious 
dislocation compared to the membrane-anchored protease form. The isolation of truncated but 
active protein was not possible. In addition, the isolation and purification of His-tagged 
truncated TMPRSS2 from crude 293T cells using Ni-NTA was also not applicable. 
Second, soluble TMPRSS2 should be obtained from membrane-anchored TMPRSS2 with a 
single site mutation at cysteine residue C365. The hampered formation of the linking disulfide 
bond between SPD and plasma membrane in the case of C365S mutated TMRSS2 did not result 
in active TMPRSS2 and therefore this approach was not of further interest. 
Last, full-length TMPRSS2 was isolated via immunoprecipitation before and after 
compartmentation. While showing activity inside the cell (HA cleavage in co-expression 
experiments), no active TMPRSS2 could be isolated, when tested with chromogenic peptide 
substrates.  
Under the given experimental conditions, none of the previous elaborated approaches to isolate 
active TMPRSS2 for enzyme kinetic and structural studies was suitable. Clearly, TMPRSS2 is 
more demanding than other serine proteases like matriptase or EK, which can easily be 
produced in large quantities using E. coli expression systems. To succeed in the future with 
active TMPRSS2 isolation, it is important to further characterize the protease and discover the 
needs for its stability outside the cell. This might include optimization of the environment, 
meaning buffer components, or the presence of stabilizing co-factors, such as a substrate or 
inhibitor. 
5.3.5. New insight into TMPRSS2 functionality 
Although it was not possible to produce large amounts of active TMPRSS2, still new insight 
on TMPRSS2 functionality could be obtained during this thesis. This includes the identification 
of TMPRSS2 as a possible substrate of matriptase in vitro (as demonstrated in Figure 5-15) 
supporting TMPRSS2 involvement in possibly more than one cascade of proteolytic reactions. 
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Figure 5-15: Matriptase can activate pro-TMPRSS2 in vitro. 
Furthermore, the importance of the TMPRSS2 stem region and single amino acids has been 
identified for TMPRSS2 activity. To highlight, in particular the SRCR domain and the disulfide 
bond between cysteine residues C244 and C365 seem essential for TMPRSS2 activity. 
Truncated as well as membrane-anchored TMPRSS2 was only found in cell organelles 
surrounding the cell nucleus. Obviously, truncated TMPRSS2 is not attached to the plasma-
membrane anymore through the anchoring system, but it does not seem to be dislocated to other 
cell compartments in Huh-7 cells or even secreted. The failed isolation experiments of also full-
length TMPRSS2 suggest, that TMPRSS2 might require a specific environment or specific 
stabilizing co-factors for activity outside the cell.  
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6. Conclusion and outlook 
Influenza is one of the commonest infectious diseases affecting millions of people every year 
including 290,000 – 650,000 heavy casualties. Influenza viruses undergo constant genetic 
changes and every 10 – 50 years new influenza virus strains emerge that potentially cause a 
severe pandemic. In this modern interconnected world, experts believe the next influenza 
pandemic will be a “devastating global health event with far-reaching consequences” [1]. Novel 
effective anti-influenza drugs are in need. One strategy of influenza research is to focus on host-
specific proteases that are essential for virus activation and spread. Trypsin-like serine proteases 
are crucial for influenza activation by mediating the cleavage of the viral surface glycoprotein 
HA and hence promoting the fusion potential of the virus. Therefore, their inhibition provides 
a promising therapeutic approach. The present work focused on the characterization of two 
relevant HA cleaving type-II transmembrane serine proteases matriptase and TMPRSS2.  
 
Matriptase characterization and inhibitor design 
Chapter 3 and chapter 4 of this thesis engaged with the recombinant production of matriptase 
(chapter 3) in order to obtain pure functional enzyme of high quality for a SAR study with novel 
monobasic (hence potentially bioavailable) matriptase inhibitors of the 3-amidinophenylalanine 
type (chapter 4). Adequate amounts of high-quality matriptase enzyme were isolated using a 
new expression system and in total 5 matriptase crystals were available at the end of this thesis 
for structural analysis. The matriptase inhibitor design in this thesis focused on matriptase-
affine compounds with a fair selectivity profile against the blood coagulation enzymes thrombin 
and fXa. In total, 18 new monobasic and potentially bioavailable, as well as four new dibasic 
compounds of the 3-amidinophenylalanine types were tested. Based on the last published 
crystal structure of this inhibitor type in complex with matriptase from 2006 (PDB code 2GV6) 
docking was used as structure-based virtual screening method for lead optimization of the 
compounds N-terminus. Selected compounds were suggested to interact with the carbonyl side 
chain of Gln175 of matriptase to achieve a higher affinity of matriptase compared to fXa. 
The 4-tert-butylureido-piperidide could be identified as suitable C-terminus in combination 
with 3-fluoro-4-hydroxymethyl biphenylsulphonyl N-terminally in order to obtain excellent 
selectivity over thrombin. The binding mode of this compound (compound 55) was 
crystallographically determined in complex with matriptase as well as trypsin. Trypsin proved 
as a suitable alternative to matriptase for detailed binding mode analysis of the compounds N-
terminus. However, different preferences were detected for the C-terminus. 
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Dibasic compounds showed higher matriptase affinity and selectivity in comparison with the 
monobasic analogues. However, the tested monobasic compounds were still decent matriptase 
inhibitors that are additionally suitable for cell culture and animal studies in their benzamidine 
prodrug forms, which are well established from related inhibitors of thrombin. In addition, 
selected monobasic as well as dibasic compounds demonstrated strong suppression of the 
replication of certain H9N2 influenza viruses in a matriptase-expressing MDCK II cell model. 
These matriptase inhibitors could be potential lead structures for the development of new drugs 
against H9 strains for influenza.  
 
TMPRSS2 characterization 
TMPRSS2 is widely discussed for its role in influenza activation. With a TMPRSS2 
dependancy of HA-activation of certain subtypes, the characterization of this protease is an 
important prerequisite for being available as a target for influenza drug design. However, only 
little is known about the physiological function of TMPRSS2 and no experimental structure 
data are available at the moment to enable a structure-based drug development. Therefore, 
chapter 5 of this thesis focused on the characterization of TMPRSS2 in order to develop a 
strategy for the isolation of proteolytically active TMPRSS2 from cell culture. Even though, no 
functional TMPRSS2 could be recovered at the end of this work some new structural 
characteristics of TMPRSS2 were identified as crucial for functionality insight the cell. In 
general, TMPRSS2 without the cytosolic part, the transmembrane domain and the LDLRA 
domain is able to undergo autocatalytically activation if an artificial signal peptide was added 
N-terminal to enable entry into the endoplasmic reticulum. The presence of the cysteine-rich 
SRCR domain and the presence of the disulfide chain that connects the SPD and the stem region 
after activation cleavage have been identified as crucial for activity. N-terminal truncation of 
TMPRSS2 did not result in obvious dislocation within the cell: as the full-length positive 
control truncated TMPRSS2 was exclusively found in cell compartments surrounding the 
nucleus in immunofluorescence experiments. However, a reduced proteolytic cleavage activity 
towards H3-HA in co-expression experiments has been observed and might be a result of 
dislocation, since truncated TMPRSS2 is not bound to the biomembrane anymore. In addition, 
TMPRSS2 has been identified as a potential substrate of matriptase in vitro, which suggests 
possible participation in several zymogen cascades.  
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7. Experimental part 
7.1. Materials and consumables 
Unless otherwise stated, standard chemicals and solvents were purchased from the companies 
VWR, Fisher Scientific, Fluka, Sigma-Aldrich, Merck, or ROTH. Aqueous solutions of acids, 
bases or salts were prepared in deionized H2O, which was made by using a NOWA pure select 
system (KSN Water Technology, Nistertal). Sterile water was obtained by autoclaving 
deionized H2O for 20 min at 121 °C or was freshly sterile filtered using a 0.22 µm syringe filter.  
7.1.1. Consumables 
Component Supplier 
6x DNA-Loading dye Thermo Fisher Scientific, Waltham  
Agar-agar  Roth, Karlsruhe 
Agarose, SeaKem® LE Lonza, Basel (CH) 
Ammonium persulfate ROTH, Karlsruhe 
Ampicillin ROTH, Karlsruhe 
Benzamidine hydrochloride Sigma-Aldrich, Taufkirchen 
Bromphenol blue Merck, Darmstadt 
Cell culture flask (25 cm2, 75 cm2, 175 cm2) Greiner Bio-One GmbH, Frickenhausen 
Cell culture plates (Ø 10 cm) Greiner Bio-One GmbH, Frickenhausen 
Cell scraper Greiner Bio-One GmbH, Frickenhausen 
CelLytic M lysis buffer Merck, Darmstadt 
Chloramphenicol ROTH, Karlsruhe 
Coomassie Brilliant Blue R250 Merck, Darmstadt 
Cover slides Greiner Bio-One GmbH, Frickenhausen 
Cuvettes Sarstedt, Nuembrecht 
DAPI Institut of Virologie, Marburg University  
Dialysis membrane ROTH, Karlsruhe 
Dimethyl sulfoxide (DMSO)  Sigma-Aldrich, Taufkirchen 
DMEM  Gibco, Karlsruhe 
Doxycycline Clonetech, Saint-Germain-en-Laye  
DTT ROTH, Karlsruhe 
Erlenmeyer flasks, baffled (0,2 - 5 liter) Schott, Mainz 
FCS Gibco, Karlsruhe 
FluroshieldTM Merck, Darmstadt 
Geneticin (50 mg/ml)  Gibco, Karlsruhe 
Glycerol  ROTH, Karlsruhe 
GSH ROTH, Karlsruhe 
GSSG ROTH, Karlsruhe 
Guanidine-HCl ROTH, Karlsruhe 
HisPur™Ni-NTA Resin Thermo Fisher Scientific, Waltham  
IGEPAL® CA-360 Sigma-Aldrich, Taufkirchen 
Imidazole Sigma-Aldrich, Taufkirchen 
IPTG ROTH, Karlsruhe 
Kanamycin ROTH, Karlsruhe 
L-Arginine Sigma- Aldrich, Taufkirchen 
L-Cystine Merck, Darmstadt 
L-Glutamine 200MM  Gibco, Karlsruhe 
LipofectamineTM 2000 Invitrogen, Karlsruhe 
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MicroSeedBeads™ Molecular Dimension, Maumee (Ohio) 
Multi well plates (6, 12, 24, 96 wells) Greiner Bio-One GmbH, Frickenhausen 
Nunc™ Microwell™ 96-well microplates Sigma-Aldrich, Taufkirchen 
OptiMEM Gibco, Karlsruhe 
PEG 8000 Fluka, München 
Penicillin-Streptomycin (each 5.000 IU/ml) Gibco, Karlsruhe 
Peptone ROTH, Karlsruhe 
Petri dishes Merck, Darmstadt 
Puromycin InvivoGen, Toulouse (France) 
PVDF-membrane Millipore, Schwalbach 
Roti®-Blue 5x ROTH, Karlsruhe 
Rotiphorese® 10x SDS-PAGE ROTH, Karlsruhe 
Rotiphorese® Gel 30 ROTH, Karlsruhe 
Silicone grease (medium viscosity) GE Bayer Silicones GmbH, Leverkusen 
Skimmed milk powder Saliter, Obergünzburg 
Sterile filter  ROTH, Karlsruhe 
SYRB®Safe DNA gel stain Thermo Fisher Scientific, Waltham  
TEMED  ROTH Karlsruhe 
Triton™ X-100 Sigma-Aldrich, Taufkirchen 
Tween®20 Sigma-Aldrich, Taufkirchen 
Urea ROTH, Karlsruhe 
Vivaflow®200 crossflow cassette (MWCO: 10,000 Da) Novagen, Darmstadt 
Vivaspin Centrifugal Concentrator  Sartorius, Göttingen 
Whatman™-filter paper Sigma-Aldrich, Taufkirchen 
Yeast extract ROTH, Karlsruhe 
β-Mercaptoethanol (ME) Merck, Darmstadt 
  
7.1.2. Enzymes, proteins molecular standards 
Protein Supplier 
DNA Ligase (5 U/µl) Thermo Fisher Scientific, Waltham  
Benzonase New England Biolabs (NEB), Ipswitch  
Bovine serum albumin (BSA) ROTH, Karlsruhe 
BSA 30 % solution Sigma-Aldrich, Taufkirchen 
EDTA-Trypsin  Gibco BRL, Karlsruhe 
Endonuclease EcoRI (Fast digest) Thermo Fisher Scientific, Waltham  
Thermo Fisher Scientific, Waltham  
Thermo Fisher Scientific, Waltham  
Thermo Fisher Scientific, Waltham  
Endonuclease NheI (Fast digest) 
Endonuclease NotI (Fast digest) 
Endonuclease XhoI (Fast digest) 
Enteropeptidase (EK) (5xHis-tagged) Kindly provided by Viktor Magdolen (TU Munich) 
FastAP Thermosensitive Alkaline Phosphatase  Thermo Fisher Scientific, Waltham  
TAGZymeDaPase Enzyme QIAGEN, Hilden 
Trypsin from bovine pancreas Type I (#T8003) Sigma-Aldrich, Taufkirchen 
Trypsin from porcine pancreas, lyophilized (8 U/mg)  Merck, Darmstadt 
Thrombin from Bovine Plasma (#T4648) Sigma-Aldrich, Taufkirchen 
Factor Xa (human) 2530PL, 100 IU, 200.35 IU/mg Enzyme Research, South Bend  
 
Molecular standards (from Thermo Scientific Fisher) 
 
(A) PageRulerTM Prestained Protein Ladder  
(B) PageRulerTM Plus Prestained Protein Ladder 
(C) FastRulerTM Low range DNA Ladder, ready to use 
(D) FastRulerTM Middle range DNA Ladder, ready to use 
(E) FastRulerTM High range DNA Ladder, ready to use 
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Figure 7-1: Molecular standards for SDS-PAGE (A-B) or agarose gels (C-E). 
7.1.3. Primary and secondary antibodies 
Primary antibodies  Working dilution 
Rabbit α-H1 (pH1N1) (polyclonal)  Institute of Virology (Marburg University) 1:3000 
Goat α-H3N2 influenza virus (polyclonal) Antikoerper-online.de (Aachen) 1:6000 
Rabbit α-H3N2 influenza virus (polyclonal) Genetex. Irvine  1:2000 
Rabbit α-FLAG® M2 (polyklonal) Sigma-Aldrich, Taufkirchen 1:8000 
Rabbit α-FLAG® (polyclonal)  Sigma-Aldrich, Taufkirchen 1:8000 
Rat α-TMPRSS2 (polyclonal) 
Mouse α-TMPRSS2 (polyclonal) 
Institute of Virology (Marburg University) 
Institute of Virology (Marburg University) 
1:4000 / 1:50 
1:3000 
Mouse α-matriptase-SPD (monoclonal) R&D Systems, Minneapolis 1:1000 
Mouse α-6x-His Tag (monoclonal) Thermo Fisher Scientific, Waltham 1:1000 
Secondary antibodies Working dilution 
Goat α-rabbit IgG HRP conjugated DAKO, Glostrup  1:8000 
Rabbit α-goat IgG HRP conjugated Sigma-Aldrich, Taufkirchen 1:8000 
Donkey α-rat, Alexa Fluor® 488 conjugated Life Technologies, Ober-Olm  1:150 
Rabbit α-mouse, HRP conjugated DAKO, Glostrup  1:8000 
 
7.1.4. Bacterial strains 
E. coli strain Genotype Supplier 
Strains for cloning and plasmid preparation 
JM109 endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-
proAB) e14- [F' traD36 proAB+ lacIq lacZΔM15] hsdR17(rK-
mK+) 
NEB 
TOP10 F- ,mcrA, Δ(mrr-hsdRMS-mcrBC), φ80lacZΔM15, ΔlacX74, 
deoR, recA1, araD139, Δ(ara-leu)7697, galU, galK, rpsL(StrR 
), endA1, nupG 
Invitrogen 
XL2-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[::Tn10 
proAB+ lacIq Δ(lacZ)M15 Amy CmR] hsdR17(rK- mK+) 
Strategene 
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E. coli strain Genotype Supplier 
XL10-Gold endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 
Tn10(TetR Amy CmR)] 
Strategene 
Strains for protein expression 
BL21 Gold (DE3) 
 
B F– ompThsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endAHte Strategene 
BL21 CodonPlus (DE3)-RIL F- ompThsdS(rB- mB-) dcm+ Tetr gal λ(DE3) endAHte 
[argUileYleuWCamR] 
Strategene 
M15[pREP4] NalSStrSRifSThi- Lac- Ara+ Gal+ Mtl- F- RecA+ Uvr+ Lon+ QIAGEN 
7.1.5. Cells lines 
HEK 293T  
 
Human embryonal kidney cells 293T, ATCC® number: CRL-11268  
MDCK-H Madin-Darby canine kidney cells ATCC®-CCL-34 
MDCK-H TMPRSS2 Madin-Darby canine kidney cells induction of TMPRSS2 expression  
(Institute of Virology, Marburg University) 
Huh-7 Human Hepato Cellular Carcinoma Cells ATTC®CCL-185 
7.1.6. Plasmids 
Empty vectors 
pCAGGS Expression plasmid for eukaryotic cells, kindly provided by DR. 
MIYAZAKI [276] to the Institute of Virology (Marburg University) 
pSecTag2/Hygro B Expression plasmid for eukaryotic cells (Thermo Scientific), kindly 
provided by PROF. VIKTOR MAGDOLEN (TU Munich) 
TMPRSS2-plasmids  
pCAGGS_TMPRSS2_FLAG Plasmid for expression of TMPRSS2 with C-terminal FLAG epitope 
(GenBank: U75329) (Institute of Virology, Marburg University) 
pCAGGS_S441A_TMPRSS2_FLAG Plasmid for expression of inactive TMPRSS2 with S441A mutation 
and C-terminal FLAG epitope (Institute of Virology, Marburg 
University) 
pTRE2pur-TMPRSS2-FLAG Plasmid for expression of TMPRSS2 with C-terminal FLAG epitope 
(Institute of Virology, Marburg University) 
pCAGGS_Δex5_TMPRSS2_FLAG Plasmid for expression of LDLRA domain lacking TMPRSS2 
(+V149I) mutation [236] 
Hemagglutinin-plasmids  
pCAGGS-HA1  Plasmid for expression of the H1-HA of A/Hamburg/5/09 (H1N1) 
(GenBank: GQ166213.2) (Institute of Virology, Marburg University) 
pCAGGS-HA3 Plasmid for expression of the H3-HA of A/HongKong/1/68 (H3N2) 
(GenBank: AF348176) (Institute of Virology, Marburg University) 
Matriptase-plasmids  
pUC57_V1M_V2Y_C122S_matriptase Synthesized by GeneCust (Ellange, Luxembourg) 
pET24b_matriptase (wt) Plasmid for expression of wt-matriptase SPD in E. coli  [159] 
pQE-30_C122S_matriptase Plasmid for expression of C122S_matriptase SPD in E. coli, kindly 
provided by PROF. VIKTOR MAGDOLEN (TU Munich) 
7.1.7. Oligonucleotides 
Name Sequence 5’ – 3’ 
Primer for cloning of truncated TMPRSS2 variants 
deltaTM-EcoRI-f CAGAATTCACTATGTGGAAGTTCATGGGCAGC 
TMP2-ab A243-f CAGAATTCACTATGGCCTGCGGGGTCAACTTG 
NotI_deltaTM_f CAGCGGCCGCTGGAAGTTCATGGGCAGCAAG 
XhoI_IgK_dTM_f CACTCGAGACTATGGAGACAGACACACTCCTG 
EcoRI-TMPRSS2_f CAGAATTCACCATGGCTTTGAACTCAGGG 
NotI_dTM_dLDLRA_f CAGCGGCCGCGTTCGCCTCTACGGACCAAAC 
NotI_dSRCR_TMPRSS2_f CAGCGGCCGCGCCTGCGGGGTCAACTTG 
NotI_ab AS173_TMPRSS2_f CAGCGGCCGCCAAGACGACTGGAACGAG 
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Name Sequence 5’ – 3’ 
NotI_ab AS186_TMPRSS2_f CAGCGGCCGCAGGGACATGGGCTATAAG 
NotI_abAS231_TMPRSS2_f CAGCGGCCGCTCTTCAAAAGCAGTGG 
TMP2-His-NotI-r CGATGCGGCCGCTACCTAGTGGTGATGGTGATGGTGTCCGCC
GTCTGCCCTCAT 
NotI-Flag TMPRSS2-r CGATGCGGCCGCCTACTTGTCATCGTCATCCTTGTAGTCTCC
GCCGTCTGCCCTCAT 
TMPR_HIS_XhoI_r CGATCTCGAGTACCTAGTGGTGATGGTGATGGTGTCCGCCGT
CTGCCCTCAT 
TMP2_His_NheI_r GAGCTAGCTACCTAGTGGTGATGGTGATGGTGTCCGCCGTCT
GCCCTCAT 
deltaTM-start-r GAAGTTTGGTCCGTAGAGGCGAACAC 
NheI_FLAG_dTM_TMPRSS2_r GAGCTAGCTACCTACTTGTCATCGTCATCCTTGTAGTCTCCG
CCGTCTGCCCTCAT 
Primer for site-directed mutagenesis of TMPRSS2 
C365S_TMPRSS2_f CCTAGTGAAACCAGTGTCTCTGCCCAACCCAGGC 
C244S_TMPRSS2_f CGCTGTATAGCCTCCGGGGTCAACTTG 
V149I_TMPRSS2_f GAGAATCGGTGTATTCGCCTCTACGG 
V479I_TMPRSS2_f GGAATGTGATGATTTTCACGGACTGG 
EKSubs-TMPRSS2_f CAACTTGAACTCAGACGACGATGACAAGATTGTGGGCGGCG 
C365S_TMPRSS2_r GCCTGGGTTGGGCAGAGACACTGGTTTCACTAGG 
C244_TMPRSS2_r CAAGTTGACCCCGGAGGCTATACAGCG 
V149I_TMPRSS2_r CCGTAGAGGCGAATACACCGATTCTC 
V479I_TMPRSS2_r CCAGTCCGTGAAAATCATCACATTCC 
EKSubs-TMPRSS2_r CGCCGCCCACAATCTTGTCATCGTCGTCTGAGTTCAAGTTG 
Primer for cloning of C122S matriptase 
C122S_matriptase_nested1_f ACAAGGTTGTGGGGGGCACGGAT 
C122S_matriptase_nested2_f GATGACGATGACAAGGTTGTGGG 
C122S_matriptase_nested3_f TTGTTGGATCCGATGACGATGAC 
C122S_matriptase_r TTGTTAAGCTTATACCCCAGTGTT    
Primer for sequencing 
pCAGGS_std_f GC CTC TGC TAA CCA TGT TCA TGC C 
pCAGGS_std_r CAT ATG TCC TTC CGA GTG AGA GAC 
All primer were customarily synthesized by Eurofins Genomic (Munich). 
 
7.1.8. Cell culture medium 
Growth medium (DMEM full medium) 1x Dulbeccos Modified Eagle Medium (DMEM) (500 ml)  
+ 10 % (v/v) fetal calf serum (FCS)  
+ 1 % (v/v) penicillin/streptomycin  
+ 1 % (v/v) L-glutamine 
Transfection medium 
 
OptiMEM 
Selection medium 
 
1x DMEM full medium 
+ 0.3 μg/ml (w/v) geneticin  
+ 0.2 μg (w/v) puromycin  
 
7.1.9. Bacteria culture medium 
All media were sterilized at 121 °C for 20 min. Antibiotics were only added after cooling down 
to 60 °C or immediately before inoculation with bacterial cells.  
LB (Lysogeny Broth)-Medium  1 %   bacto-Trypton 
0.5% yeast extrakt 
1%    NaCl 
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LB/Amp-medium  LB medium with ampicillin (100μg/ml) 
LB/Kan-medium  LB medium with kanamycin (30 μg/ml) 
LB/Amp-agar plates  LB medium with 15 g/l bacto agar and ampicillin (100 μg/ml) 
7.1.10. Commercially available reaction kits 
CellTiter-Glo® 2.0 Cell Viability Assay Promega, Mannheim 
E.Z.N.A. Transfilter Plasmid Maxi Kit  Omega Bio Tek, Norcross 
GeneJET Plasmid Maxiprep Kit Thermo Scientific 
Phusion High-Fidelity PCR Kit ThermoFisher Scientific, Waltham  
ProteoJET™ Cytoplasmic and Nuclear Protein Extraction Kit  ThermoFisher Scientific, Waltham 
PureYield™ Plasmid Miniprep System Promega, Mannheim 
QuikChange Lightning Site-Directed Mutagenesis Kit ThermoFisher Scientific, Waltham 
Super Signal Dura Maximum Sensitivity Substrate  ThermoFisher Scientific, Waltham  
Super Signal Femto Maximum Sensitivity Substrate  ThermoFisher Scientific, Waltham  
Wizard® SV Gel and PCR Clean-Up System Promega, Mannheim 
7.1.11. Devices and special eqipment 
ÄKTA prime GE Healthcare 
Autoclave type FVA2 Fedegari 
Centrifuge Avanti J-10 / J-25 Beckman Coulter 
Centrifuge Biofuge fresco Heraeus 
ChemiDoc™ Imaging System BioRad 
Fluoroskan Ascent microplate reader Thermo Scientific 
HisTrap FF (+ crude) Ni-NTA column GE Healthcare 
Incubator shaker Innova 4.3 New Brunswick Scientific 
Incubator shaker Innova 4230 New Brunswick Scientific 
Microscope Axiovert 200M (fluorescence microscope) Zeiss 
Microscope SZ-PT (light microscope) Olympus 
Nanodrop 2000c Thermo Scientific 
thermo cycler (for PCR) MJ Research 
PD-10 desalting column (gravity flow) GE Healthcare 
Peristaltic pump P-1 GE Healthcare 
pH-meter Five EasyTM FE20 Mettler Toledo 
Pipettes (various) Eppendorf 
SDS-Page Mini-PROTEAN® Tetra Electrophoresis System BioRad 
SuperdexTM 75 10/300 column for size-exclusion  GE Healthcare 
Thermomixer Comfort 2ml Eppendorf 
Ultrasonic bath Elmasonic S 10/(H) Elma 
Ultrasonic Sonifier 250 Branson 
Vortex mixer VF1 Janke & Kunkel 
Balance type 572/45 Kern 
7.1.12. Software and websites 
Ascent Software Thermo Fisher Scientific 
Axio vision Sowtware for microscoping from ZEISS 
Excel  Microsoft® 
ExPASy applications SIB Bioinformatics Resource Portal [277] 
Fiji image processing package (http://fiji.sc/) 
ImageLab™ software Bio Rad 
MEROPS Peptidase Database (https://www.ebi.ac.uk/merops/) 
Origin 8.1 OriginLab® www.originlab.com 
PDB Protein data bank [278] 
PINGUI [279] (www.kolblab.org/scubidoo/pingui/) 
PyMol Molecular Graphics System, Schrödinger 
UniProt https://www.uniprot.org/ 
CHAPTER 7: EXPERIMENTAL PART 
_________________________________________________________________________________________________________________ 
 
 
123 
7.2. Molecular biological methods 
Standard molecular biology methods were applied according to [280] and are not described in 
every detail. 
7.2.1. Standard polymerase chain reaction (PCR) 
Standard PCR reactions for cloning purposes within this thesis were performed by using the 
Phusion High-Fidelity PCR Kit following manufacturer’s instructions. 
 
Reaction mixture (50 µl) Thermocycler protocol 
 
Cycles 
5xPhusion HF buffer (+MgCl2) 10 µl 
  
     T 
 
        t 
 
dNTP mix, 10 mM 1 µl Initial denaturation 98 °C 30 s  
Forward primer (10 pmol/µl) 1.5 µl Denaturation 98 °C 30 s  
Reverse primer (10 pmol/µl) 1.5 µl Primer annealing 65 °C 1 min   30 x 
Template DNA 50-100 ng Elongation 72 °C 2 min  
Phusion DNA polymerase, 2 U/μL 1 µl Final elongation 72 °C 10 min  
H2O to 50 µl Storage 4 °C        ∞  
  
7.2.2. Site-directed mutagenesis using PCR 
Single amino acid changes within the TMPRSS2 gene were carried out using the QuikChange 
Lightning Site-Directed Mutagenesis Kit following the manufacturer instructions. Site directed 
mutagenesis was done after a 5-step protocol, starting with a PCR-reaction. After the digestion 
with DpnI nuclease, the plasmid was transformed into E. coli, isolated and finally analyzed by 
sequencing. Forward and reverse primer were designed with the triplet encoding for the to be 
exchanged amino acid being located in the middle and flanked by at least 10 template DNA 
complementary nucleotides on each site. The amount of 125 ng primer was used in every PCR 
reaction and calculated with the formula for ssDNA with 330 ng/nmol as the average molecular 
weight (MW) of a nucleotide: 
 
Equation (1)   x pmoles of oligo =
125 ng
330
ng
nmol
  x   number of nucleotides
x 1000 
 
A pTRE2 vector carrying the full-length TMPRSS2 gene served as template DNA. PCR 
reactions were done in 50 µl volume following: 
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Reaction mixture Thermocycler protocol 
 
Cycles 
10x QuikChange Lightning buffer 5 µl  T t  
dNTP mix 1 µl Initial denaturation 95°C 30 s  
QuikSolution reagent 1.5 µl Denaturation 95°C 30 s  
forward primer 125 ng Primer annealing 60°C 1 min   18 x 
reverse primer 125 ng Elongation 68°C 6 min  
pTET TMPRSS2 50-100 ng Final elongation 68°C 2 min  
QuikChange Lightning enzyme 1 µl Storage 4°C ∞  
H2O  to 50 µl     
 
After the PCR, 1 U DpnI enzyme was added to each reaction, gently mixed and incubated for 
1 h at 37 °C. Since the template plasmid DNA was isolated from dam+ E. coli strains, such as 
XL2Blue, XL10Gold or JM109 strains, it is methylated. DpnI digests exclusively the 
methylated/hemimethylated parental template DNA and hence mainly mutated plasmid DNA 
was transformed into E. coli in the following step. Test tubes with 5 ml selective LB medium 
were each inoculated with a single colony and liquid cultures were grown overnight at 37 °C. 
Plasmid DNA was isolated using the PureYield™ Plasmid Miniprep System (Promega). The 
concentration and purity of isolated DNA was checked photometrically and the success of 
mutation was determined by sequencing (Eurofins Genomic). 
7.2.3. Agarose gel electrophoresis 
Electrophoresis through agarose is a standard technique to separate DNA molecules regarding 
their size. In this thesis, 1 % (w/v) agarose gels were prepared in 1 x TAE buffer and used to 
separate, identify and purify nucleic acid fragments. Samples in the FastDigest Green Buffer 
could be loaded directly. PCR-products and DNA samples digested with other enzymes than 
FastDigest enzymes were mixed with 1:5 volume of 6x Loading Dye prior loading. All agarose 
gels contained 1 µl of SYBR®Safe DNA gel stain to visualize the DNA under UV-light and 
were run in 1x TAE buffer. The ready-to-use Fast Ruler DNA Ladders (low, middle or high 
range, Figure 7-1) were used as molecular standards. 
TAE buffer (1x) 
40 mM Tris acetate, pH 8.0  
20 mM Acetic acid 
  1 mM EDTA  
7.2.4. DNA extraction and PCR product purification 
The Wizard® SV Gel and PCR Clean-Up System (Promega) was used according to 
manufacturer’s instructions in order to purify PCR products or to extract DNA fragments from 
agarose gels. For the latter application, desired DNA band were cut out of the agarose gel and 
dissolved in 100-150 µl in the kit’s membrane binding buffer. 
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7.2.5. Restriction digestion of DNA 
DNA digestion was carried out by restriction endonucleases following the manufacturer's 
instructions (7.1.2.) The linearization of vector DNA was done in a 40 µl reaction volume 
containing 1-2 µg plasmid DNA. The amplified insert DNA was digested in a 25 µl reaction 
volume containing 20.5 µl of the respective PCR product. In order to control the success of a 
ligation reaction, 100 - 300 ng of isolated plasmid DNA (from a single E. coli clone) was 
digested in a 10 µl volume and analyzed by agarose gel electrophoresis. 
For digestions with FastDigest enzymes the 10x FastDigest Green Buffer was used for all 
combinations of enzymes. In case of others than FastDigest enzymes the buffers were chosen 
according to suggestions of the DoubleDigest Calculator of Thermo Scientific. FastDigest 
enzymes were incubated 30 min to 1 h and other restriction enzymes for 1 to 3 h at 37 °C, 
respectively. As a typical example, the following protocol shows the digestions of insert DNA 
and pCAGGS-MCS with EcoRI and NheI. 
 
 Insert   vector 
 [µl]   [µl] 
FastDigest Buffer (10x) 2.5  FastDigest Green Buffer (10x) 4 
FastDigest EcoRI 1  FastDigest EcoRI 1 
FastDigest NheI 1  FastDigest NheI 1 
PCR-product 20.5  pCAGGS-MCS (680 ng/µl) 2.5 
H2O -  H2O 31.5 
  
Incubation for 1 h at 37 °C 
 
     
7.2.6. Treatment of DNA fragments with alkaline phosphatase 
Linearized vector DNA was treated with alkaline phosphatase (FastAP, Thermo Scientific) to 
remove the 5 ́phosphate groups in order to lower the self-ligation rate. 1 µl FastAP was added 
to the restriction enzyme digestion mix after 30 min. Ligation of DNA fragments was 
performed using T4 ligase. For the ligation reaction, the digested insert DNA and the digested 
plus dephosphorylated vector DNA were mixed in a ratio of 5:1 in a reaction volume of 15 µl 
respectively. Samples were incubated overnight at 16 °C and further stored at 4 °C until 
transformation. Alternatively, samples were incubated for 2 h at room temperature with further 
incubation for at least 2 days at 4 °C. 
  
T4 ligase buffer (10x) 1.5 µl 
Insert:vector [5:1] 12.5 µl 
T4 ligase 1 µl 
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7.2.7. Cloning of C122S-matriptase SPD 
The pQE-30 plasmid carrying the C122S-matriptase construct was cloned in the facilities of 
PROF. VIKTOR MAGDOLEN (TU Munich) using the pUC57_V1M_V2Y_C122S_matriptase 
plasmid (custom synthesized by GeneCust) as template. In a three-step nested PCR reaction the 
6xHis-tag and an EK-cleavage site were introduced upstream of the wild-type amino acids V16 
and V17 using the respective primer as shown in 7.1.7. 
7.2.8. Cloning of mutated full-length TMPRSS2 variants 
For subcloning of the mutated full-length TMPRSS2 genes into the pCAGGS-MCS mammalian 
expression vector a standard PCR reaction was performed using a sensed oligonucleotide 
introducing an EcoRI restriction site and the anti-sensed oligonucleotide to obtain a C-terminal 
FLAG tag and a NheI restriction site. PCR products and plasmid DNA were digested with 
EcoRI/NheI and purified with the Wizard® SV Gel and PCR Clean-Up System. The vector 
DNA was dephosphorylated, separated with agarose gel electrophoresis and extracted prior to 
purification. Following ligation reaction, the plasmid was transformed into E. coli and plated 
on selective LB/Amp agar plates. Several (5-8) overnight cultures per fragment were prepared 
by inoculating LB/Amp medium with single colonies. Plasmid DNA was extracted using the 
PureYield™ Plasmid Miniprep System, digested with EcoRI/NheI and run in an agarose gel. 
Samples showing bands of the expected size of linearized vector DNA as well as insert DNA 
were sequenced using the standard pCAGGS sequencing oligonucleotides by Eurofins 
Genomic. Sequencing positive clones were re-transformed into E. coli and large amounts of 
plasmid DNA was prepared with the E.Z.N.A. Transfilter Plasmid Maxi Kit for transient 
transfection experiments. 
7.2.9. Cloning of truncated TMPRSS2 variants 
In order to produce truncated, but still active and correctly folded TMPRSS2, an artificial signal 
peptide was added N-terminally to ensure the entry into the secretory pathway of truncated 
TMPRSS2 variants. In this thesis, the secretion signal from the V-J2-C region of the mouse Ig 
kappa-chain (Igᴋ-SP, Igᴋ) was used. For this purpose, the respective TMPRSS2 section was 
first introduced into the pSecTag2 HygroB plasmid harboring the Igᴋ-signal peptide upstream 
the multiple cloning site (MCS). In a second step, the TMPRSS2 gene including the Igᴋ-SP N-
terminally was amplified by a second PCR and subcloned into the pCAGGs-MCS vector as the 
expression vector of choice. 
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Subcloning of truncated TMPRSS2 into pSecTag2 Hygro B 
In a first step, all truncated forms of TMPRRS were amplified by PCR using appropriate sensed 
primer to introduce NotI N-terminally and anti-sensed primer introducing a C-terminal 6xHis-
tag and a XhoI restriction site. Fragments comprising of amino acids  106-492 (∆TM + 
∆TM_S441A + ∆TM_C365S), 149-492 (∆LDLRA + ∆LDLRA_C365S), 173-492, 186-492, 
232-492 and 243-492 (∆SRCR + ∆SRCR_C365S) were amplified by standard PCR using the 
pCAGGS-TMPRSS2_FLAG plasmid as template and NotI_deltaTM_f, NotI_dLDLRA_f, 
NotI_173-492_f, NotI_186-492_f, NotI_232-492_f, NotI_dSRCR_f and 
TMPRSS2_His_XhoI_r as oligonucleotides. Each fragment was digested with NotI and XhoI 
and purified with the Wizard® SV Gel and PCR Clean-Up System. The pSecTag2 HygroB 
plasmid DNA was linearized by NotI/XhoI digestion, dephosphorylated and purified with the 
aforementioned kit after agarose gel electrophoresis and subsequent gel extraction. After the 
ligation reaction, plasmid DNA was transformed into E. coli and plated on LB/Amp-agar plates. 
Several (5-8) overnight cultures per fragment were prepared by inoculating 5 ml LB/Amp-
medium each with single colonies. Plasmid DNA was extracted using the PureYield™ Plasmid 
Miniprep System, digested with NotI and XhoI and analyzed by agarose gel electrophoresis. 
Samples showing bands of the expected size of linearized vector DNA and insert DNA were 
sequenced using the standard pCAGGs sequencing oligonucleotides (by Eurofins Genomic). 
Sequencing positive clones served as template DNA for the following subcloning into the 
pCAGGS-MCS expression vector. 
 
Subcloning of truncated Igᴋ-TMPRSS2 into pCAGGS-MCS 
For subcloning the Igᴋ containing truncated TMPRSS2 variant into the pCAGGS-MCS 
expression vector a standard PCR reaction was performed using a sensed oligonucleotide 
complementary to the Igᴋ-SP sequence of the pSecTag2 HygroB plasmid. Sensed 
oligonucleotides introduce an XhoI restriction site and anti-sensed oligonucleotides were 
designed to either keep the 6xHis-tag C-terminally or substitute it with a FLAG-tag. In both 
cases, a NheI restriction site was introduced at the very end. PCR products and vector DNA 
were digested with XhoI plus NheI and purified with the Wizard® SV Gel and PCR Clean-Up 
System. The vector DNA was dephosphorylated, separated with gel electrophoresis and 
extracted prior to purification. After ligation, the plasmid DNA was transformed into E. coli 
and plated on LB/Amp-agar plates. Several (5-8) overnight cultures per fragment were prepared 
by inoculating 5 ml LB/Amp-medium with a single colony each. Plasmid DNA was extracted 
using the PureYield™ Plasmid Miniprep System, digested with XhoI and NheI and analyzed 
by agarose gel electrophoresis. Samples showing bands of the expected size of linearized vector 
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DNA as well as insert DNA were sequenced using the standard pCAGGs sequencing 
oligonucleotides (Eurofins Genomic). Sequencing positive clones were re-transformed into E. 
coli and large amounts of plasmid DNA was prepared with the E.Z.N.A. Transfilter Plasmid 
Maxi Kit for transient transfection experiments. 
7.3. Microbiological methods 
7.3.1. Growth and storage of bacterial strains 
Bacteria were grown at 37 °C on LB agar plates or in liquid LB medium that was supplemented 
for positive selection with appropriate antibiotics in the respective concentrations. All media 
were sterilized for 20 min at 121 °C. For permanent storage, cell strains carrying the plasmid 
of interest were grown overnight in selective LB medium and were flash frozen in liquid 
nitrogen after being mixed with glycerol at a final concentration of 25 %.  
7.3.2. Heat-shock based transformation of chemically competent E. coli cells 
For transformation, 20-40 µl of competent E. coli cells were thawed on ice and mixed with 
either 50-100 ng experimental DNA or 2-4 µl of ligation mixture. Tubes were incubated on ice 
for 10-30 min, heat-shocked for 30 s at 42 °C and immediately transferred on ice for at least 2 
min. 760 – 780 µl LB medium at RT was added and the cells were incubated at 37 °C for 1 h 
with shaking at 350 rpm. Cells were pelleted by centrifugation for 1 min at 10.000 rpm. 700 µl 
LB medium was discarded and in the remaining liquid resuspended cells were plated on 
selective LB agar. Plates were incubated bottom up overnight at 37 °C and used for maximal 
three weeks stored at 4 °C. 
7.3.3. Recombinant production of matriptase in E. coli 
Overnight cultures of 200 – 300 ml sterilized selective LB medium were inoculated with single 
colonies, containing the respective expression plasmid, and incubated at 37 °C overnight with 
continuous shaking.  Alternatively, glycerol stocks were used for inoculation. The overnight 
cultures were diluted 1:40-1:50 into 6-12 liters fresh selective LB medium and were further 
incubated at 37 °C with vigorous shaking at 120-150 rpm. The protein expression was induced 
by the addition of 1 mM IPTG (from a freshly prepared 1 M IPTG stock) when OD600 reached 
0.6 – 0.9. Bacterial cells were harvested 4 h after induction by centrifugation at 4 °C and 
8000 rpm for 15 min. If not processed immediately after harvesting, pellets were flash frozen 
in liquid nitrogen and stored at -80 °C until use. For expression of wild type matriptase-SPD a 
glycerol stock of BL21(DE3) CodonPlus (DE3)-RIL cells containing the pET24-matriptase 
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plasmid was used. The pQE-30-matriptase-C122S plasmid was expressed by M15[pREP4] 
cells after fresh transformation. 
7.4. Cell culture methods 
7.4.1. Thawing, freezing and passaging of cells 
A frozen 1 ml cell suspension aliquot was shortly thawed in a water bath at 37 °C and mixed 
with 3 ml DMEM cell culture medium. After centrifugation for 5 min at 900 x g and RT the 
cell pellet was resuspended in 1 ml DMEM full medium and transferred to a T75 culture flask 
containing DMEM full medium. Cells were incubated at 37 °C and 5 % CO2 until a confluency 
of 95-100 % was reached. For passaging cells, medium was aspirated and cells were washed 
with DMEM full medium once and detached by incubating with 2 ml trypsin/EDTA at 37 °C. 
After 5-15 min, the reaction was blocked by adding 8 ml of DMEM full medium and the 
resuspended cells were transferred into fresh DMEM full medium. For 1:10 dilution, 1 ml of 
cell suspension was transferred to a T75 flask. For freezing cells, detached cells were first 
centrifuged for 5 min at 900 x g. The cell pellet was resuspended in 4 ml DMEM full medium 
supplemented with 25 % DMSO as cryo protectant. 1 ml aliquots were frozen in cryo vials, by 
storing the vials in an isopropanol freezing container for 24 h at -80 °C before being finally 
transferred into a liquid nitrogen dewar for long-term storage. 
7.4.2. Transient transfection of eukaryotic cells with Lipofectamine™ 2000 
LipofectamineTM2000 is used for transfection of different cell lines with plasmid DNA. As a 
cationic lipid it forms a complex with negatively charged DNA molecules, which then enters 
the cellular membrane through endocytosis. Cells were seeded into appropriate well plates or 
cell culture flasks and transfected when the desired cell confluency was reached.  
 
 
Cell line Confluency for transfection  
[%] 
HEK 293T 90 - 95 
HUH-7 70 - 80 
MDCK-H 70 - 80 
 
For all transfections, the serum-free OptiMem was used as medium. Quantity of 
Lipofectamine2000 and plasmid DNA in up-scaling approaches were adjusted regarding cell 
number and surface area of the used culture vessel.  
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Culture vessel Surface are 
per well1 
Shared reagent DNA Lipofectamine 
2000™ Vol. of plating 
medium 
Vol. of dilution 
medium 
 
12-well 4 cm2 1 ml 2 x 100 µl 1.6 µg 2 µl 
6-well 10 cm2 2 ml 2 x 250 µl 4.0 µg 4 µl 
10 cm 60 cm2 15 ml 2 x 1.5 ml 24 µg 60 µl 
T75 75 cm2 15 ml 2 x 1.5 ml 36 µg 75 µl 
¹ Surface areas may vary depending on the manufacturer. 
Modified after: https://www.thermofisher.com. 
 
The transfection procedure was performed as recommended by the manufacturer. The 
following protocol for the transfection in a 12-well format is to be seen as an example. 
 
1. 1.6 µg plasmid DNA of each to be transfected sample was mixed with 100 µl OptiMEM in 1.5 ml reaction 
tubes 
2. Lipofectamine Master-Mix (MM) was prepared (100 µl OptiMEM mixed with 2 µl Lipofectamine2000 
reagent per number of transfections, e.g. 5 samples: 500 µl OptiMEM + 10 µl Lipofectamine2000) 
3. 5 min incubation at room temperature of each tube individually 
4. 100 µl Lipofectamine MM was added to each 100 µl OptiMEM/DNA sample 
5. 20 min incubation at room temperature (Lipofectamine/DNA complex formation) 
6. Growth medium from 293T cells was changed to 800 µl OptiMEM meanwhile 
7. 200 µl OptiMEM containing the Lipofectamine/DNA complex was added (dropwise) to the 
corresponding well 
8. Cells were incubated at 37 °C for 24-48 h with a medium change after 4-6 h post transfection to 1 ml 
DMEM full medium. 
7.5. Biochemical methods 
7.5.1. Purification and refolding of wt-matriptase from BL2(DE3)CodonPlus RIL cells 
Cell lysis and purification 
Cell pellets from 6 liters cultured LB medium were used per purification procedure. Frozen 
cells were thawed at RT and each pellet of 2 liters cell culture was resuspended in 40 ml IB-
buffer containing 3 mM DTT. Cells were broken by sonication on ice for two times 4 min at 
70 % output. To digest the nucleic acids, 1 µg/ml benzonase was added and the cell suspension 
was incubated for 30 min on ice. Inclusion bodies were harvested by centrifugation for 30 min 
at 20.000 rpm, washed twice with IB-buffer, and finally resuspended in 5 ml/g pellet of 6 M 
Guanidine lysis buffer A (pH 8.0). To complete denaturation, the suspension was incubated 
overnight at RT on the end-over-end rotator. Insoluble components were separated by 
centrifugation for 1 h at 20.000 rpm. The supernatant was loaded with a peristaltic pump at a 
flow rate of 1 ml/min onto a 5 ml Ni-NTA column, which had been equilibrated previously 
with the guanidine lysis buffer.  The column was connected to the Äkta system and washed 
with Urea wash buffer A (pH 6.3) until a constant baseline signal was reached. Proteins were 
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eluted with Urea elution buffer A at a pH of 4.5 and fractions covering the elution peak were 
pooled and concentrated to at least 2.5 mg/ml. The pH was adjusted to 8.0 with 5 M NaOH and 
the protein solution was incubated overnight with 7.5 mM GSH and 0.75 mM GSSG at RT. To 
remove GSH and GSSG, protein solution was dialyzed against Urea dialysis Buffer (pH 5.0) at 
RT for 8 h with changing the buffer thrice.  
 
IB-buffer  
(pH 7.5) 
Guanidine lysis 
 buffer A 
(pH 8.0) 
Urea wash 
 buffer A 
(pH 6.3) 
Urea elution  
buffer A 
(pH 4.5) 
Urea dialysis 
 buffer 
(pH 5.0) 
50 mM Tris-HCl 6 M Guanidine-HCl 8 M Urea 8 M Urea 6 M Urea 
154 mM NaCl 0.01 M Tris-HCl 0.01 M Tris-HCl 0.01 M Tris-HCl 0.01 M Tris-HCl 
3 mM DTT 0.1 M NaH2PO4 0.1 M NaH2PO4 0.1 M NaH2PO4 0.1 M NaH2PO4 
 10 mM β-ME 10 mM β-ME 10 mM β-ME  
 
Refolding of denaturized proteins by rapid dilution 
The purified and denaturized proteins were renatured using the rapid dilution technique. 
Therefore, the suspension was dropwise diluted 50 – 100 times into ice-cold RD-Refolding 
buffer under moderate stirring. After incubation for 3 days at RT, the protein solution was 
filtered and concentrated to a final volume of approximately 100 ml with the Vivaflow®200 
crossflow cassette (MWCO: 10.000 Da). Prior to the 6xHis-tag removal, and hence matriptase 
activation, buffer was exchanged to 1x TAGZyme buffer using PD10 columns under gravity 
flow. The protein concentration was adjusted to > 0.3 mg/ml.  
 
RD-Refolding buffer  
(pH 7.5) 
TAGZyme buffer 
(pH 7.0) 
50 mM Tris-HCl 20 mM NaH2PO4 
500 mM L-Arginin 150 mM NaCl 
100 mM NaCl  
20 mM CaCl2  
1 mM EDTA  
0.5 mM Cystein  
 
Activation of MK(H)6-matriptase by the dipeptidyl aminopeptidase-1 (DAPase-I) 
For the 6xHis-tag removal, 2.5 mU TAGZyme™ DAPase™ (QIAGEN, Hilden) was used per 
50 µg of protein. First, DAPase was diluted to 1 U/ml in TAGZyme buffer, mixed 1:2 with 
2 mM cysteamine-HCl (part of the kit) and activated for 1 h at 37 °C. Respective amount of 
activated DAPase was mixed with the matripase solution and incubated for 2.5 h at 30 °C. The 
recombinant C-terminally His-tagged DAPase removes dipeptides sequentially from the N-
terminus of proteins. Some amino acids in P1’ or P2’ position stop or strongly inhibit cleavage. 
In case of matriptase only the N-terminal His-tag will be removed, since amino acid residues 
with hydrophobic side chains (such as valine residues 615 and 616) inhibit DAPase activity. 
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Precipitates were removed by centrifugation and filtration. The clear protein solution was 
checked visually for protease activity by incubation with the chromogenic Mes-DCha-Gly-Arg-
pNA and was further stored at 4 °C for 16 h. His-tagged DAPase and non-activated matriptase 
were removed via reverse IMAC. Protein solution was therefore mixed 1:1 with Ni-NTA lysis 
buffer and pumped over a Ni-NTA column. While DAPase and non-activated matriptase bind 
to the Ni-NTA resin of the column, the flow through contains the active protease. The volume 
of active matriptase was reduced to < 5ml by concentration and subsequently further purified 
by gel filtration using a Superdex®75 with 1x PBS pH 7.5 as running solution. Fractions of 
active matriptase were pooled and stored at a concentration of 0.3 mg/ml at -80 °C. Bound 
proteins on the Ni-NTA column were washed and eluted with Ni-NTA elution buffer to allow 
column reuse. 
 
Ni-NTA lysis buffer 
(pH 8.0) 
Ni-NTA wash buffer 
(pH 6.3) 
Ni-NTA elution buffer 
(pH 4.5) 
50 mM NaH2PO4 50 mM NaH2PO4 50 mM NaH2PO4 
300 mM NaCl 150 mM NaCl 150 mM NaCl 
10 mM Imidazole   
 
7.5.2. Purification and refolding of C122S-matriptase from M15 cells 
 
Cell lysis and purification 
Cell pellets from 8-12 liters cultured medium were used per purification procedure. Frozen cells 
were defrosted at RT and each pellet of 2-3 liters cell culture was resuspended in 40 ml of 6 M 
Guanidine lysis buffer B containing 1 mM β-ME. To complete cell lysis and inclusion body 
denaturation, the suspension was incubated overnight at RT on the end-over-end rotator. 
Insoluble components were separated by centrifugation for 1 h at 20.000 rpm. To reduce 
viscosity, the supernatant was filtered through a 0.8 µm syringe filter or was passed several 
times through a gauche needle before being loaded onto Ni-NTA column with a peristaltic 
pump at 1-2 ml/min. The column was washed with minimum 5 column volumes of 8 M Urea 
lysis buffer before being connected to the Äkta system. The column was washed with Urea 
wash buffer B until a constant baseline signal was reached and proteins were eluted with Urea 
elution buffer B at pH 4.5. The fractions covering the elution peak were pooled and diluted with 
Urea wash buffer B to a protein concentration of 0.1-0.5 mg/ml or a maximum volume of 
100 ml. To ensure reduction of all cysteine residues prior refolding, 20 mM DTT was added. 
The protein solution was incubated overnight at RT on the end-over-end rotator or for at least 
3 h before starting the refolding process. 
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Guanidine lysis buffer B 
(pH 8.0) 
Urea lysis buffer 
(pH 8.0) 
Urea wash buffer B 
(pH 6.3) 
Urea elution buffer B 
(pH 4.5) 
6 M Guanidine-HCl 8 M Urea 8 M Urea 8 M Urea 
0.01 M Tris-HCl 0.01 M Tris-HCl 0.01 M Tris-HCl 0.01 M Tris-HCl 
0.1 M NaH2PO4 0.1 M NaH2PO4 0.1 M NaH2PO4 0.1 M NaH2PO4 
1 mM β-ME 1 mM β-ME 1 mM β-ME 1 mM β-ME 
 
 
Refolding of denaturized proteins by step wise dialysis 
Denaturized and purified proteins were refolded via stepwise dialysis. The protein solution was 
transferred into a dialysis tube with a molecular weight cut off (MWCO) of 10 – 12 kDa and 
dialyzed in different refolding buffers with decreasing urea concentrations at 4 °C. For the 
initial dialysis step, the protein solution was incubated in 3 liters Dialysis buffer I (pH 7.5), 
containing 4 M urea, for at least 6 h (or overnight). The dialysis tube was next incubated in 
3 liters of 2 M urea containing Dialysis buffer II. This buffer was supplemented with GSH and 
GSSG in a ratio of 10:1 (2.5 mM / 0.25 mM) as oxido-shuffling system to support the correct 
forming of disulfide bridges during refolding. After 2 days, the dialysis tube was transferred to 
3 liters of 1 M urea containing dialysis Dialysis buffer III, supplemented with 1.25 mM GSH 
and 0.125 mM GSSG, and was further incubated for 2 days at 4 °C before being transferred to 
4 liters of the urea free Dialysis buffer IV. Protein solution was dialyzed overnight with a buffer 
exchange after 4 h. The refolded protein was concentrated to a volume of 50 – 70 ml or a 
maximum protein concentration of 1 mg/ml. 
 
Dialysis buffer I 
(pH 7.5) 
Dialysis buffer II 
(pH 7.5) 
Dialysis buffer III 
(pH 7.5) 
Dialysis buffer IV 
(pH 7.8) 
4 M Urea 2 M Urea 1 M Urea 100 mM NaCl 
0.25 M L-Arginin 0.5 M L-Arginin 0.25 M L-Arginin 50 mM Tris-Cl 
100 mM NaCl 100 mM NaCl 100 mM NaCl 0.005 % Tween 20 
50 mM Tris-HCl 50 mM Tris-HCl 50 mM Tris-Cl  
20 mM CaCl2 20 mM CaCl2 20 mM CaCl2  
1 mM EDTA 1 mM EDTA 1 mM EDTA  
0.005 % Tween 20 0.005 % Tween 20 0.005 % Tween 20  
 2.5 mM GSH 1.5 mM GSH  
 0.25 mM GSSG 0.15 mM GSSG  
 
 
Activation of MRGS(H)6GSDDDDK-C122S-matriptase by enteropeptidase (EK) 
For activation of C122S-matriptase, the protein solution was mixed with 5xHis-tagged EK 
(provided by Viktor Magdolen (TU Munich, Germany) and produced by Wolfgang Skala 
(following Skala et al., 2013)) in a matriptase/enteropeptidase ratio of 500-700 : 1. The solution 
was incubated overnight at RT on the end-over-end rotator. Precipitate was removed by 
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filtration and the clear protein solution was checked visually for activity by incubation with the 
chromogenic substrate Mes-DCha-Gly-Arg-pNA. The activated matriptase was separated from 
the non-activated protein as well as 5xHis-tagged EK by reverse IMAC. The protein solution 
was loaded onto a 5 ml Ni-NTA column and the flow through containing the activated protein 
was collected and concentrated to a volume smaller than 5 ml. C122S-matriptase was further 
purified by gel filtration using a Superdex®75 which was run with Storage buffer (C122S-
matriptase) at RT. Active matriptase of 0.28 mg/ml in C122S-matriptase storage buffer was 
flash frozen in liquid nitrogen and stored at -80 °C. For crystallization experiments, the freshly 
produced matriptase was concentrated to 5 - 10 mg/ml or flash frozen at ~ 1 mg/ml for later 
experiments. 
 
Storage buffer (C122S-matriptase) 
(pH 7.8) 
100 mM NaCl 
50 mM Tris-Cl 
5 % Glycerol (v/v) 
 
7.5.3. Isolation of plasmid DNA from E. coli 
Plasmid DNA was isolated from E. coli cells grown overnight in the LB/Amp medium. Routine 
plasmid isolation was carried out by alkaline lysis method using the PureYield™ Plasmid 
Miniprep System (Promega) or the E.Z.N.A. Transfilter Plasmid Maxi Kit (Omega). DNA was 
isolated and purified via anion exchange resin according to manufacturer’s instructions 
respectively. 
 
Miniprep (PureYield™ Plasmid Miniprep System) 
Small amounts of DNA that were used as template DNA for cloning purposes as well as for 
sequencing experiments were isolated from 2-4 ml overnight cultures and was eluted into 30 – 
40 µl H2O.  
 
Maxiprep (E.Z.N.A. Transfilter Plasmid Maxi Kit) 
For transient expression experiments, larger DNA amounts were required. Therefore, 200-
600 ml overnight cultures were used to isolate DNA, which was finally eluted with a volume 
of 500 – 1000 µl H2O each. 
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7.5.4. Ultraviolet-Visible (UV-Vis) Spectroscopy using Nanodrop™2000c 
A nanodrop™2000 spectrophotometer (Thermo Scientific) was used following the 
manufacturer’s manual to measure quantity and purity of nucleic acids and the concentrations 
of proteins as well as bacterial culture density following the Beer-Lambert law respectively. 
 
Determination of quantity and purity of total DNA 
Nucleic acids absorb UV light due to the heterocyclic rings of the nucleotides with a maximum 
absorption at 260 nm. For quantity/quality determination of the DNA preparation, 2µl were 
loaded onto the nanodrop’s pedestal (after zeroizing with H2O) and measured at wavelengths 
of 260 and 280 nm. At a concentration of 50 µg/ml and a 1 cm path length, dsDNA has an 
OD260 of 1. Based on this assumption, DNA is quantified and recorded by the nanodrop 
software as ng/µl automatically. For purity assessment the A260/A280 ratio is commonly used, 
with A260/A280 = 1.8 considering the DNA sample pure from contaminations, such as 
proteins. DNA samples with A260/A280 of 1.8 - 2.0 were considered sufficiently pure for 
further experiments. 
 
Determination of protein concentration 
Protein concentration is measured using the Protein A280 method, which is applicable to 
purified proteins that contain the amino acids Trp and Tyr or Cys-Cys disulfide bonds and 
therefore exhibit absorbance at 280 nm. After blank measurement with the protein’s storage 
buffer, 2 µl protein sample were loaded to the nanodrop’s pedestal and measured at wavelengths 
230 nm, 260 nm and 280 nm. The chosen sample type was “Other protein (Ɛ+ MW) “, with the 
extinction coefficient/1000 (Ɛ) and molecular weight (MW) in kilodaltons being calculated with 
the ExPASy ProtParam tool based on the protein amino acid sequence. 
 
 before activation 
MW in [kDa] 
after activation 
MW in [kDa] 
extinction coefficient 
/ 1000 [(mg/ml)-1cm1] 
 
wt-matriptase 28.41 27.50 
27.50 
53.32 
53.32 C122S-matriptase 27.50 
 
Determination of bacterial concentration in culture (OD600 measurement) 
The number of microbial cells were determined by measuring bacterial culture density at 
600 nm using the cuvette option. Sterilized LB medium served as blank. 
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7.5.5. Preparation of 293T cell lysates for western blotting 
Cell lysis prior to western blot analysis was performed by sonication directly in 1x SDS buffer 
or chemically by using the CelLytic M lysis buffer (Merck). 293T cells were therefore harvested 
by resuspension in the growth medium 48 h after transfection with subsequent centrifugation 
for 5 min at 8.000 rpm. 
 
Cell lysis by sonication in 1x SDS sample buffer 
Transient transfected cells were washed in PBSdef once, pelleted and finally resuspended in an 
adequate volume of PBSdef (30 - 60 µl), depending on the pellet size. Cell were mixed with an 
equal volume of 2x SDS sample buffer and sonified for 1 min.  
 
Cell lysis with CelLyticM buffer 
Transiently transfected 293T cells were washed in PBSdef, pelleted and resuspended in an 
adequate volume of CelLyticM lysis buffer (50 – 80 µl). After 30 min incubation on ice with 
light shaking, cell debris was pelleted by centrifugation for 5 min at 13.000 rpm at 4 °C. 50 µl 
of supernatant was transferred to a fresh reaction tubes and mixed with 10 µl of 6x SDS sample 
buffer supplemented with DTT. 
 
1x PBSdef (pH 7.5) 2x SDS Buffer (+β-ME) 6x SDS Buffer (+DTT) 
8 g NaCl 1.2 ml 1 M Tris-HCl (pH 6.8) 1.2 ml 1 M Tris-HCl (pH 6.8) 
0.2 g KCl 4 ml 10 % SDS 1.2 g SDS 
1.15 g Na2HPO4 2 ml Glycerol 4.7 ml Glycerol 
0.2 g KH2PO4 0.02 % (w/v) Bromophenol blue 6 mg Bromophenol blue 
Add 1 liter H2O 0.2 ml β-ME 0.93 g DTT 
 2.6 ml H2O 2.1 ml H2O 
 Aliquots frozen at -20 °C Aliquots frozen at -20 °C 
7.5.6. Sodiumdodecylsulfat-polyacrylamid gelelectrophoresis (SDS-PAGE) 
In this thesis, SDS-PAGE was used to separate proteins before western blotting or to confirm 
presence and purity of samples during protein purification procedures. Either way, lysates or 
protein solutions were mixed with 2x - 6x SDS buffer (to a final concentration: 1x) and were 
separated in 12 % - 15 % polyacrylamide gels. Prior loading, samples were incubated at 95 °C 
for 5 – 20 min (depending on sample viscosity) and centrifuged for 5 min at 13.000 rpm. 
 
SDS-PAGE for western blotting 
For western blotting purposes polyacrylamide gels made of a 4.4 % stacking gel and 12 % 
separation gel were prepared as followed: 
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stacking gel (4.4%)  seperation gel (12%) 
0.5 M Tris-HCl (pH 6.8) 1.3 ml   1.5 M Tris-HCl (pH 8.8) 2.5 ml 
Rotiphorese®Gel30 750 µl   Rotiphorese®Gel30 4 ml 
dH2O 2.9 ml   dH2O 3.3 ml 
10 % SDS 100 µl   10 % SDS 100 µl 
10% APS 60 µl   10% APS 100 µl 
TEMED 10 µl   TEMED 10 µl 
 
10 µl – 20 µl of protein samples in 1x SDS buffer were loaded onto the gels and proteins were 
separated beginning with 10 min at 100 V and completed by running 40 – 50 min at 150 V. 
Western blotting was performed as described below. 
 
SDS-PAGE for validation of protein expression or purification 
In order to check presence or purity of proteins, 15 % separation gels were used. Three protions 
of protein samples were diluted in one portion 4x SDS sample buffer (1x final concentration), 
incubated for 5 min at 95 °C, separated at 120 – 160 V for 60 – 90 min and finally visualized 
by either staining at RT in Coomassie staining solution for 1 h or in a 1x RotiBlue Solution 
overnight. Gels were destained in the corresponding destaining solution to remove background 
color of the gel and photographed for analysis (smartphone camera). 
 
4x SDS sample buffer Coomassie staining solution Coomassie destaining solution 
2 ml 1M Tris-HCl (pH 6.8) 40 % Methanol 20 % Methanol 
0.8 g SDS 10 % Glacial acetic acid 10 % Glacial acetic acid 
4 ml Glycerol 0.1 % (1g/L) Coomassie R250  
0.4 ml β-ME   
4 mg Bromophenol blue 1x RotiBlue solution (1L) RotiBlue destaining solution 
H2O to 10 ml 20 % 5x RotiBlue Solution 25 % Methanol 
 
7.5.7. Immunodetection by western blotting 
The sensitive detection of specific proteins from crude cell lysates, supernatants or purified 
protein samples was performed by western blotting and immunostaining using the “semi-dry” 
blotting technique [281]. Proteins were first separated by SDS-PAGE and subsequently 
transferred to a polyvinylidene difluoride membrane (PVDF) using a semi-dry blotter (Bio-
Rad, Munich). Prior to blotting, the membrane was activated for 30 s in methanol and 
subsequently incubated in Transfer buffer in parallel with the SDS-gel and six Whatman™-
filter paper per membrane. The proteins were transferred at 40 mA per membrane for 70 min. 
After the transfer, the membrane was immediately incubated for at least 1 h in WB blocking 
buffer to saturate unspecific binding sites. Primary antibody was added and incubation took 
place overnight at 4 °C with smooth movement. After being washed three times for 10 min in 
PBS/Tween, the membrane was incubated with the respective HRP conjugated secondary 
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antibody in WB blocking buffer for 1 h at RT and finally washed thrice with PBS/Tween as 
described above. Antibody dilutions were used as described in section 7.1.3. Detection was 
performed using the enhanced chemiluminescence (ECL) method with SuperSignal™ 
WestFemto or SuperSignal™ West Dura as ECL-substrates according to manufacturer’s 
instructions. Blots were incubated for at least 5 minutes with the substrate in darkness before 
signals were detected in the ChemiDoc™ Imaging System using the ImageLab™ software. 
 
Transfer buffer WB blocking buffer PBS/Tween 
5.8 g Tris base 1x PBS 1x PBS 
2.9 g Glycine 0.1 % Tween-80 0.1 % Tween-80 
200 ml Ethanol 7 % Skimmed milk  
fill to 1 liter with H2O   
 
7.5.8. Immunofluorescence of transiently transfected Huh-7 cells 
Fixation, permeabilization and blocking of Huh-7 cells 
For fixation of transiently transfected Huh-7 cells (grown on cover slides in 24-well plates), the 
medium was removed carefully 24 h after transfection and the cells were washed with ice cold 
1x PBSdef twice. Cells were coated with ice cold acetone/methanol mixture (ratio 1:1) and 
incubated on ice for 20 min. The acetone/methanol solution was removed, the cells washed two 
times with 1x PBSdef and incubated for 1-2 h with IF blocking buffer. 
IF blocking buffer 
1x PBS 
2 % BSA 
 
Incubation with primary and secondary antibody 
Cells were incubated with the primary rat α-TMPRSS2 antibody in a 1:50 dilution in IF-
blocking buffer in a dark and wet environment. After 1 h, cells were washed with 1x PBSdef 
thrice and subsequently incubated 1 h with a mixture of an α-rat Alexa-488 conjugated 
secondary antibody in a 1:150 dilution and 1:50 diluted DAPI both in IF blocking buffer in the 
dark wet environment. Cells were washed with 1x PBSdef twice and once with H2O before being 
covered with FluroshieldTM mounting medium on a microscope slide. Cells were incubated at 
RT in the dark overnight, analyzed and photographed with the camera enclosed to the ApoTome 
fluorescence microscope (Zeiss) and further stored at 4 °C. 
7.5.9. Compartmentation of stably and transiently transfected MDCK-H cells 
Compartmentation was performed using the buffer supplements digitonin and igepal [275] to 
fractionate proteins from different cell compartments or by using the ProteoJET™ Cytoplasmic 
and Nuclear Protein Extraction Kit (Thermo Scientific) following manufacturer's instructions. 
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MDCK-TMPRSS2 cells or transiently transfected MDCK-H cells with truncated constructs 
were harvested carefully 48 h after induction or transfection with a cell scraper and washed 
twice with chilled 1x PBSdef. All steps were performed on ice or 4 °C with pre-chilled buffers.  
 
Compartmentation using digitonin and igepal 
Fractionizing cell compartments by sequential lysis of cell membranes was performed after the 
method of BAGHIROVA and team [275] (as shown in Figure 7-2). Cytosolic proteins were isolated 
by using a digitonin supplemented buffer. The steroidal saponin binds with cholesterol and 
other β-hydroxysterols and hence permeabilizes the cholesterol rich plasma membrane by pore 
formation, but not the cholesterol poor membranes of cellular organelles [282]. In a second step, 
proteins of membrane bound organelles were isolated by using low concentrations of the non-
ionic and non-denaturizing detergent igepal to permeabilize the membrane of the ER, Golgi and 
mitochondrion while keeping the nucleus membrane intact. Proteins from 1/2 T75 culture flask 
or from a 10 cm dish were isolated by using 400 µl of Buffer A and B respectively. Each isolated 
fraction was analyzed by western blotting or further used for immunoprecipitation or treatment 
of H1-HA transfected 293T cells. 
 
Buffer A Buffer B 
150 mM NaCl 150 mM NaCl 
50 mM HEPES (pH 7.4) 50 mM HEPES (pH 7.4) 
25 µg/ml Digitonin 1 % (v/v) Igepal 
1 M Hexlene glycol 1 M Hexlene glycol 
 
 
Compartmentation using the ProteoJET™ Cytoplasmic and Nuclear Protein Extraction Kit 
Cells of 1/2 T75 culture flash were used to separate cytoplasmic and nuclear proteins by 
following the manufacturer's instruction. All buffers were supplemented as recommended with 
0.1 M DTT, but not treated with protease inhibitors. The cytoplasmic fraction contained 
cytosolic, as well as proteins from membrane-bound organelles. 
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Figure 7-2: Cell compartmentation using digitonin and igepal containing lysis buffers.  
7.5.10. Immunoprecipitation using the ANTI-FLAG M2 Affinity Gel 
FLAG-tagged TMPRSS2 was isolated from stably transfected MDCK-TMPRSS2 cells 48 h 
post induction with doxycyclin according to manufacturer's instructions (Merck). Cell lysate 
was incubated with equilibrated ANTI-FLAG® M2 Affinity Gel overnight at 4 °C on the end-
over-end rotator. The next day, the affinity gel was washed with TBS thrice, and bound proteins 
were eluted by incubation with 0.1 M glycine (pH 3.0). After 5 min incubation at RT, affinity 
gel was separated by centrifugation and the supernatant was directly mixed 1:10 with 10x TBS 
to neutralize the low pH glycine. Eluted proteins were immediately visually checked for activity 
by incubating with the chromogenic substrate Mes-DCha-Gly-Arg-pNA. Alternatively, bound 
proteins were eluted directly by incubation in 2x SDS buffer for 10 min at 95 °C and analyzed 
via SDS-PAGE and western blotting.  
 
10x TBS 1x TBS 
500 mM Tris-HCl (pH 7.5) 50 mM Tris-HCl (pH 7.5) 
1.5 M NaCl 150 mM NaCl 
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7.5.11. Enzyme kinetic measurements 
All enzyme kinetic measurements were performed using synthetic fluorogenic 7-amino-4-
methylcoumarin (AMC) substrates at λex = 355 nm and λem = 460 nm in a Fluoroskan Ascent 
reader (Thermo Scientific). All substrates were synthesized in house and prepared as a 10 mM 
stock solution in 100 % ultrapure water or in case of lower soluble compounds in 50 % DMSO. 
Stock solutions of synthesized inhibitors were prepared in a concentration of 10 mM in 100 % 
DMSO, which were subsequently diluted with Enzyme kinetic buffer to appropriate final 
concentrations. The lowest inhibitor concentration in the assay was chosen to be at least 10-
fold higher than the used enzyme concentration. The reaction volume of 140 µl consisted of 
100 µl Enzyme kinetic buffer (with or without respective inhibitor concentration), 20 µl 
substrate and 20 µl enzyme solution. After adding the enzyme, the substrate turnover was 
detected at RT in 15 s intervals for 10-20 min by measuring the fluorescence increase. The 
resulting steady-state rates were calculated using the Ascent software, inhibition constants were 
calculated with Excel or Origin 8.1. All enzymes were diluted in the enzyme dilution buffer 
EVP (“Enzymverdünnungspuffer”) to reach a substrate turnover of at least 100 RFU after 
10 min of measurement. 
 
EVP Enzyme kinetic buffer 
154 mM NaCl 50 mM Tris-HCl (pH 8.0) 
0.1 % BSA 154 mM NaCl 
 0.01 % Triton X-100 
  
Table 7-1: Used substrates and enzymes for enzyme kinetic measurements 
 Substrate sequenceP4-P1' Enzyme (origin) Assay concentration 
   [E]# [Smax]* S1# S2# 
MI P4 P3 P2 P1 P1'  [pM] [µM] [µM] [µM] 
109 Tos Gly Pro Arg AMC Thrombin (bovine) 61 20 10 5 
505 H dArg Pro Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
202 
189 
100 
100 
- - 
506 H dArg Gly Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
202 
189 
100 
100 
- - 
507 Mes dArg Pro Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
Factor Xa (human) 
202 
189 
110 
50 
100 
50 
14.29 
14.29 
50 
7.15 
7.15 
25 
508 Mes dArg Gly Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
Trypsin (porcine) 
202 
189 
77 
50 
20 
40 
- 
- 
20 
- 
- 
10 
1314 Mes dArg Val Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
202 
189 
100 
100 
- - 
1319 H dhPhe Pro Arg AMC 
Matriptase, wt (human) 
Matriptase, C122S (human) 
202 
189 
100 
100 
- - 
*highest substrate concentration for determination of Km and Vmax 
# final substrate concentration for Ki determination or enzyme concentration for kinetic measurements 
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Determination of Km und Vmax 
In order to compare the kinetics of both matriptase variants and to detect the appropriate 
substrate for inhibition assays the standard values KM, Vmax, and Vmax/KM/ were determined 
using the Michaelis-Menten equation (1), with Vmax as the maximum reaction rate, [S] for 
substrate concentration and KM as Michaelis-Menten constant. 
 
Equation (2)    𝑣 =
𝑉𝑚𝑎𝑥 [𝑆]
Km+[S]
 
The KM values corresponds to the substrate concentration, which provides the half-maximal 
rate (Vmax/2) under the used measurement conditions. Progress curves were measured with six 
different substrate concentrations prepared by a serial 1:1 dilution in ultrapure H2O starting 
with the highest concentration (Smax in Table 7-1 ). 
 
Determination of the inhibitory constant Ki  
Ki values of all substrates in this thesis were calculated by fitting the determined steady-state 
rates (v) at 2 different substrate (S) and 5 different inhibitor (I) concentrations using Equation 
3. In parallel, also Dixon plots were used for Ki value calculations and visualization of the data 
points [283]. The given Ki values represent the mean of standardly three independent 
measurements (independent dilutions) of at least 2 different weighted portions.  
 
Equation (3)    𝑣 =
Vmax∗[S]
Km(1+
[I]
Ki
)+ [S]
 
 
The highest inhibitor concentration was chosen to have an inhibitory effect of approximately 
50 % (I1=100 %) and was subsequently diluted to I2 = 75 %, I3 = 50 % and I4 = 25 % with 
Enzyme kinetic buffer. The fifth value represented the steady-state rate in absence of the 
inhibitor (I0 = 0 %). 
7.6. Biostructural methods 
7.6.1. Crystallization by vapor diffusion 
For in house crystallization, hanging drop vapor diffusion technique was performed at 18 °C. 
If not otherwise stated, the reservoirs of 24 well-plates were filled with 500 - 800 µl respective 
crystallization buffer. Protein and buffer were mixed 1:1 on clean cover slides in a maximum 
volume of 4 µl. Cover slides were arranged on top of the reservoirs with the drop facing the 
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reservoir solution. To ensure proper closure, wells were sealed with medium viscous silicone 
grease. Crystal formation and growth was monitored with a light microscope. For experimental 
hanging drop crystallization set up, matriptase was concentrated to 5-10 mg/ml and incubated 
with 10-20 mM benzamidine 2 HCl or 1-2 mM of inhibitor 17 (Table 4-1) for 30 min on ice 
before being mixed 1:1 with the respective crystallization buffer. Different crystallization 
buffers were prepared and used for screening of varying pH, precipitants, salts and additives 
and are not all described in detail. 
7.6.2. Microseeding experiments with C122S-matriptase inhibitor complex 
For microseeding experiments a seeding stock was prepared using MicroSeedBeadsTM 
(Molecular Diemensions). A tangly crystal, grown in 0.1 M Tris HCl (pH 8.5), 35 % (w/v) PEG 
5000 and 0.2 M MgCl2 was pulverized by vortexing in 50 µl of original reservoir solution. After 
a serial ten times dilution in fresh buffer, seed stocks were flash frozen in liquid nitrogen and 
stored at -80°C unless used directly. Before use, seeding stock were vortexted thoroughly and 
centrifuged for 1 min at 10.000 rpm. C122S-matriptase was concentrated to 3-4 mg/ml and 
mixed with respective crystallization buffer and seeding stock on a cover slide in the ratio 3:2:1 
(v/v/v) (e.g., 1.2 µl protein, 0.8 µl buffer and 0.4 µl seeding stock).  
7.6.3. High-throughput (HT) nanodrop crystallization of C122S-matriptase 
To identify suitable crystallization conditions, freshly prepared C122S-matriptase was sent to 
the crystallization laboratory MarXtal (Marburg, Germany). Using a HT nanodrop 
crystallization robot, commercially available screens, including the Morpheus Screen 
(Molecular Dimensions; exact conditions unknown), NeXtal Tubes JCSG Core Suite III and 
Core Suite IV screens (QIAGEN, Hilden). With each screen 96 different conditions were tested 
in a sitting drop set up. Matriptase was concentrated to 7 mg/ml and incubated for 1 h with 
either 10 mM benzamine 2 HCl or 1 mM of inhibitor 17 (Table 4-1) on ice before being filtered 
in order to remove precipitants and other particles. To monitor crystal growth, pictures were 
taken periodically using the Formulatrix Rock ImagerTM starting directly after the drop set up. 
Further pictures were taken once per day for the first 5 days and then after one week, two weeks 
and finally after three weeks and upon request (after 3 months and 1 year).  
  
CHAPTER 7: EXPERIMENTAL PART 
_________________________________________________________________________________________________________________ 
 
 
144 
7.6.4. Microseed Matrix Screening (MMS) with C122S-matriptase 
 
Based on a protocol from D’ARCY [193]crystalline C122S-matriptase material from a previous 
experiment was homogenized thorough vortexing with MicroSeedBeadsTM (Molecular 
Dimensions) in 100 µl of the respective crystallization buffer. The seeding stock was diluted 
1:10, vortexed, centrifuged and the supernatant was used in the crystal set up with the respective 
crystallization buffer and C122S-matriptase at 6.4 mg/ml in a ratio of 1:2:3 (100 nl seeding 
stock; 200 nl crystallization buffer; 300 nl C122S-matriptase). Pictures were taken periodically 
using the Formulatrix Rock ImagerTM as described above. The seed stock and the 1:10 dilution 
were flash frozen in liquid nitrogen and stored at -80°C for further use. 
7.6.5. Soaking and freezing of C-122S matriptase crystal 
Based on earlier protocols [159] soaking of the C122S-matriptase crystal was performed for 3 h 
at 18 °C in the crystallization buffer containing 1 mM of the respective compound. Crystals 
were then briefly dipped in the glycerol containing cryo buffer and subsequently frozen in liquid 
nitrogen. 
 
 
C122S-matriptase soaking buffer 
Component Stock solutions Final concentration 
Sodium acetate 1 M 0.1 M 
Sodium formate 7 M 2 M 
Compound 55 100 mM  
in DMSO 
1 mM 
 
 
C122S-matriptase cryo buffer 
Component Stock solutions Final concentration 
Sodium acetate 1 M 0.1 M 
Sodium formate 7 M 2 M 
Glycerol 100 % 16 % 
   
Seeding set up Drop I Drop II 
Seeding material 
 
 
 
 
 
 
 
 
 
 
Commercial screen well JCSG Core Suite IV No. 74 JCSG Core Suite III well E4 
Crystallization buffer 
0.1 M MES (pH 6.0) 
1.0 M C4H4KNaO6 
0.1 M MES (pH 6.5) 
1.6 M MgCl2 
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7.6.6. Co-crystallization and freezing of bovine trypsin with compound 55 and 56 
Co-crystallization of bovine β-trypsin with compound 55 (Table 4-8) and 56 (Table 4-9) was 
performed as described previously [128]. For the preparation of the protein-inhibitor solution, 
trypsin (#T8003 Sigma-Aldrich, Germany) was dissolved in 10 mM CaCl2 and 1 mM HCl to a 
concentration of 20 - 40 mg/ml and incubated on ice for 30 min. Inhibitors were prepared as 10 
mM solutions in 30 % DMSO and diluted 1:10 in a solution consisting of 50 % protein solution 
and 40 % H2O (= Protein-inhibitor solution). In total, three different Protein-inhibitor solutions 
(a-b) were prepared with varying protein concentrations. Each Protein-inhibitor solution was 
tested in combination with two different crystallization buffers containing different PEG 8000 
concentrations (20 or 25 %). 
 
  Protein-inhibitor solution 
 Stock solutions Volume [µl] Final concentration  
    
Protein:  
a) 20 mg/ml 
b) 30 mg/ml 
c) 40 mg/ml 
50 µl 
 
a) 10 mg/ml 
b) 15 mg/ml 
c) 20 mg/ml 
Inhibitor: 10 mM 10 µl 1 mM 
H2O: - 40 µl - 
  Σ= 100 µl            
 
Trypsin - Crystallization buffer 
Component Stock solutions  Final buffer composition 
   Buffer 1 (B1) Buffer 2 (B2) 
Imidazole (pH 8.0) 1 M (pH: 8.0)  0.1 M 0.1 M 
(NH4)2SO4 3.8 M  0.1 M 0.1 M 
PEG 8000 50 % (w/v)  20 % (v/v) 25 % (v/v) 
NaN3 5 % (w/v)  0.1 % (v/v) 0.1 % (v/v) 
 
One 24-well plate per inhibitor was prepared by filling 500 µl B1 or B2 in the respective well. 
2 µl of protein-inhibitor solution was mixed with 2 µl buffer on cover slides. Each protein 
concentration was screened for the same buffer conditions 4 times. Crystals appeared in all 
wells overnight and reached full size after one week. Freezing of the crystals was performed by 
CrystalsFirst GmbH (Marburg) using a cryo buffer of unknown composition. 
7.6.7. Data collection, processing and refinement 
All data sets were collected at the synchrotron BESSY II (Berlin-Adlershof, HZB, Germany) 
[284]. The data sets were processed and scaled using XDS. Molecular replacement was done 
using Phaser from the CCP4 suite [285, 286] using PDB entry 2GV6 for matriptase [159] and 2ZFS 
for trypsin [287] as starting models. The refinement of the C122S-matriptase and trypsin crystals 
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was performed by CrystalsFirst GmbH (Marburg). The final models, giving the best possible 
explanation of the electron density, were deposited in the PDB with code 6T9T for the 
matriptase/compound 55-complex, 6T9V for trypsin in complex with compound 55 and 6T9U 
for trypsin in complex with inhibitor 56.  
7.7. Synthesis of compounds 
The synthesis of the 3-aminidinophenylalanine-derived inhibitors was done by OLIVER 
PILGRAM following previously described methods [159, 218].  
7.8. Computational methods 
The computational part was carried out in collaboration with the the computational chemist DR. 
FLORENT CHEVILLARD. 
7.8.1. Creation of core compound  
The crystal structure of matriptase in complex with compound 20 (Figure 4-2; PDB code: 
2GV6) was used as starting point for docking studies in scope of this thesis. In order to target 
specific single amino acids in the distal matriptase S3/4 binding pocket, the N-terminal 
naphthylsulfonyl of compound 20 was substituted with a 3-iodo-benzene to which an additional 
aryl moiety was attached by SUZUKI coupling (as done for similar compounds earlier 
including inhibitor 17 [217, 218, 224]). As this “virtual” compound is too big and flexible for 
docking studies solely 1-iodo-3-(methylsulfonyl)benzene (Figure 7-3) was used as a surrogate 
compound as the benzene ring and sulfone group were sufficient as core segment to have a 
shape reference for visual inspection of the docking poses. 
 
Figure 7-3: 1-iodo-3-(methylsulfonyl)benzene  
7.8.2. Dataset creation 
As 3-iodophenylsulfonyl cyanophenylalanine contains an aryl halide moiety suitable for 
modifications by Suzuki coupling, compatible extensions are any boronic acid. Three building 
block catalogs were downloaded from Chembridge (https://www.chembridge.com), Sigma 
Aldrich (https://www.sigmaaldrich.com) and Enamine (www.enamine.net) as SMILES files. 
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Boronic acids were extracted from those datasets using the "Filter your library" module from 
the PINGUI toolbox (www.kolblab.org/scubidoo/pingui/). After removing duplicates by using 
the isomeric canonical SMILES employing a python script based on RDKit the initial possible 
building block amount was reduced from 3054 to 2630. Starting from the 1-iodo-3-
(methylsulfonyl)benzene as surrogate, virtual products were then generated using the "Create 
your virtual library" module from PINGUI by selecting "Suzuki" as reaction and uploading the 
aforementioned boronic acids datasets. In total, 2151 virtual products were downloaded as 
SMILES and prepared for docking. 
7.8.3. Data preparation, docking and selection of molecules 
Docking calculations were performed based on the matriptase crystal structure in complex with 
compound 20 (Figure 4-2) Virtual products were protonated using QUACPAC (openeye.com) 
and 3D conformers were generated using OMEGA (openeye.com) with a maximum of 100 
conformers for each virtual product. All virtual product conformers were placed within the 
binding site of matriptase using HYBRID (openeye.com). The top 500 virtual product docking 
poses (based on the docking score) were carefully visually inspected. For each pose, the main 
quality criterion was the overlap of the sulfone benzene group with the reference compound 20. 
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Summary in German  
Matriptase und TMPRSS2 sind humane Transmembran Serinproteasen, die in der Lage sind, 
verschiedene Subtypen des Influenza-A Oberflächenproteins Hemagglutinin proteolytisch zu 
spalten und somit die Vermehrung von Influenzaviren in der Wirtszelle ermöglichen. Die 
Charakterisierung dieser Wirtsproteasen ist eine wichtige Voraussetzung zur Entwicklung 
wirksamer und selektiver Inhbibitoren als potentielle Wirkstoffe zur Therapie von 
Influenzainfektionen. In der vorliegenden Arbeit wurde ein Expressionssystem zur Herstellung 
rekombinanter C122S mutierter Matriptase etabliert und das erhaltene Protein im Folgenden 
für die enzymkinetische Charakterisierung verschiedener Inhibitoren sowie zur Strukturanalyse 
eingesetzt. Des Weiteren wurden verschiedene verkürzte und/oder mutierte TMPRSS2 Formen 
hergestellt und auf ihre proteolytische Aktivität mit dem Ziel untersucht, eine isolierbare 
TMPRSS2 Variante für enzymkinetische Messungen bereit zu stellen. 
 
Herstellung rekombinanter Matriptase 
In dem Wirtsorganismus E. coli wurden zwei verschiedene Matriptasevarianten produziert und 
miteinander enzymkinetisch verglichen. Die Serinproteasedomänen der Wildtyp-Matriptase 
und der mutierten C122S-Matriptase wurden jeweils mit 6 verschiedenen AMC-Substraten 
vermessen und zeigten dasselbe enzymkinetische Profil. Die etwas schlechteren Ausbeuten bei 
der Produktion der C122S-Matriptasevariante wurde durch die deutlich kostengünstigere 
Herstellung kompensiert. Im Folgenden wurden größere Mengen der C122S-Matriptase 
produziert und für Kristallisationationsexperimente eingesetzt. Durch den Einsatz der 
Hochdurchsatz Kristallisationsrobotik konnte ein geeigneter Kristall zur Sturkturanalyse 
gefunden werden. Mittels „Micoseed Matrix Screening“ konnten in einem zweiten Ansatz 4 
weitere gut geformte Matriptase Proteinkristalle erhalten werden, indem zwei für die 
Röntgenstrukturanalyse qualitativ nicht geeignete und zerkleinerte Proteinkristalle dem neuen 
Kristallisationsansatz beigefügt wurden.  
 
Neue 3-Amidinophenylalanin-Derivate als selektive Matriptaseinhibitoren 
Im Fokus der Entwicklung neuer monobasischer 3-Amidinophenylalanin Derivate im Rahmen 
dieser Arbeit standen potente Matriptase Verbindungen die eine hohe Selektivität gegenüber 
den Serinproteasen der Blutgerinnungskaskade Faktor Xa und Thrombin aufweisen. Insgesamt 
wurden 18 monobasische und somit potentiell bioverfügbare, als auch 4 dibasische 
Verbindungen getestet. Auf Basis einer Kristallstruktur der Matriptase in Komplex mit einem 
Inhibitor des 3-Amidinophenylalanin-Typs (PDB code: 2GV6, Verbindung 20) wurde Docking
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 genutzt um mögliche Optimierungen des N-Terminus zu identifizieren. Es wurden 
Verbindungen mit einer 3-Hydroxymethylgruppe ausgesucht, da eine Interaktion mit dem 
Gln175 der Matriptase vorhergesagt wurde, die zu einer erhöhten Matriptase Affinität, aber 
nicht fXa Affinität, beitragen soll. Die monobasische Verbindung 55 mit einem 4-tert-
Butylureido Piperidin am C- und 3-Fluor-4-Hydroxymethyl Biphenylsulphonyl am N-
Terminus zeigte eine hervorragende Selektivität gegenüber Thrombin (1533-fach). Der 
kristallographische Bindemodus dieser Verbindung in Komplex mit Matriptase zeigte eine 
Interaktion der 4-Hydroxymethylgruppe mit dem Gln175, was zu einer moderaten Selektivität 
gegenüber fXa führte (12-fach). Der Bindemodus von Verbindung 55 (als auch Verbindung 56) 
wurde zudem in Komplex mit Trypsin bestimmt. Das gut verfügbare Trypsin erwies sich als 
geeignete Alternative zu Matriptase, wenn eine Interaktion des Inhibitors mit der S3/4 
Bindetasche im Fokus steht. Der Inhibitor C-Terminus zeigte dagegen eine abweichende 
Orientierung in beiden Proteasen. Die Trypsin/Verbindung 56-Kristallstruktur zeigte 
außerdem, dass ein N-terminales 3-Hydroxymethyl theoretisch mit dem Gln175 in Matriptase 
interagieren würde. Verbindungen mit einem 3-Hydroxymethyl zeigten allerdings eine 
verminderte Matriptase Affinität (als auch Selektivität) in enzymkinetischen Messungen. 
 
Charakterisierung von TMPRSS2 
Aufgrund erfolgloser Isolierversuche aktiver TMPRSS2 aus E.coli Bakterien wurden 
verschiedene Strategien entwickelt um die anspruchsvolle Transmembran Serinprotease aus 
Säugerzellen zu isolieren. Dazu wurden zunächst verkürzte als auch mutierte TMPRSS2-
Varianten eingesetzt um strukturelle Eigenschaften zu identifizieren, die essentiell für eine 
Proteaseaktivität sind. Die Hauptstrategie basierte auf dem Entfernen von mindestens der 
Transmembrandomäne um löslisches und somit leichter isolierbares Enzym zu erhalten. 
Obwohl im Rahmen dieser Thesis keine aktive TMPRSS2 isoliert wurde, konnten durch diese 
Versuche neue Erkenntnisse zur TMPRSS2 Funktionalität gewonnen werden. Es wurde 
gezeigt, dass der zytosolische Teil, die Transmembrandomäne als auch die LDLRA Domäne 
keine Voraussetzung zur autokatalytischen Aktivierung von TMPRSS2 sind. Die SRCR 
Domäne als auch die Disulfidbrücke, welche die Proteasendomäne mit der Stammregion nach 
der Aktivierungsspaltung verbindet, sind hingegen essentiell für TMPRSS2 Aktivität in der 
Zelle. Trotz Entfernung der in der Zellmembran verankernden Transmembrandomäne konnte 
in Immunofluoreszens-Versuchen keine offensichtliche Dislokalisation der verkürzten 
Varianten im Vergleich zum Wildtyp festgestellt werden. Des Weiteren wurde TMPRSS2 in 
vitro als ein Substrat der Matriptase identifiziert. Dies deutet auf die Involvierung von 
TMPRSS2 in mehreren Zymogenkaskaden hin.
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